

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 10-K**

(Mark One)

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended December 31, 2024

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 1-12981

**AMETEK, Inc.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of  
incorporation or organization)

1100 Cassatt Road

Berwyn, Pennsylvania

(Address of principal executive offices)

14-1682544

(I.R.S. Employer

Identification No.)

19312-1177

(Zip Code)

Registrant's telephone number, including area code: ( 610 ) 647-2121

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Common Stock, \$0.01 Par Value (voting)

Trading symbol(s)

AME

Name of each exchange on which registered

New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The aggregate market value of the voting stock held by non-affiliates of the registrant was approximately \$ 38.6 billion as of June 30, 2024, the last business day of the registrant's most recently completed second fiscal quarter.

The number of shares of the registrant's Common Stock outstanding as of January 31, 2025 was 230,659,382 .

**Documents Incorporated by Reference**

Part III incorporates information by reference from the Proxy Statement for the Annual Meeting of Stockholders on May 7, 2025 .

---

---

AMETEK, Inc.

2024 Form 10-K Annual Report  
Table of Contents

		<b><u>Page</u></b>
	<b><u>PART I</u></b>	
Item 1.	<a href="#">Business</a>	2
Item 1A.	<a href="#">Risk Factors</a>	10
Item 1B.	<a href="#">Unresolved Staff Comments</a>	17
Item 1C.	<a href="#">Cybersecurity</a>	17
Item 2.	<a href="#">Properties</a>	17
Item 3.	<a href="#">Legal Proceedings</a>	18
Item 4.	<a href="#">Mine Safety Disclosures</a>	18
	<b><u>PART II</u></b>	
Item 5.	<a href="#">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a>	19
Item 6.	<a href="#">[Reserved]</a>	21
Item 7.	<a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	22
Item 7A.	<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	30
Item 8.	<a href="#">Financial Statements and Supplementary Data</a>	31
Item 9.	<a href="#">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a>	80
Item 9A.	<a href="#">Controls and Procedures</a>	80
Item 9B.	<a href="#">Other Information</a>	80
Item 9C.	<a href="#">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a>	80
	<b><u>PART III</u></b>	
Item 10.	<a href="#">Directors, Executive Officers and Corporate Governance</a>	81
Item 11.	<a href="#">Executive Compensation</a>	81
Item 12.	<a href="#">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a>	82
Item 13.	<a href="#">Certain Relationships and Related Transactions, and Director Independence</a>	82
Item 14.	<a href="#">Principal Accountant Fees and Services</a>	82
	<b><u>PART IV</u></b>	
Item 15.	<a href="#">Exhibits and Financial Statement Schedules</a>	83
Item 16.	<a href="#">Form 10-K Summary</a>	86
	<a href="#">SIGNATURES</a>	87

## PART I

### Item 1. Business

#### General Development of Business

AMETEK, Inc. ("AMETEK" or the "Company") is incorporated in Delaware. Its predecessor was originally incorporated in Delaware in 1930 under the name American Machine and Metals, Inc. AMETEK is a leading global manufacturer of electronic instruments and electromechanical devices with operations in North America, Europe, Asia and South America. AMETEK maintains its principal executive offices at 1100 Cassatt Road, Berwyn, Pennsylvania, 19312. Listed on the New York Stock Exchange (symbol: AME), the common stock of AMETEK is a component of the Standard and Poor's 500 and the Russell 1000 Indices.

#### Products and Services

AMETEK's products are marketed and sold worldwide through two operating groups: Electronic Instruments ("EIG") and Electromechanical ("EMG"). Electronic Instruments is a leader in the design and manufacture of advanced instruments for the process, power and industrial, and aerospace markets. Electromechanical is a differentiated supplier of precision motion control solutions, highly engineered medical components and devices, thermal management systems, specialty metals and electrical interconnects. Its end markets include aerospace and defense, medical, automation and other industrial markets.

#### Competitive Strengths

Management believes AMETEK has significant competitive advantages that help strengthen and sustain its market positions. Those advantages include:

*Significant Market Share.* AMETEK maintains significant market share in a number of targeted niche markets through its ability to produce and deliver high-quality, differentiated products at competitive prices. EIG has significant market positions in niche segments of the process, power and industrial, and aerospace markets. EMG holds significant positions in niche segments of the aerospace and defense, automation and medical markets.

*Technological and Development Capabilities.* AMETEK believes it has certain technological advantages over its competitors that allow it to maintain its leading market positions. Historically, the Company has demonstrated an ability to develop innovative new products and solutions that support customer needs. AMETEK has consistently added to its investment in research, development and engineering, and improved its new product development efforts with the adoption of Design for Six Sigma and Value Analysis/Value Engineering methodologies. These have improved the pace and quality of product innovation and resulted in the introduction of a steady stream of new products across all of AMETEK's businesses and aligned with attractive secular growth markets.

*Efficient and Flexible Manufacturing Operations.* Through its Operational Excellence initiatives, AMETEK has established a lean and flexible manufacturing platform for its businesses. In its effort to achieve best-cost manufacturing, AMETEK has operating facilities, as of December 31, 2024, in China, Czechia, Malaysia, Mexico, and Serbia. These facilities offer proximity to customers and provide opportunities for increasing international sales. Acquisitions also have allowed AMETEK to achieve operating synergies by consolidating operations, product lines and distribution channels, benefiting both of AMETEK's operating groups.

*Experienced Management Team.* Another component of AMETEK's success is the strength of its management team and that team's commitment to improving Company performance. AMETEK senior management has extensive industry experience and an average of approximately 23 years of AMETEK service. The management team is focused on delivering strong, consistent and profitable growth, growing

shareholder value, and creating a sustainable future for all stakeholders. Individual performance is tied to financial results through Company-established stock ownership guidelines and equity incentive programs.

## **Business Strategy**

AMETEK is committed to achieving earnings growth through the successful implementation of the AMETEK Growth Model. The goal of the Growth Model is high single digit annual percentage growth in sales and double digit annual percentage growth in earnings per share over the business cycle, strong cash flow generation, and a superior return on total capital. Other financial initiatives have been or may be undertaken, including public and private debt or equity issuance, bank debt refinancing, local financing in certain foreign countries and share repurchases.

AMETEK's Growth Model integrates the four growth strategies of Operational Excellence, Strategic Acquisitions, Global and Market Expansion, and New Product Development with a focus on cash generation and capital deployment.

*Operational Excellence.* Operational Excellence is AMETEK's cornerstone strategy for accelerating growth, improving profit margins and strengthening its competitive position across its businesses. Operational Excellence focuses on initiatives to drive increased organic sales growth, improvements in operating efficiencies and sustainable practices. It emphasizes team building and a participative management culture. AMETEK's Operational Excellence strategies include lean manufacturing, global sourcing, Design for Six Sigma, Value Engineering/Value Analysis, growth kaizens, and digitalization. Each plays an important role in improving efficiency, enhancing the pace and quality of innovation and driving profitable sales growth. Operational Excellence initiatives have yielded lower operating and administrative costs, shortened manufacturing cycle times, resulted in higher cash flow from operations and increased customer satisfaction. They also have played a key role in achieving synergies with newly acquired companies.

*Strategic Acquisitions.* Acquisitions are a key to achieving the goals of the AMETEK Growth Model. Since the beginning of 2020 through December 31, 2024, AMETEK has completed 14 acquisitions with annualized sales totaling approximately \$1.4 billion. AMETEK targets companies that offer a compelling strategic, technical and cultural fit. It seeks to acquire businesses in adjacent markets with complementary products and technologies. It also looks for businesses that provide attractive growth opportunities aligned with strong secular growth themes, often in new and emerging markets. AMETEK's management team has developed considerable skill in identifying, acquiring and integrating new businesses. As it has executed its acquisition strategy, AMETEK's mix of businesses has shifted toward those that are more highly differentiated and, therefore, offer better opportunities for growth and profitability.

*Global & Market Expansion.* AMETEK has experienced significant growth outside the United States, reflecting an expanding international customer base, investments in its global infrastructure and the attractive growth potential of its businesses in overseas markets. While Europe remains its largest overseas market, AMETEK has pursued growth opportunities worldwide, especially in key emerging markets. It has grown sales in Latin America and Asia by driving its global and market expansion strategy and initiatives. AMETEK also has expanded its sales, service, and engineering capabilities globally. Recently acquired businesses have further added to AMETEK's international presence.

*New Product Development.* New products are essential to AMETEK's long-term growth. As a result, AMETEK has maintained a consistent investment in new product development and engineering. AMETEK's businesses help solve our customers' most complex challenges with differentiated technology solutions. In 2024, AMETEK added to its highly differentiated product portfolio with a range of new products across many of its businesses.

AMETEK focuses on cash generation and capital deployment. AMETEK generates strong cash flow given its asset-light business model and strong operational execution. This cash flow supports AMETEK's capital

deployment strategy with its primary focus on strategic, value-enhancing acquisitions. AMETEK is also committed to paying a consistently increasing cash dividend.

Attracting, retaining, and developing talent is critical to the success and sustainability of the AMETEK Growth Model as our employees are responsible for successfully driving these strategies.

## **2024 Overview**

### *Operating Performance*

In 2024, the Company posted record sales, operating income, net income, diluted earnings per share, and operating cash flow. The Company achieved these results from contributions from recent acquisitions, as well as the Company's Operational Excellence initiatives. See "Results of Operations" in Part II, Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations for further details.

In 2024, the Company achieved record sales of \$6,941.2 million, an increase of 5.2% from 2023. Diluted earnings per share for 2024 were a record \$5.93, an increase of \$0.26 or 4.5%, compared with \$5.67 per diluted share in 2023.

### *Recent Acquisitions*

AMETEK spent \$117.5 million in cash in October 2024, net of cash acquired, to purchase Virtek Vision International ("Virtek"), a leading provider of advanced laser-based projection and inspection systems.

### *Financing*

In the third quarter of 2024, the Company paid in full, at maturity, a \$300 million in aggregate principal amount of 3.73% senior notes.

### *Recently Adopted Accounting Pronouncement*

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which requires disclosure of significant segment expenses and other segment items on an annual and interim basis under ASC 280. The Company retrospectively adopted ASU 2023-07, effective December 31, 2024, and the adoption resulted in additional disclosures in the Reportable Segments footnote.

## **Description of Business**

Described below are the products and markets of each reportable segment:

### **EIG**

EIG is a leader in the design and manufacture of advanced analytical, test and measurement instruments for the process, aerospace, medical, research, power and industrial markets.

EIG is a leader in many of the specialized markets it serves. Products supplied to these markets include process control instruments for the life sciences, pharmaceutical, semiconductor, automation, power, food and beverage, oil and gas, and petrochemical industries. It provides a growing range of instruments to the research and laboratory equipment, ultra-precision manufacturing, optics, medical, and test and measurement markets. It is a leader in power quality monitoring and metering, uninterruptible power systems, programmable power equipment, electromagnetic compatibility test equipment, sensors for gas turbines, dashboard instruments for heavy trucks, and instrumentation and controls for the food and beverage industries. EIG supplies the aerospace industry with aircraft

and engine sensors, monitoring systems, embedded computing systems, power supplies, fuel and fluid measurement systems, and data acquisition systems.

In many instances, EIG's products differ from or are technologically superior to its competitors' products. EIG has achieved competitive advantage through continued investment in research, development and engineering to develop market-leading products and solutions that serve niche markets.

In 2024, 51% of EIG's net sales were to customers outside the United States. At December 31, 2024, EIG employed approximately 11,600 people, of whom approximately 900 were covered by collective bargaining agreements. At December 31, 2024, EIG had operating facilities in the United States, the United Kingdom, Germany, Canada, Denmark, Finland, France, Switzerland, Argentina, Austria, Serbia, and Mexico. EIG also shares operating facilities with EMG in China, Serbia, and Mexico.

#### *Process and Analytical Instrumentation Markets and Products*

Process and analytical instrumentation sales represented 69% of EIG's 2024 net sales. These businesses include process analyzers, emission monitors and spectrometers; elemental and surface analysis instruments; level, pressure and temperature sensors and transmitters; radiation measurement devices; level measurement devices; precision manufacturing systems; materials- and force-testing instruments; contact and non-contact metrology products; and clinical and educational communication solutions. Among the industries it serves are power generation; pharmaceutical manufacturing; medical and healthcare; research and development; water and waste treatment; renewable energy production, semiconductor manufacturing; natural gas distribution; emissions monitoring, and oil, gas, and petrochemical refining. Its instruments are used for precision measurement in a number of applications, including radiation detection, trace element and materials analysis, nanotechnology research, ultraprecise manufacturing, advanced optical metrology, and test and measurement.

Acquired in October 2024, Virtek is a leading provider of advanced laser-based projection and inspection systems. Virtek's advanced 3D laser projectors, smart cameras, and quality control inspection systems complement the Company's existing Creaform business capabilities.

#### *Aerospace and Power Instrumentation Markets and Products*

Aerospace and Power Instrumentation sales represented 31% of EIG's 2024 net sales. These businesses produce a wide array of instrumentation, systems and sensors for applications in the aerospace, power and industrial markets.

These businesses produce power monitoring and metering instruments, uninterruptible power supply systems and programmable power supplies used in a wide range of industrial settings. It is a leader in the design and manufacture of power measurement, quality monitoring and event recorders for use in power generation, transmission and distribution. These businesses provide uninterruptible power supply systems, multifunction electric meters, and highly specialized communications equipment for smart grid applications and renewable energy applications. It also offers precision power supplies and power conditioning products, and electrical immunity and EMC test equipment, sensors for electric vehicle testing, gas turbines, dashboard instruments for heavy trucks and other vehicles, and instrumentation and controls for the food and beverage industries.

AMETEK's aerospace products are designed to customer specifications and manufactured to stringent operational and reliability requirements. These products include airborne data systems, turbine engine temperature measurement products, vibration-monitoring systems, cockpit instruments and displays, fuel and fluid measurement products, embedded computing systems, and sensors and switches. AMETEK serves all segments of the commercial and military aerospace market, including commercial airliners, business jets, regional aircraft and helicopters.

AMETEK operates in highly specialized aerospace market segments in which it has proven technological or manufacturing advantages versus its competition. Among its more significant competitive advantages is its 70-year-plus reputation as an established aerospace supplier. AMETEK has long-standing relationships with the world's

leading commercial and military aircraft, jet engine and original equipment manufacturers and aerospace system integrators. AMETEK also is a leading provider of spare part sales, repairs and overhaul services to commercial aerospace.

Acquired in October 2023, Amplifier Research is a leading provider of amplifiers and electromagnetic compatibility testing equipment. Amplifier Research's diverse product portfolio complements the Company's existing capabilities in the electromagnetic compatibility testing market.

Acquired in August 2023, UEI is a designer and manufacturer of high-performance test, measurement, simulation and control solutions. UEI's innovative solutions complement the Company's existing testing and data acquisition expertise.

#### *Customers*

EIG is not dependent on any single customer such that the loss of that customer would have a material adverse effect on EIG's operations. Approximately 6% of EIG's 2024 net sales were made to its five largest customers. No single customer comprises more than 2% of net sales.

#### **EMG**

EMG is a leader in the design and manufacture of highly engineered medical components and devices, automation solutions, thermal management systems, specialty metals and electrical interconnects. EMG is a leader in many of the niche markets in which it competes. Products supplied to these markets include single-use and consumable surgical instruments, implantable components, and drug delivery systems used across a wide range of medical applications, advanced precision motion control solutions, which are used in a wide range of automation applications across the medical, semiconductor, aerospace, defense, and food and beverage industries, as well as highly engineered electrical connectors and electronics packaging used in aerospace and defense, medical, and industrial applications.

EMG supplies high-purity powdered metals, strip and foil, specialty clad metals and metal matrix composites. EMG's heat exchangers provide electronic cooling and environmental control for the aerospace and defense and semiconductor industries. EMG's motors are widely used in commercial appliances, food and beverage machines, hydraulic pumps and industrial blowers. Additionally, EMG operates a global network of aviation maintenance, repair and overhaul ("MRO") facilities.

EMG designs and manufactures products that, in many instances, are significantly different from or technologically superior to competitors' products. It has achieved competitive advantage through continued investment in research, development and engineering, efficiency improvements from operational excellence, acquisition synergies and improved supply chain management.

In 2024, 41% of EMG's net sales were to customers outside the United States. At December 31, 2024, EMG employed approximately 9,500 people, of whom approximately 2,300 were covered by collective bargaining agreements. At December 31, 2024, EMG had operating facilities in the United States, the United Kingdom, China, Germany, France, Italy, Poland, Mexico, Serbia, Czechia, Malaysia, and Taiwan. EMG also shares operating facilities with EIG in China, Serbia, and Mexico.

#### *Automation and Engineered Solutions Markets and Products*

Automation and Engineered Solution sales represented 73% of EMG's 2024 net sales. These businesses produce precision motion control solutions, brushless motors, blowers and pumps, heat exchangers and other electromechanical systems. These products are used in a wide variety of high-precision automation applications, including semiconductor equipment, and laboratory and medical equipment.



AMETEK is a leader in highly engineered single-use and consumable surgical instruments, implantable components and drug delivery systems. Its electrical connectors and electronics packaging are designed specifically for harsh environments and highly customized applications, and are used to protect sensitive devices and mission-critical electronics. In addition, AMETEK is an innovator and market leader in specialized metal powder, strip, wire and bonded products used in medical, aerospace and defense, telecommunications, automotive and general industrial applications.

Acquired in March 2023, Bison is a designer and manufacturer of custom motion control solutions. Bison's engineering expertise and broad product portfolio complement the Company's existing motion control and automation solutions business.

Acquired in December 2023, Paragon is a leading provider of highly engineered medical components and instruments. Paragon's product portfolio includes single-use and consumable surgical instruments and implantable components sold to a diverse blue-chip customer base of leading medical device manufacturers. Paragon expands the Company's presence in the MedTech space and provides access to new market segments with strong growth rates.

#### *Aerospace Markets and Products*

Aerospace sales represented 27% of EMG's 2024 net sales. These businesses produce motor-blower systems and heat exchangers used in thermal management and other applications on a variety of military and commercial aircraft and military ground vehicles. In addition, these businesses provide the commercial and military aerospace industry with third-party MRO services on a global basis with facilities in the United States, Europe and Asia.

#### *Customers*

EMG is not dependent on any single customer such that the loss of that customer would have a material adverse effect on EMG's operations. Approximately 14% of EMG's 2024 net sales were made to its five largest customers. No single customer comprises greater than 4% of net sales.

#### **Marketing**

AMETEK's marketing efforts generally are organized and carried out at the business level. EIG makes use of specialized distributors and sales representatives to market its products along with a direct sales force for its technically sophisticated products. Within aerospace, the specialized customer base of aircraft and jet engine manufacturers is served primarily by direct sales engineers. Given the technical nature of its many products, as well as its significant market share, EMG conducts much of its domestic and international marketing activities through a direct sales force and makes some use of sales representatives and distributors, both in the United States and in other countries.

#### **Competition**

In general, AMETEK's markets are highly competitive with competition based on technology, performance, quality, service and price.

In EIG's markets, AMETEK believes it ranks as a leader in certain analytical measurement and control instruments, and power and industrial markets. It also is a major instrument and sensor supplier to commercial aviation. In process and analytical instruments, numerous companies compete in each market on the basis of product quality, performance and innovation. In power and industrial and in aerospace, AMETEK competes with a number of companies depending on the specific market segment.

EMG's businesses compete with a number of companies in each of its markets. Competition is generally based on product innovation, performance and price. There also is competition from alternative materials and processes.

## **Availability of Raw Materials**

AMETEK's reportable segments obtain raw materials and supplies from a variety of sources and generally from more than one supplier. For EMG, however, certain items, including various base metals and certain steel components, are available from only a limited number of suppliers. AMETEK believes its sources and supplies of raw materials are adequate for its needs.

## **Environmental and Other Governmental Regulation**

AMETEK's operations and properties are subject to laws and regulations relating to environmental protection, including those governing air emissions, water discharges, waste management, and workplace safety. The Company uses, generates and disposes of hazardous substances and waste in its operations and could be subject to material liabilities relating to the investigation and clean-up of contaminated properties and related claims. The Company is required to conform our operations and properties to these laws and adapt to regulatory requirements in all countries as these requirements change. The Company has a robust Environmental Health and Safety program responsible for supporting its environmental monitoring and compliance efforts. In connection with acquisitions, the Company will assess potential material environmental liabilities, and determine regulatory and fiduciary obligations during the course of the due diligence process. In addition, new laws and regulations, the discovery of previously unknown contamination or the imposition of new requirements could increase costs or subject AMETEK to new or increased liabilities.

Information with respect to environmental matters is set forth in Note 13 to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.

## **Patents, Licenses and Trademarks**

AMETEK owns numerous unexpired U.S. and foreign patents, including counterparts of its more important U.S. patents, in the major industrial countries of the world. It is a licensor or licensee under patent agreements of various types, and its products are marketed under various registered and unregistered U.S. and foreign trademarks and trade names. AMETEK, however, does not consider any single patent or trademark, or any group of them, essential either to its business as a whole or to either one of its reportable segments. The annual royalties received or paid under license agreements are not significant to either of its reportable segments or to AMETEK's overall operations.

## **Sustainability and Human Capital Management**

### *Sustainability*

AMETEK is committed to providing a consistent and excellent return to our stakeholders, all while maintaining a strong commitment to environmental stewardship, social responsibility, inclusion, and sound corporate governance. We believe that effectively prioritizing and managing our sustainability initiatives will help create long-term value and a better future for our stakeholders.

Our Sustainability Report highlights our sustainability initiatives and is available on our website at <https://www.ametek.com/who-we-are/sustainability>.

Key elements in the Company's approach to sustainability include the following:

*Core Values.* Our core values — Ethics and Integrity, Respect for the Individual, Inclusion, Teamwork, and Social Responsibility — remain the most critical components of our sustainability efforts. Sustainability is an integral aspect of the core values that guide the way we do business.

*Upholding Sound Governance.* Our commitment to transparency, accountability, and ethical and responsible decision-making is demonstrated through our core values, corporate governance structure, compliance measures, and focus on sustainability oversight. Together, AMETEK's governance structure underpins our distributed

operating structure and provides our colleagues with the foundation to advance sustainability initiatives across their businesses.

*Protecting Our Environment.* Our ongoing commitment to serve as environmental stewards and protect the environment for future generations is reflected in our proactive approach to environmental management and sustainability. From emissions reduction initiatives to optimizing resource consumption, we emphasize environmental protection in every facet of our operations. We are firmly committed to reducing our carbon footprint and have made outstanding progress toward our stated greenhouse gas emissions reduction target.

*Investing in Our People.* Our people are the most essential resource in driving AMETEK's long-term success and in achieving our sustainability ambitions. AMETEK is committed to developing an inclusive culture to help power innovation, growth, and greater opportunities for all employees. Through strategic investments in talent acquisition, learning and development, and employee well-being, we foster a culture of empowerment, innovation, and inclusivity, driving our collective success and sustainable growth. We are continually expanding our employee development, engagement, and training initiatives to provide meaningful opportunities for personal and professional development.

*Driving Sustainable Product Solutions.* AMETEK is committed to advancing a low-carbon economy. Our growing portfolio of clean technology and sustainability-related solutions includes a wide range of products and solutions that have a positive, global environmental impact across a broad set of diverse end markets, supporting customers in achieving their sustainability goals and creating a more sustainable future. Through collaborative partnerships with our customers, we develop solutions which help reduce carbon emissions, promote renewable energy adoption, improve efficiency and productivity, and improve healthcare outcomes.

*Partnering with Our Communities.* We cultivate strong and lasting relationships with the communities in which we operate, actively contributing to their social and economic prosperity. Our charitable arm, the AMETEK Foundation, provides wide-ranging support to non-profit and educational organizations. Through employee volunteerism, financial support, and contributions from the AMETEK Foundation, we partner to strengthen the work of non-profit charities around the world.

#### *Human Capital Management*

As a global organization, we have seen firsthand that the innovation needed to solve our customers' biggest challenges can only come from employees that are fully engaged and committed, and who have diverse perspectives and backgrounds. Our Board regularly receives updates and presentations on key topics, including sustainability, compliance, inclusion, and employee development and succession.

Our executive management team reviews the key talent across our company and assesses the adequacy of talent to meet business challenges and future growth needs. We have an active Inclusion Council, which drives initiatives focused on mentorship, education and career guidance.

We have created a leadership development program for employees on track to become P&L leaders in the company. This focused and intensive program involves both internal and external training on leadership effectiveness as well as specific job-related skills. In addition, participants receive hands-on experience in key AMETEK business system processes such as growth kaizens and acquisition due diligence. We have a long-standing commitment to responsible corporate conduct. Each employee is provided with annual performance goals which are reviewed in a performance review with their manager. Employee feedback is actively encouraged through an open-door policy for all managers, regular town hall/all hands meetings, executive presentations with Q&A sessions, a regular CEO podcast for all employees, and a hotline that can be used to report complaints.

Giving back to our community is an important part of our culture. Established in 1960, the AMETEK Foundation's mission is to empower AMETEK colleagues making a positive impact in their local communities, with a focus on health and welfare, civic and social service programs, and education.

As of December 31, 2024, we have approximately 21,500 employees. Our compensation programs are designed to provide competitive salaries and benefit programs to attract, retain and motivate a world-class

workforce. Selected employees participate in short and long-term incentive programs that align employee and shareholder interests and promote long-term retention. Additionally, we strive to protect health and safety in every aspect of our enterprise – from the way we design, manufacture and deliver our products to the way our customers use them. We continue to drive towards our goal of zero lost-time work incidents. In 2024, we achieved a lost-time incident rate that was significantly below the industry average. We continue to enhance our safety initiatives as each facility is tasked with identifying opportunities for additional safety measures. Businesses with zero incidents share best practices and ensure ongoing training to maintain their safety excellence. In addition to our EHS facility audits, our facilities include safety committees, continual training, documented self-audits, and behavior-based safety observations and feedback.

Our U.S. Federal Employment Information Report (EEO-1) for 2023 is available at [www.ametek.com](http://www.ametek.com).

#### **Available Information**

AMETEK's annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934 are made available free of charge on the Company's website at [www.ametek.com](http://www.ametek.com) in the "Investors – Reporting" section as soon as reasonably practicable after such material is electronically filed with, or furnished to, the U.S. Securities and Exchange Commission. All reports filed with the Securities Exchange Commission can also be viewed on their website at [www.sec.gov](http://www.sec.gov). AMETEK has posted in the "Investors – Governance" section of its website its corporate governance guidelines, Board committee charters, codes of ethics, and social and environmental policies. Those documents also are available free of charge in published form to any stockholder who requests them by writing to the Investor Relations Department at AMETEK, Inc., 1100 Cassatt Road, Berwyn, Pennsylvania, 19312.

#### **Item 1A. Risk Factors**

You should consider carefully the following risk factors and all other information contained in this Annual Report on Form 10-K and the documents we incorporate by reference in this Annual Report on Form 10-K. Any of the following risks could materially and adversely affect our business, financial condition, results of operations and cash flows.

##### **Risks Related to Our Operations**

***Our growth could suffer if the markets into which we sell our products and services decline, do not grow as anticipated, experience cyclicity, or a general downturn in the economy could adversely affect our business.***

A number of the industries in which we operate are cyclical in nature and therefore are affected by factors beyond our control. A downturn in the U.S. or global economy, and, in particular, in the aerospace and defense, oil and gas, process instrumentation or power markets could have an adverse effect on our business, financial condition and results of operations.

Our growth depends in part on the growth of the markets which we serve. Visibility into the future performance of certain of our markets is limited (particularly for markets into which we sell through distribution). Our quarterly sales and profits depend substantially on the volume and timing of orders received during the fiscal quarter, which are difficult to forecast. Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which would adversely affect our financial statements. A number of our businesses operate in industries that may experience periodic, cyclical downturns. In addition, in certain of our businesses, demand depends on customers' capital spending budgets, as well as government funding policies. Matters of public policy and government budget dynamics, as well as product and economic cycles, can affect the spending decisions of these customers. Demand for our products and services is also sensitive to changes in customer order patterns, which may be affected by announced price changes, changes in incentive programs, new

product introductions and customer inventory levels. Any of these factors could adversely affect our growth and results of operations in any given period.

***We may not properly execute, or realize anticipated cost savings or benefits from, our Operational Excellence initiatives.***

Our success is partly dependent upon properly executing and realizing cost savings or other benefits from our ongoing production and procurement initiatives. These initiatives are primarily designed to make the Company more efficient, which is necessary in the Company's highly competitive industries. These initiatives are often complex, and a failure to implement them properly may, in addition to not meeting projected cost savings or benefits, adversely affect our business and operations.

***Foreign and domestic economic, political, legal, compliance and business factors could negatively affect our international sales and operations.***

International sales for 2024 and 2023 represented 47.4% of our consolidated net sales. As a result of our growth strategy, we anticipate that the percentage of sales outside the United States will increase in the future. As of December 31, 2024, we have manufacturing operations in 20 countries outside the United States, with significant operations in Canada, China, France, Germany, Mexico, Serbia, Poland and the United Kingdom. A disruption of our ability to obtain a supply of goods from these countries or a change in the cost to purchase, manufacture, or distribute these products could have an adverse effect on our sales and operations. International sales and operations are subject to the customary risks of operating in an international environment, including:

- Imposition of trade or foreign exchange restrictions, including in the United States;
- Overlap of different tax structures, including the development of a global minimum tax;
- Unexpected changes in regulatory requirements, including in the United States;
- Trade protection measures, such as the imposition of or increase in tariffs and other trade barriers, including in the United States;
- The difficulty and/or costs of designing and implementing an effective control environment across diverse regions and employee bases;
- Restrictions on currency repatriation;
- General economic conditions;
- Unstable political situations and social unrest, both internationally and in the United States;
- Increasing trade tensions between the United States and certain countries, including China;
- Nationalization of assets; and
- Compliance with a wide variety of international and U.S. laws and regulatory requirements.

Furthermore, fluctuations in foreign currency exchange rates, including changes in the relative value of currencies in the countries where we operate, subject us to exchange rate exposure and may adversely affect our financial statements. For example, increased strength in the U.S. dollar will increase the effective price of our products sold overseas, which may adversely affect sales or require us to lower our prices. In addition, our consolidated financial statements are presented in U.S. dollars, and we must translate our assets, liabilities, sales and

expenses into U.S. dollars for external reporting purposes. As a result, changes in the value of the U.S. dollar due to fluctuations in currency exchange rates or currency exchange controls may materially and negatively affect the value of these items in our consolidated financial statements, even if their value has not changed in their local currency.

***Our international sales and operations may be adversely impacted by compliance with export laws.***

We are required to comply with various import, export, export control and economic sanctions laws, which may affect our transactions with certain customers, business partners and other persons, including in certain cases dealings with or between our employees and subsidiaries. In certain circumstances, export control and economic sanctions regulations may prohibit the export of certain products, services and technologies and in other circumstances, we may be required to obtain an export license before exporting a controlled item. In addition, failure to comply with any of these regulations could result in civil and criminal, monetary and non-monetary penalties, disruptions to our business, limitations on our ability to import and export products and services and damage to our reputation.

***Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents or business partners.***

We cannot provide assurance that our internal controls and compliance systems will always protect us from acts committed by employees, agents or business partners of ours (or of businesses we acquire or partner with) that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, export and import compliance, money laundering and data privacy. In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the U.S. and in other jurisdictions and related shareholder lawsuits could lead to substantial civil and criminal, monetary and non-monetary penalties and could cause us to incur significant legal and investigatory fees. In addition, we rely on our suppliers to adhere to our supplier standards of conduct and violations of such standards of conduct could occur that could have a material effect on our financial statements.

***Any inability to hire, train and retain a sufficient number of skilled officers and other employees could impede our ability to compete successfully.***

If we cannot hire, train and retain a sufficient number of qualified employees, we may not be able to effectively integrate acquired businesses and realize anticipated results from those businesses, manage our expanding international operations and otherwise profitably grow our business. Even if we do hire and retain a sufficient number of employees, the expense necessary to attract and motivate these officers and employees may adversely affect our results of operations.

***If we are unable to develop new products on a timely basis, it could adversely affect our business and prospects.***

We believe that our future success depends, in part, on our ability to develop, on a timely basis, technologically advanced products that meet or exceed appropriate industry standards. Maintaining our existing technological advantages will require us to continue investing in research and development and sales and marketing. There can be no assurance that we will have sufficient resources to make such investments, that we will be able to make the technological advances necessary to maintain such competitive advantages or that we can recover major research and development expenses. We are not currently aware of any emerging standards or new products which could render our existing products obsolete, although there can be no assurance that this will not occur or that we will be able to develop and successfully market new products.

***Our technology is important to our success and our failure to protect this technology could put us at a competitive disadvantage.***

Many of our products rely on proprietary technology; therefore, we endeavor to protect our intellectual property rights through patents, copyrights, trade secrets, trademarks, confidentiality agreements and other contractual provisions. Despite our efforts to protect proprietary rights, unauthorized parties or competitors may copy or otherwise obtain and use our products or technology. In addition, our ability to protect and enforce our intellectual property rights may be limited in certain countries outside the U.S. Actions to enforce our rights may result in substantial costs and diversion of resources and we make no assurances that any such actions will be successful.

***A disruption in, shortage of, or price increases for, supply of our components and raw materials may adversely impact our operations.***

While we manufacture certain parts and components used in our products, we require substantial amounts of raw materials and purchase some parts and components, including semiconductor chips and other electronic components, from suppliers. The availability and prices for raw materials, parts and components may be subject to curtailment or change due to, among other things, suppliers' allocation to other purchasers, interruptions in production by suppliers, changes in exchange rates and prevailing price levels. In addition, our facilities, supply chains, distribution systems, and products may be impacted by natural or man-made disruptions, including armed conflict, damaging weather or other acts of nature, pandemics or other public health crises. A shutdown of, or inability to utilize, one or more of our facilities, our supply chain, or our distribution system could significantly disrupt our operations, delay production and shipments, damage our relationships and reputation with customers, suppliers, employees, stockholders and others, result in lost sales, result in the misappropriation or corruption of data, or result in legal exposure and large remediation or other expenses. Furthermore, certain items, including base metals and certain steel components, are available only from a limited number of suppliers and are subject to commodity market fluctuations. Shortages in raw materials or price increases therefore could affect the prices we charge, our operating costs and our competitive position, which could adversely affect our business, financial condition, results of operations and cash flows.

***We are subject to numerous governmental regulations, which may be burdensome or lead to significant costs.***

Our operations are subject to numerous federal, state, local and foreign governmental laws and regulations. In addition, existing laws and regulations may be revised or reinterpreted and new laws and regulations, including with respect to privacy legislation and climate change, may be adopted or become applicable to us or customers for our products. These laws continue to develop and may be inconsistent from jurisdiction to jurisdiction. Complying with emerging and changing international requirements may cause the Company to incur substantial costs or require the Company to change its business practices. We cannot predict the form any such new laws or regulations will take or the impact any of these laws and regulations will have on our business or operations.

***We operate in highly competitive industries, which may adversely affect our results of operations or ability to expand our business.***

Our markets are highly competitive. We compete, domestically and internationally, with individual producers, as well as with vertically integrated manufacturers, some of which have resources greater than we do. The principal elements of competition for our products are product technology, quality, service, distribution and price. Although we believe EIG is a market leader, competition is strong and could intensify in the markets served by EIG. In the aerospace markets served by EIG, a limited number of companies compete on the basis of product quality, performance and innovation. EMG's competition in specialty metal products stems from alternative materials and processes. Our competitors may develop new or improve existing products that are superior to our products or may adapt more readily to new technologies or changing requirements of our customers. There can be

no assurance that our business will not be adversely affected by increased competition in the markets in which it operates or that our products will be able to compete successfully with those of our competitors.

***Our business and financial performance could be adversely impacted by a significant disruption in, or breach in security of, our information technology systems.***

We rely on information technology systems, some of which are managed by third-parties, to process, transmit and store electronic information (including sensitive data such as confidential business information and personally identifiable data relating to employees, customers, other business partners and patients), and to monitor, manage, and support a variety of critical business processes and activities including receiving and fulfilling orders, billing, collecting and making payments, shipping products, providing services and support to customers and fulfilling contractual obligations. Despite our implementation of certain controls to protect our systems and sensitive, confidential or personal data or information, these systems, products, data and services may be damaged, compromised, disrupted or shut down due to attacks by computer hackers, computer viruses, ransomware, human error or malfeasance, power outages, hardware failures, telecommunication or utility failures, catastrophes or other unforeseen events. In any such circumstances, our system redundancy and other disaster recovery planning may be ineffective or inadequate. Further, we also face information security risks due to our reliance on internet technology and use of hybrid work arrangements, which could strain our technology resources or create additional opportunity for cyber-attackers to exploit vulnerabilities.

Attacks may also target hardware, software and information installed, stored or transmitted in our products after such products have been purchased and incorporated into third-party products, facilities or infrastructure. Like most multinational corporations, our information technology systems have been subject to computer viruses, malicious codes, unauthorized access and other cyber-attacks and we expect the sophistication and frequency of such attacks to continue to increase. Any of the attacks, breaches or other disruptions or damage described above could interrupt our operations or the operations of our customers and partners, delay production and shipments, result in theft of intellectual property and trade secrets, damage customer and business partner relationships and our reputation or result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased costs for security and remediation, each of which could adversely affect our business, reputation and financial statements. Further, given the increasing sophistication of cyber-attacks and the complexity of techniques used, any of these attacks or breaches could potentially persist for an extended period before being detected. As a result, it could take a significant time before an investigation can be completed and new disclosure regulations could result in us being required to disclose information about a material cybersecurity incident before it has been mitigated or resolved, or even fully investigated. Although we maintain cyber risk insurance, damages and claims arising from such incidents may not be covered or may exceed the amount of any insurance available.

**Risks Related to Our Acquisitions**

***Our growth strategy includes strategic acquisitions. We may not be able to consummate future acquisitions or successfully integrate recent and future acquisitions.***

A portion of our growth has been attributed to acquisitions of strategic businesses. We plan to continue making strategic acquisitions to enhance our global market position and broaden our product offerings. Although we have been successful with our acquisition strategy in the past, our ability to successfully effectuate acquisitions will be dependent upon a number of factors, including:

- Our ability to identify acceptable acquisition candidates;
- The impact of increased competition for acquisitions, which may increase acquisition costs, affect our ability to consummate acquisitions on favorable terms, and result in us assuming a greater portion of the seller's liabilities;



- Successfully integrating acquired businesses, including integrating the management, technological and operational processes, procedures and controls of the acquired businesses with those of our existing operations;
- Adequate financing for acquisitions being available on terms acceptable to us;
- Unexpected losses of key employees, customers and suppliers of acquired businesses;
- Mitigating assumed, contingent and unknown liabilities; and
- Challenges in managing the increased scope, geographic diversity and complexity of our operations.

The process of integrating acquired businesses into our existing operations may result in unforeseen operating difficulties and may require additional financial resources and attention from management that would otherwise be available for the ongoing development or expansion of our existing operations. Furthermore, even if successfully integrated, the acquired business may not achieve the results we expected or produce expected benefits in the time frame planned. Failure to continue with our acquisition strategy and the successful integration of acquired businesses could have an adverse effect on our business, financial condition, results of operations and cash flows.

***The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.***

Certain of the acquisition agreements by which we have acquired companies require the former owners to indemnify us against certain liabilities related to the operation of the company before we acquired it. In most of these agreements, however, the liability of the former owners is limited, and certain former owners may be unable to meet their indemnification responsibilities. We may also obtain representation and warranty insurance to address certain potential risks and liabilities. We cannot assure you that these indemnification provisions and insurance policies will protect us fully or at all, and as a result we may face unexpected liabilities that adversely affect our financial statements.

#### **Risks Related to Our Financial Condition**

***Certain environmental risks may cause us to be liable for costs associated with hazardous or toxic substance clean-up which may adversely affect our financial condition.***

Our businesses, operations and facilities are subject to a number of federal, state, local and foreign environmental and occupational health and safety laws and regulations concerning, among other things, air emissions, discharges to waters and the use, manufacturing, generation, handling, storage, transportation and disposal of hazardous substances and wastes. Environmental risks are inherent in many of our manufacturing operations. Certain laws provide that a current or previous owner or operator of property may be liable for the costs of investigating, removing and remediating hazardous materials at such property, regardless of whether the owner or operator knew of, or was responsible for, the presence of such hazardous materials. In addition, the Comprehensive Environmental Response, Compensation and Liability Act generally imposes joint and several liability for clean-up costs, without regard to fault, on parties contributing hazardous substances to sites designated for clean-up under the Act. We have been named a potentially responsible party at several sites, which are the subject of government-mandated clean-ups. As the result of our ownership and operation of facilities that use, manufacture, store, handle and dispose of various hazardous materials, we may incur substantial costs for investigation, removal, remediation and capital expenditures related to compliance with environmental laws. While it is not possible to precisely quantify the potential financial impact of pending environmental matters, based on our experience to date, we believe that the outcome of these matters is not likely to have a material adverse effect on our financial position or future results of operations. In addition, new laws and regulations, new classification of hazardous materials, stricter enforcement of existing laws and regulations, the discovery of previously unknown contamination or the imposition of new clean-up requirements could require us to incur costs or become the basis for new or increased liabilities that

could have a material adverse effect on our business, financial condition and results of operations. There can be no assurance that future environmental liabilities will not occur or that environmental damages due to prior or present practices will not result in future liabilities.

***We are subject to a variety of litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our financial statements.***

We are subject to a variety of litigation and other legal and regulatory proceedings incidental to our business (or the business operations of previously owned entities), including claims for damages arising out of the use of products or services and claims relating to intellectual property matters, employment matters, tax matters, commercial disputes, competition and sales and trading practices, environmental matters, personal injury, insurance coverage and acquisition-related matters, as well as regulatory investigations or enforcement. These lawsuits may include claims for compensatory damages, punitive and consequential damages and/or injunctive relief. The defense of these lawsuits may divert our management's attention, we may incur significant expenses in defending these lawsuits, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial statements. Moreover, any insurance or indemnification rights that we may have may be insufficient or unavailable to protect us against such losses. In addition, developments in proceedings in any given period may require us to adjust the loss contingency estimates that we have recorded in our financial statements, record estimates for liabilities or assets previously not susceptible of reasonable estimates or pay cash settlements or judgments. Any of these developments could adversely affect our financial statements in any particular period. We cannot assure you that our liabilities in connection with litigation and other legal and regulatory proceedings will not exceed our estimates or adversely affect our financial statements and reputation. However, based on our experience, current information and applicable law, we do not believe that any amounts we may be required to pay in connection with litigation and other legal and regulatory proceedings in excess of our reserves will have a material effect on our financial statements.

***Restrictions contained in our revolving credit facility and other debt agreements may limit our ability to incur additional indebtedness.***

Our existing revolving credit facility and other debt agreements (each a "Debt Facility" and collectively, "Debt Facilities") contain restrictive covenants, including restrictions on our ability to incur indebtedness. These restrictions could limit our ability to effectuate future acquisitions, limit our ability to pay dividends, limit our ability to make capital expenditures or restrict our financial flexibility. Our Debt Facilities contain covenants requiring us to achieve certain financial and operating results and maintain compliance with specified financial ratios. Our ability to meet the financial covenants or requirements in our Debt Facilities may be affected by events beyond our control, and we may not be able to satisfy such covenants and requirements. A breach of these covenants or our inability to comply with the financial ratios, tests or other restrictions contained in a Debt Facility could result in an event of default under one or more of our other Debt Facilities. Upon the occurrence of an event of default under a Debt Facility, and the expiration of any grace periods, the lenders could elect to declare all amounts outstanding under one or more of our other Debt Facilities, together with accrued interest, to be immediately due and payable. If this were to occur, our assets may not be sufficient to fully repay the amounts due under our Debt Facilities or our other indebtedness.

***Our goodwill and other intangible assets represent a substantial proportion of our total assets and the impairment of such substantial goodwill and intangible assets could have a negative impact on our financial condition and results of operations.***

Our total assets include substantial amounts of intangible assets, primarily goodwill. At December 31, 2024, goodwill and other intangible assets, net of accumulated amortization, totaled \$10,471.1 million or 72% of our total assets. The goodwill results from our acquisitions, representing the excess of cost over the estimated fair value of the net tangible and other identifiable intangible assets we have acquired. If future operating performance at one or more of our reporting units were to fall significantly below current levels, we could record, under current applicable accounting rules, a non-cash charge to operating income for goodwill or other intangible asset impairment. Any

determination requiring the impairment of a significant portion of goodwill or other intangible assets would negatively affect our financial condition and results of operations.

**Item 1B. Unresolved Staff Comments**

None.

**Item 1C. Cybersecurity**

AMETEK's cybersecurity risk management practices are based on the widely recognized National Institute of Standards and Technology Framework for Improving Critical Infrastructure Cybersecurity (The NIST Cybersecurity Framework and the NIST 800-171 Revision 2 Standard). This guidance was developed with private sector input and provides a framework and toolkit for organizations to manage cybersecurity risk.

We utilize a broad team of in-house information technology and security personnel, as well as third-party consultants, services and software, to help manage our cybersecurity efforts and initiatives. We regularly assess our threat landscape and monitor our systems and other technical security controls. Additionally, we maintain information security policies and procedures, including a breach response plan and maintenance of backup and protective systems.

We regularly review our policies, practices, and plans with assistance from third-party experts and advisors. Our Chief Information Officer is responsible for corporate-wide data security. Our management team is actively engaged in regular reviews of cyber risks. Additionally, our full Board of Directors receives quarterly briefings on enterprise-wide cybersecurity risk management and our overall cybersecurity risk environment.

We have implemented two risk management groups, the Enterprise Risk Management Committee, and the Cybersecurity Steering Committee. These committees meet quarterly. They are responsible for the overall governance of our cyber management. The implementation of the Cyber policies and strategy is the responsibility of the Chief Information Officer and the Director of Cyber Security. The CIO reports to the Chief Administrative Officer and the Director of Cyber Security reports to the CIO. We also have a team of full-time cybersecurity specialists who hold various industry technology accreditations. The CIO has more than 35 years in Senior IT Leadership positions, and the Director of Cyber Security has more than 30 years IT experience overall, 15 of which are in leadership roles.

Operationally, we deploy multiple layers of cyber defenses including multiple tools and processes that identify security risks across our global networks, largely in real time. We also maintain good relationships with law enforcement agencies to remain informed on potential cyber risks.

Mandatory cybersecurity training is conducted eight times a year for all of AMETEK's employees with email access. The training provides critical information on how employees can protect themselves and AMETEK against cybersecurity risks. AMETEK financial professionals receive additional training due to the nature of their roles.

**Item 2. Properties**

At December 31, 2024, the Company conducted business from office and operating facilities at owned and leased locations throughout the United States and select global markets. The Company leases a facility in Berwyn, Pennsylvania for its corporate headquarters.

The Company believes that all facilities have been adequately maintained, are in good operating condition, and are suitable for our current needs.

**Item 3. Legal Proceedings**

Please refer to Note 13 to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for information regarding certain litigation matters.

The Company is subject to a variety of litigation and other legal and regulatory proceedings incidental to its business (or the business operations of previously owned entities), including claims for damages arising out of the use of the Company's products or services and claims relating to intellectual property matters, employment matters, tax matters, commercial disputes, competition and sales and trading practices, environmental matters, personal injury, insurance coverage and acquisition-related matters, as well as regulatory investigations or enforcement. Based upon the Company's experience, the Company does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position or cash flows.

**Item 4. Mine Safety Disclosures**

Not Applicable.

## PART II

### Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

The principal market on which the Company's common stock is traded is the New York Stock Exchange and it is traded under the symbol "AME." On January 31, 2025, there were approximately 1,700 holders of record of the Company's common stock.

Market price and dividend information with respect to the Company's common stock is set forth below. Future dividend payments by the Company will be dependent on future earnings, financial requirements, contractual provisions of debt agreements and other relevant factors.

Under its share repurchase program, the Company repurchased approximately 1,258,200 shares of its common stock for \$223.1 million in 2024 and approximately 55,800 shares of its common stock for \$7.8 million in 2023.

The objective and rationale of the share repurchases is to enhance shareholder value through the opportunistic repurchases of the Company's common stock. The Company takes a balanced approach when determining how to deploy capital, including strategic acquisitions, dividends, and share repurchases. The factors evaluated when considering how to deploy capital include: the Company's share price, the Company's cash balances, balance sheet flexibility, business prospects, the leverage of the Company, and other investment opportunities.

#### Issuer Purchases of Equity Securities

The following table reflects purchases of AMETEK, Inc. common stock by the Company during the three months ended December 31, 2024:

Period	Total Number of Shares Purchased (1)(2)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plan (2)	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan
October 1, 2024 to October 31, 2024	—	\$ —	—	\$ 748,135,553
November 1, 2024 to November 30, 2024	105,801	179.68	105,801	729,125,335
December 1, 2024 to December 31, 2024	739,179	184.08	739,179	593,058,748
Total	844,980	\$ 183.53	844,980	

(1) Represents shares surrendered to the Company to satisfy tax withholding obligations in connection with employees' share-based compensation awards.

(2) Consists of the number of shares purchased pursuant to the Company's Board of Directors \$1 billion authorization for the repurchase of its common stock announced in May 2022, which replaces the previous \$500 million authorization for repurchase of its common stock announced in February 2019. Such purchases may be effected from time to time in the open market or in private transactions, subject to market conditions and at management's discretion.


**Securities Authorized for Issuance Under Equity Compensation Plan Information**

The following table sets forth information as of December 31, 2024 regarding all of the Company's existing compensation plans pursuant to which equity securities are authorized for issuance to employees and non-employee directors:

<b>Plan category</b>	<b>Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)</b>	<b>Weighted average exercise price of outstanding options, warrants and rights (b)</b>	<b>Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)</b>
Equity compensation plans approved by security holders	2,139,951	\$ 114.33	5,131,945
Equity compensation plans not approved by security holders	—	—	—
<b>Total</b>	<b>2,139,951</b>	<b>\$ 114.33</b>	<b>5,131,945</b>

Stock Performance Graph

The following graph and accompanying table compare the cumulative total stockholder return for AMETEK over the last five years ended December 31, 2024 with total returns for the same period for the Standard and Poor's ("S&P") 500 Index and S&P 500 Industrials. AMETEK's stock price is a component of both indices. The performance graph and table assume a \$100 investment made on December 31, 2019 and reinvestment of all dividends. The stock performance shown on the graph below is based on historical data and is not necessarily indicative of future stock price performance.



Item 6. Reserved

## Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

This report includes forward-looking statements based on the Company's current assumptions, expectations and projections about future events. When used in this report, the words "believes," "anticipates," "may," "expect," "intend," "estimate," "project" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such words. In this report, the Company discloses important factors that could cause actual results to differ materially from management's expectations. For more information on these and other factors, see "Forward-Looking Information" herein.

The following Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with "Item 1A. Risk Factors," and the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.

### Business Overview

AMETEK's operations are affected by global, regional and industry-specific economic factors. However, the Company's strategic geographic and industry diversification, and its mix of products and services, have helped to mitigate the potential adverse impact of any unfavorable developments in any one industry or the economy of any single country on its consolidated operating results. In 2024, the Company posted record sales, operating income, net income, diluted earnings per share, and operating cash flow. Positive market trends, the Company's backlog, contributions from recent acquisitions, and continued focus on and implementation of Operational Excellence initiatives had a positive impact on 2024 results. The Company also benefited from its strategic initiatives under AMETEK's four key strategies: Operational Excellence, Strategic Acquisitions, Global & Market Expansion and New Products.

Highlights in 2024 were:

- Net sales for 2024 were a record \$6,941.2 million, an increase of \$344.2 million or 5.2%, compared with net sales of \$6,597.0 million in 2023.
- Net income for 2024 was a record \$1,376.1 million, an increase of \$62.9 million or 4.8%, compared with \$1,313.2 million in 2023.
- Diluted earnings per share for 2024 were a record \$5.93, an increase of \$0.26 or 4.5%, compared with \$5.67 per diluted share in 2023.
- Cash provided by operating activities totaled a record \$1,828.8 million in 2024, an increase of \$93.5 million or 5.4%, compared with cash provided by operating activities of \$1,735.3 million in 2023.
- The Company's backlog of unfilled orders at December 31, 2024 was \$3,403.2 million.
- In October 2024, the Company spent \$117.5 million in cash, net of cash acquired, to purchase Virtek Vision International ("Virtek"), a leading provider of advanced laser-based projection and inspection systems.
- EBITDA (earnings before interest, income taxes, depreciation, and amortization) was a record \$2,151.6 million in 2024, compared with \$2,014.7 million in 2023.
- In the third quarter of 2024, the Company paid in full, at maturity, a \$300 million in aggregate principal amount of 3.73% senior notes.
- The Company continued its emphasis on investment in research, development and engineering, spending \$371.9 million in 2024. Approximately 27% of sales in 2024 were from products introduced in the past three years.



## Results of Operations

The following "Results of Operations of the year ended December 31, 2024 compared with the year ended December 31, 2023" section presents an analysis of the Company's consolidated operating results displayed in the Consolidated Statement of Income. A discussion regarding our financial condition and results of operations for the year ended December 31, 2023 compared to the year ended December 31, 2022 can be found under Item 7 in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on February 22, 2024.

### ***Results of Operations for the year ended December 31, 2024 compared with the year ended December 31, 2023***

Net sales for 2024 were \$6,941.2 million, an increase of \$344.2 million or 5.2%, compared with net sales of \$6,597.0 million in 2023. The increase in net sales for 2024 was due to a 7% increase from acquisitions, partially offset by a 2% organic sales decline. EIG net sales were \$4,659.9 million in 2024, an increase of 0.8%, compared with \$4,624.3 million in 2023. EMG net sales were \$2,281.3 million in 2024, an increase of 15.6%, compared with \$1,972.7 million in 2023.

Total international sales for 2024 were \$3,291.7 million or 47.4% of net sales, an increase of \$163.5 million or 5.2%, compared with international sales of \$3,128.2 million or 47.4% of net sales in 2023. The increase in international sales was primarily driven by strong demand in Europe and Asia, as well as contributions from the 2023 acquisitions. Export shipments from the United States, which are included in total international sales, were \$1,880.8 million in 2024, an increase of \$148.4 million or 8.6%, compared with \$1,732.4 million in 2023.

Orders for 2024 were \$6,810.3 million, a decrease of \$102.1 million or 1.5% compared with \$6,912.4 million in 2023. The decrease in orders was due to a 2% organic order decrease, a 1% unfavorable effect of foreign currency translation, partially offset by a 2% increase from acquisitions. The organic orders decrease is due to customer inventory normalization in our automation and engineered solutions core businesses. The Company's backlog of unfilled orders at December 31, 2024 was \$3,403.2 million, a decrease of \$130.9 million or 3.7%, compared with \$3,534.1 million at December 31, 2023.

Segment operating income for 2024 was \$1,884.9 million, an increase of \$77.4 million or 4.3%, compared with segment operating income of \$1,807.5 million in 2023. Segment operating income, as a percentage of net sales, decreased to 27.2% in 2024, compared with 27.4% in 2023. Segment operating income and operating margins in 2024 included \$29.2 million of integration costs related to the Paragon acquisition, which negatively impacted segment operating margins by 40 basis points. The dilutive impact of the 2023 acquisitions negatively impacted segment operating margins by 110 basis points in 2024. Excluding the dilutive impact of the 2023 acquisitions and the Paragon integration costs, segment operating margins increased 130 basis points compared to 2023, due to the continued benefits from the Company's Operational Excellence initiatives.

Cost of sales for 2024 was \$4,464.7 million or 64.3% of net sales, an increase of \$252.2 million or 6.0%, compared with \$4,212.5 million or 63.9% of net sales for 2023. The cost of sales increase was primarily due to the net sales increase discussed above.

Selling, general and administrative expenses for 2024 were \$696.9 million or 10.0% of net sales, an increase of \$19.9 million or 2.9%, compared with \$677.0 million or 10.3% of net sales in 2023. Selling expenses increased primarily due to the increase in net sales discussed above. General and administrative expenses for 2024 were \$105.3 million, compared with \$100.1 million in 2023.

Consolidated operating income was \$1,779.6 million or 25.6% of net sales for 2024, an increase of \$72.1 million or 4.2%, compared with \$1,707.5 million or 25.9% of net sales in 2023.

Other expense, net was \$5.1 million for 2024, compared with \$19.3 million of other expense in 2023, a change of \$14.2 million. During 2024, the Company recorded higher pension income of \$6.5 million and lower acquisition-related due diligence expense compared to 2023.

The effective tax rate for 2024 was 17.2%, compared with 18.3% in 2023. See Note 9 to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for further details.

Net income for 2024 was \$1,376.1 million, an increase of \$62.9 million or 4.8%, compared with \$1,313.2 million in 2023.

Diluted earnings per share for 2024 were \$5.93, an increase of \$0.26 or 4.5%, compared with \$5.67 per diluted share in 2023.

### **Segment Results**

**EIG's** net sales totaled a record \$4,659.9 million for 2024, an increase of \$35.6 million or 0.8%, compared with \$4,624.3 million in 2023. The net sales increase was due to a 2% increase from acquisitions, partially offset by a 1% organic sales decrease.

EIG's operating income was a record \$1,428.4 million for 2024, an increase of \$117.4 million or 9.0%, compared with \$1,311.0 million in 2023. EIG's operating margins were a record 30.7% of net sales for 2024, compared with 28.3% of net sales in 2023. EIG's operating margins increased in 2024 compared to 2023 due to the continued benefits from the Company's Operational Excellence initiatives.

**EMG's** net sales totaled a record \$2,281.3 million for 2024, an increase of \$308.6 million or 15.6%, compared with \$1,972.7 million in 2023. The net sales increase was due to a 20% increase from acquisitions, partially offset by a 5% organic sales decrease. The organic sales decrease for 2024 is due to customer inventory normalization in our automation and engineered solutions core businesses.

EMG's operating income was \$456.5 million for 2024, a decrease of \$40.1 million or 8.1%, compared with \$496.6 million in 2023. EMG's operating margins were 20.0% of net sales for 2024, compared with 25.2% of net sales in 2023. EMG's operating margins were negatively impacted by the dilutive impact of the 2023 acquisitions. EMG's operating income and operating margins for 2024 included \$29.2 million of integration costs related to the Paragon acquisition, which negatively impacted segment operating margins by 130 basis points. The dilutive impact of the 2023 acquisitions negatively impacted EMG operating margins by 270 basis points in 2024. Excluding the dilutive impact of the 2023 acquisitions and the Paragon integration costs, EMG operating margins decreased 120 basis points compared to 2023, due to the organic sales decrease discussed above.

### **Liquidity and Capital Resources**

Cash provided by operating activities totaled \$1,828.8 million in 2024, an increase of \$93.5 million or 5.4%, compared with cash provided by operating activities of \$1,735.3 million in 2023. The increase in cash provided by operating activities for 2023 was primarily due to higher net income, net of higher noncash depreciation and amortization expense related to recent acquisitions, and improved working capital management.

Free cash flow (cash flow provided by operating activities less capital expenditures) was \$1,701.7 million in 2024, compared with \$1,599.1 million in 2023. EBITDA (earnings before interest, income taxes, depreciation and amortization) was \$2,151.7 million in 2024, compared with \$2,014.7 million in 2023. Free cash flow and EBITDA are presented because the Company is aware that they are measures used by third parties in evaluating the Company. (See "Non-GAAP Financial Measures" for a reconciliation of U.S. GAAP measures to comparable non-GAAP measures).

Cash used by investing activities totaled \$244.8 million in 2024, compared with cash used by investing activities of \$2,376.4 million in 2023. In 2024, the Company paid \$117.5 million, net of cash acquired, to purchase Virtek Vision International, compared to \$2,237.9 million, net of cash acquired, to purchase Bison Gear & Engineering Corp., United Electronic Industries, Amplifier Research Corp. and Paragon Medical in 2023. Additions to property, plant and equipment totaled \$127.1 million in 2024, compared with \$136.2 million in 2023.

Cash used by financing activities totaled \$1,602.5 million in 2024, compared with \$697.3 million of cash provided by financing activities in 2023. At December 31, 2024, total debt, net was \$2,079.7 million, compared with \$3,313.3 million at December 31, 2023. In 2024, total borrowings decreased by \$1,189.7 million, compared with an increase of \$892.3 million in 2023. At December 31, 2024, the Company had available borrowing capacity of \$2,020.3 million under its revolving credit facility and term loan, excluding the \$700 million accordion feature.

At December 31, 2024, the Company had \$230.0 million outstanding on the revolver with a maturity date of May 2027. The amount outstanding under the revolver that the Company expects, but is not required, to repay in 2025 is recorded in current liabilities on the consolidated balance sheet at December 31, 2024.

In the third quarter of 2024, the Company paid in full, at maturity, a \$300 million in aggregate principal amount of 3.73% senior notes. The debt-to-capital ratio was 17.7% at December 31, 2024, compared with 27.5% at December 31, 2023. The net debt-to-capital ratio (total debt, net less cash and cash equivalents divided by the sum of net debt and stockholders' equity) was 15.0% at December 31, 2024, compared with 25.0% at December 31, 2023. The net debt-to-capital ratio is presented because the Company is aware that this measure is used by third parties in evaluating the Company. (See "Non-GAAP Financial Measures" for a reconciliation of U.S. GAAP measures to comparable non-GAAP measures).

In 2024, the Company repurchased approximately 1.2 million shares of its common stock for \$212.0 million, compared with \$7.8 million used for repurchases of approximately 0.1 million shares in 2023. At December 31, 2024, \$604.1 million was available under the Company's Board of Directors authorization for future share repurchases.

Additional financing activities for 2024 included cash dividends paid of \$258.8 million, compared with \$230.3 million in 2023. Effective February 9, 2024, the Company's Board of Directors approved a 12% increase in the quarterly cash dividend on the Company's common stock to \$0.28 per common share from \$0.25 per common share. Proceeds from the exercise of employee stock options were \$66.9 million in 2024, compared with \$50.9 million in 2023.

As a result of all of the Company's cash flow activities in 2024, cash and cash equivalents at December 31, 2024 totaled \$374.0 million, compared with \$409.8 million at December 31, 2023. At December 31, 2024, the Company had \$361.5 million in cash outside the United States, compared with \$375.9 million at December 31, 2023. The Company utilizes this cash to fund its international operations, as well as to acquire international businesses. The Company is in compliance with all covenants, including financial covenants, for all of its debt agreements. The Company believes it has sufficient cash-generating capabilities from domestic and unrestricted foreign sources, available credit facilities and access to long-term capital funds to enable it to meet its operating needs and contractual obligations for the foreseeable future.

#### *Subsequent Events*

On January 6, 2025, the Company established a commercial paper program under which it may issue short-term, unsecured commercial paper notes. Amounts available under the commercial paper program may be borrowed, repaid and re-borrowed, with the aggregate face or principal amount of the notes outstanding under the commercial paper program at any time not to exceed \$2.3 billion. The notes will have maturities of up to 364 days from the date of issue. The Company intends the commercial paper program to provide additional financing flexibility for various purposes including acquisitions. The Company expects that outstanding indebtedness of the Company under both the revolving credit facility and the commercial paper program will not exceed \$2.3 billion at any time.

Effective February 7, 2025, the Company's Board of Directors approved an 11% increase in the quarterly cash dividend on its common stock to \$0.31 per share from \$0.28 per share.

Effective February 7, 2025, the Company's Board of Directors approved a \$1.25 billion share repurchase authorization. This new authorization replaces the previous \$1 billion share repurchase authorization approved in May 2022.

#### Acquisition subsequent to December 31, 2024

In January 2025, the Company acquired Kern Microtechnik ("Kern"), a leading manufacturer of high-precision machining and optical inspection solutions supporting a wide range of applications within the medical, semiconductor, research, and space markets. Kern has annual sales of approximately 50 million Euros. Kern will join EIG.

#### Contractual Obligations and Other Commitments

Material contractual obligations arising in the normal course of business primarily consist of purchase obligations, long-term debt and related interest payments, and leases. See Note 10 to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for more information on the nature and timing of debt obligations.

Leases expire over a range of years from 2025 to 2038. Most of the leases contain renewal or purchase options, subject to various terms and conditions. See Note 14 to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for more information on the nature and timing of lease obligations.

Purchase obligations primarily consist of contractual commitments to purchase certain inventories at fixed prices. At December 31, 2024, the Company had \$695.9 million of purchase obligations due within one year and \$66.0 million of purchase obligations due in more than one year.

The Company has standby letters of credit and surety bonds of \$173.1 million related to performance and payment guarantees at December 31, 2024. Based on experience with these arrangements, the Company believes that any obligations that may arise will not be material to its financial position.

#### Non-GAAP Financial Measures

EBITDA represents earnings before interest, income taxes, depreciation and amortization. EBITDA is presented because the Company is aware that it is used by rating agencies, securities analysts, investors and other parties in evaluating the Company. It should not be considered, however, as an alternative to operating income as an indicator of the Company's operating performance or as an alternative to cash flows as a measure of the Company's overall liquidity as presented in the Company's consolidated financial statements. Furthermore, EBITDA measures shown for the Company may not be comparable to similarly titled measures used by other companies. The following table presents the reconciliation of net income reported in accordance with U.S. generally accepted accounting principles ("GAAP") to EBITDA:

	Year Ended December 31,		
	2024	2023	2022
	(In millions)		
Net income	\$ 1,376.1	\$ 1,313.2	\$ 1,159.5
Add (deduct):			
Interest expense	113.0	81.8	83.2
Interest income	(5.8)	(11.1)	(1.7)
Income taxes	285.4	293.2	269.2
Depreciation	135.3	122.5	113.7
Amortization	247.7	215.1	205.8
Total adjustments	775.6	701.5	670.2
EBITDA	\$ 2,151.7	\$ 2,014.7	\$ 1,829.7

Free cash flow represents cash flow from operating activities less capital expenditures. Free cash flow is presented because the Company is aware that it is used by rating agencies, securities analysts, investors and other parties in

evaluating the Company. The following table presents the reconciliation of cash flow from operating activities reported in accordance with U.S. GAAP to free cash flow:

	Year Ended December 31,		
	2024	2023	2022
	(In millions)		
Cash provided by operating activities	\$ 1,828.8	\$ 1,735.3	\$ 1,149.4
Deduct: Capital expenditures	(127.1)	(136.2)	(139.0)
Free cash flow	<u>\$ 1,701.7</u>	<u>\$ 1,599.1</u>	<u>\$ 1,010.4</u>

Net debt represents total debt, net minus cash and cash equivalents. Net debt is presented because the Company is aware that it is used by rating agencies, securities analysts, investors and other parties in evaluating the Company. The following table presents the reconciliation of total debt, net reported in accordance with U.S. GAAP to net debt:

	December 31,	
	2024	2023
	(In millions)	
Total debt, net	\$ 2,079.7	\$ 3,313.3
Less: Cash and cash equivalents	(374.0)	(409.8)
Net debt	<u>1,705.7</u>	<u>2,903.5</u>
Stockholders' equity	<u>9,655.3</u>	<u>8,730.2</u>
Capitalization (net debt plus stockholders' equity)	<u>\$ 11,361.0</u>	<u>\$ 11,633.7</u>
Net debt as a percentage of capitalization	<u>15.0 %</u>	<u>25.0 %</u>

#### Internal Reinvestment

##### Capital Expenditures

Capital expenditures were \$127.1 million or 1.8% of net sales in 2024, compared with \$136.2 million or 2.1% of net sales in 2023. Capital expenditures in 2025 are expected to be approximately 2% of net sales, with a continued emphasis on spending to improve productivity.

##### Research, Development and Engineering

The Company is committed to, and has consistently invested in, research, development and engineering activities to design and develop new and improved products and solutions. Research, development and engineering costs were \$371.9 million in 2024, \$351.7 million in 2023 and \$322.1 million in 2022. These amounts included research and development expenses of \$236.6 million, \$220.8 million and \$198.8 million in 2024, 2023, and 2022, respectively. All such expenditures were directed toward the development of new products and solutions and the improvement of existing products and solutions.

#### Environmental Matters

Information with respect to environmental matters is set forth in Note 13 to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.

#### Critical Accounting Policies and Estimates

Critical accounting policies are those policies that can have a significant impact on the presentation of the Company's financial condition and results of operations and that require the use of complex and subjective estimates based on the Company's historical experience and management's judgment. Because of the uncertainty inherent in such estimates, actual results may differ materially from the estimates used. Below are the policies used in preparing

the Company's financial statements that management believes are the most dependent upon the application of estimates and assumptions. A complete list of the Company's significant accounting policies is in Note 1 to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.

- *Business Combinations.* The Company allocates the purchase price of an acquired company, including when applicable, the acquisition date fair value of contingent consideration between tangible and intangible assets acquired and liabilities assumed from the acquired business based on their estimated fair values, with the residual of the purchase price recorded as goodwill. Third party appraisal firms and other consultants are engaged to assist management in determining the fair values of certain assets acquired and liabilities assumed. In the absence of a third party appraisal, the Company uses internal valuation estimates based on pertinent data from comparable prior acquisitions. Estimating fair values requires significant judgments, estimates and assumptions, including but not limited to: discount rates, future cash flows and the economic lives of trade names, technology, and customer relationships. These estimates are based on historical experience and information obtained from the management of the acquired companies and are inherently uncertain.
- *Goodwill and Other Intangible Assets.* Goodwill and other intangible assets with indefinite lives, primarily trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. The Company performs either a qualitative or quantitative analysis to determine if it is more likely than not that the fair values of its reporting units are less than the respective carrying values of those reporting units. The Company elected to bypass performing the qualitative screen and performed a quantitative analysis of the goodwill impairment test in the current year. The Company may elect to perform a qualitative analysis in future periods.

The Company principally relies on a discounted cash flow analysis to determine the fair value of each reporting unit, which considers cash flows discounted at an appropriate discount rate. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization and working capital requirements, which are based on the Company's long-range plan and are considered level 3 inputs. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both equity and debt, including a risk premium. While the Company uses the best available information to prepare its cash flow and discount rate assumptions, actual future cash flows or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged. In order to evaluate the sensitivity of the goodwill impairment test to changes in the fair value calculations, the Company applied a hypothetical 10% decrease in fair values of each reporting unit. The 2024 results (expressed as a percentage of carrying value for the respective reporting unit) showed that, despite the hypothetical 10% decrease in fair value, the fair values of the Company's reporting units still exceeded their respective carrying values by 95% to 388%.

The impairment test for indefinite-lived intangibles other than goodwill (primarily trademarks and trade names) consists of a comparison of the estimated fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company can elect to perform a qualitative analysis to determine if it is more likely than not that the fair values of its indefinite-lived intangible assets are less than the respective carrying values of those assets. The Company elected to bypass the performing the qualitative screen. The Company may elect to perform the qualitative analysis in future periods. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method using level 3 inputs, which is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is determined by applying a royalty rate to a projection of net revenues discounted using an appropriate discount rate. Each royalty rate is determined based on the profitability of the trade name to which it relates and observed market royalty rates. Certain impairment models have discount rates calculated based on a debt/equity cost of capital. While the Company uses the

best available information to prepare its cash flow and discount rate assumptions, actual future cash flows or market conditions could differ significantly resulting in future impairment charges related to recorded intangible balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.

The Company's acquisitions have generally included a significant goodwill component and the Company expects to continue to make acquisitions. At December 31, 2024, goodwill and other indefinite-lived intangible assets totaled \$7,579.2 million or 51.8% of the Company's total assets. The Company completed its required annual impairment tests in the fourth quarter of 2024 and determined that the carrying values of the Company's goodwill and indefinite-lived intangibles were not impaired. There can be no assurance that goodwill or indefinite-lived intangibles impairment will not occur in the future.

- **Income Taxes.** The process of providing for income taxes and determining the related balance sheet accounts requires management to assess uncertainties, make judgments regarding outcomes and utilize estimates. The Company conducts a broad range of operations around the world and is therefore subject to complex tax regulations in numerous international taxing jurisdictions, resulting at times in tax audits, disputes and potential litigation, the outcome of which is uncertain. Management must make judgments currently about such uncertainties and determine estimates of the Company's tax assets and liabilities. To the extent the final outcome differs, future adjustments to the Company's tax assets and liabilities may be necessary.

The Company assesses the realizability of its deferred tax assets, taking into consideration the Company's forecast of future taxable income, available net operating loss carryforwards and available tax planning strategies that could be implemented to realize the deferred tax assets. Based on this assessment, management must evaluate the need for, and the amount of, valuation allowances against the Company's deferred tax assets. To the extent facts and circumstances change in the future, adjustments to the valuation allowances may be required.

The Company assesses the uncertainty in its tax positions by applying a minimum recognition threshold which a tax position is required to meet before a tax benefit is recognized in the financial statements. Once the minimum threshold is met, using a more likely than not standard, a series of probability estimates is made for each item to properly measure and record a tax benefit. The tax benefit recorded is generally equal to the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination. The underlying probabilities are determined based on the best available objective evidence such as recent tax audit outcomes, published guidance, external expert opinion, or by analogy to the outcome of similar issues in the past. There can be no assurance that these estimates will ultimately be realized given continuous changes in tax policy, legislation and audit practice. The Company recognizes interest and penalties accrued related to uncertain tax positions in income tax expense.

#### **Recent Accounting Pronouncements**

See Note 2, Recent Accounting Pronouncements, to the Company's Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for information regarding recently issued accounting pronouncements.

#### **Forward-Looking Information**

Certain matters discussed in this Form 10-K are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 ("PSLRA"), which involve risk and uncertainties that exist in the Company's operations and business environment and can be affected by inaccurate assumptions, or by known or unknown risks and uncertainties. Many such factors will be important in determining the Company's actual future results. The Company wishes to take advantage of the "safe harbor" provisions of the PSLRA by cautioning readers that numerous important factors in some cases have caused, and in the future could cause, the Company's actual

results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company. Some, but not all, of the factors or uncertainties that could cause actual results to differ from present expectations are set forth above and under Item 1A. Risk Factors. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, unless required by the securities laws to do so.

**Item 7A. Quantitative and Qualitative Disclosures About Market Risk**

The Company's primary exposures to market risk are fluctuations in interest rates and foreign currency exchange rates, which could impact its financial condition and results of operations. The Company addresses its exposure to these risks through its normal operating and financing activities. The Company's differentiated and global business activities help to reduce the impact that any particular market risk may have on its operating income as a whole.

The Company's short-term debt carries variable interest rates and generally its long-term debt carries fixed rates. These financial instruments are more fully described in the Notes to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.

The foreign currencies to which the Company has the most significant exchange rate exposure are the Euro, the British pound, the Japanese yen, the Chinese renminbi, the Canadian dollar, and the Mexican peso. The Company evaluates foreign currency exposures on a centralized basis and aims to balance, where possible, non-functional currency denominated assets to non-functional currency denominated liabilities to have a natural hedge and minimize foreign exchange impacts. In the event a natural hedge is not available, the Company takes steps to mitigate foreign currency risk through the use of local borrowings and occasional derivative financial instruments in the currency affected. The effect of translating foreign subsidiaries' balance sheets into U.S. dollars is included in other comprehensive income within stockholders' equity. Foreign currency transactions have not had a significant effect on the operating results reported by the Company because revenues and costs associated with the revenues are generally transacted in the same foreign currencies.

Based on a hypothetical ten percent adverse movement in interest rates or foreign currency exchange rates, the Company's best estimate is that the potential losses in future earnings, fair value of risk-sensitive financial instruments and cash flows are not material, although the actual effects may differ materially from the hypothetical analysis.



Item 8. Financial Statements and Supplementary Data

	<u>Page</u>
<b>Index to Financial Statements (Item 15(a)(1))</b>	
<a href="#">Reports of Management</a>	32
<a href="#">Reports of Independent Registered Public Accounting Firm</a> Ernst & Young LLP, Philadelphia, Auditor Firm ID:	42 33
<a href="#">Consolidated Statement of Income for the years ended December 31, 2024, 2023 and 2022</a>	37
<a href="#">Consolidated Statement of Comprehensive Income for the years ended December 31, 202 4, 2023 and 2022</a>	38
<a href="#">Consolidated Balance Sheet at December 31, 202 4 and 2023</a>	39
<a href="#">Consolidated Statement of Stockholders' Equity for the years ended December 31, 202 4, 2023 and 2022</a>	40
<a href="#">Consolidated Statement of Cash Flows for the years ended December 31, 202 4, 2023 and 2022</a>	41
<a href="#">Notes to Consolidated Financial Statements</a>	42

**Financial Statement Schedules (Item 15(a)(2))**

Financial statement schedules have been omitted because either they are not applicable, or the required information is included in the financial statements or the notes thereto.

## Management's Responsibility for Financial Statements

Management has prepared and is responsible for the integrity of the consolidated financial statements and related information. The statements are prepared in conformity with U.S. generally accepted accounting principles consistently applied and include certain amounts based on management's best estimates and judgments. Historical financial information elsewhere in this report is consistent with that in the financial statements.

In meeting its responsibility for the reliability of the financial information, management maintains a system of internal accounting and disclosure controls, including an internal audit program. The system of controls provides for appropriate division of responsibility and the application of written policies and procedures. That system, which undergoes continual reevaluation, is designed to provide reasonable assurance that assets are safeguarded, and records are adequate for the preparation of reliable financial data.

Management is responsible for establishing and maintaining adequate internal control over financial reporting. AMETEK, Inc. maintains a system of internal controls that is designed to provide reasonable assurance as to the fair and reliable preparation and presentation of the consolidated financial statements; however, there are inherent limitations in the effectiveness of any system of internal controls.

Management recognizes its responsibility for conducting the Company's activities according to the highest standards of personal and corporate conduct. That responsibility is characterized and reflected in a code of business conduct for all employees and in a financial code of ethics for the Chief Executive Officer and Senior Financial Officers, as well as in other key policy statements publicized throughout the Company.

The Audit Committee of the Board of Directors, which is composed solely of independent directors who are not employees of the Company, meets with the independent registered public accounting firm, the internal auditors and management to satisfy itself that each is properly discharging its responsibilities. The report of the Audit Committee is included in the Company's Proxy Statement for the 2025 Annual Meeting of Stockholders. Both the independent registered public accounting firm and the internal auditors have direct access to the Audit Committee.

The Company's independent registered public accounting firm, Ernst & Young LLP, is engaged to render an opinion as to whether management's financial statements present fairly, in all material respects, the Company's financial position and operating results. This report is included herein.

## Management's Report on Internal Control over Financial Reporting

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, AMETEK, Inc. conducted an evaluation of the effectiveness of the Company's internal control over financial reporting as of December 31, 2024 based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on that evaluation, our management concluded that the Company's internal control over financial reporting was effective as of December 31, 2024.

The Company acquired Virtek Vision International ("Virtek") in October 2024. As permitted by the U.S. Securities and Exchange Commission staff interpretative guidance for newly acquired businesses, the Company excluded Virtek from management's assessment of the effectiveness of the Company's internal control over financial reporting as of December 31, 2024. Virtek constituted 0.9% of total assets as of December 31, 2024 and 0.2% of net sales for the year then ended.

The Company's internal control over financial reporting as of December 31, 2024 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report, which is included herein.

/s/ DAVID A. ZAPICO

Chairman of the Board and Chief Executive Officer

February 20, 2025

/s/ DALIP M. PURI

Executive Vice President – Chief Financial Officer

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  
ON INTERNAL CONTROL OVER FINANCIAL REPORTING**

To the Shareholders and the Board of Directors of AMETEK, Inc.

**Opinion on Internal Control over Financial Reporting**

We have audited AMETEK, Inc.'s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, AMETEK, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria.

As indicated in the accompanying *Management's Report on Internal Control over Financial Reporting*, management's assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Virtek Vision International ("Virtek"), which are included in the 2024 consolidated financial statements of the Company and constituted 0.9% of total assets as of December 31, 2024 and 0.2% of net sales for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Virtek.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of AMETEK, Inc. as of December 31, 2024 and 2023, the related consolidated statements of income, comprehensive income, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated February 20, 2025 expressed an unqualified opinion thereon.

**Basis for Opinion**

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying *Management's Report on Internal Control over Financial Reporting*. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

**Definition and Limitations of Internal Control Over Financial Reporting**

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ ERNST & YOUNG LLP  
Philadelphia, Pennsylvania  
February 20, 2025

## REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of AMETEK, Inc.:

### Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of AMETEK, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of income, comprehensive income, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 20, 2025 expressed an unqualified opinion thereon.

### Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

### Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.

***Impairment Assessment of Indefinite-Lived Intangible Assets (other than Goodwill)***

***Description of the Matter***

At December 31, 2024, the Company's indefinite-lived intangible assets (other than goodwill) totaled \$1,023.3 million, consisting of trademarks and trade names. As described in Note 1 to the consolidated financial statements, indefinite-lived intangible assets are not amortized but are tested for impairment at least annually in the Company's fourth quarter.

Auditing management's indefinite-lived intangible asset impairment tests was complex and highly judgmental due to the significant measurement uncertainty in estimating the fair value of the trademarks and trade names. In particular, the fair value estimates were sensitive to significant assumptions such as discount rate, forecasted revenues and royalty rates, which are affected by expectations about future market or economic conditions.

***How We Addressed the Matter in Our Audit***

We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company's indefinite-lived intangible asset impairment process. For example, we tested controls over management's review of the valuation models and significant assumptions, including forecasted financial information, as well as management's controls to validate that the data used in the valuations was complete and accurate.

To test the estimated fair value of the Company's indefinite-lived intangible assets, we performed audit procedures that included, among others, assessing the fair value methodologies utilized by management and the significant assumptions discussed above, including the underlying data used in the analyses. For example, when evaluating the significant assumptions, we compared them to current financial and operating plans, market and industry studies, historical trends, and royalty rates used in prior periods. We also assessed the historical accuracy of management's forecasts and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value estimates of the trademarks and trade names that would result from changes in the assumptions. We involved our valuation specialists to assist in evaluating the discount rate, royalty rate and valuation methodologies used by the Company.

***Estimating the Fair Value of the Intangibles from the Acquisition of Paragon Medical***

***Description of the Matter***

As described in Note 6 to the consolidated financial statements, the Company completed the acquisition of Paragon Medical in December 2023 for consideration of \$1.9 billion, net of cash acquired. The preliminary estimates of the fair value of intangible assets made as of the acquisition date were revised during the measurement period in 2024 as the third-party valuation was received and finalized. This third-party valuation resulted in adjustments to the preliminary estimates of the fair value of the intangible assets for the indefinite-lived trade name, customer relationships, and purchased technology. As of December 31, 2024, the purchase price allocated to intangible assets (other than goodwill) was \$852.3 million.

Auditing the Company's accounting for its acquisition of Paragon Medical was complex due to the significant estimation uncertainty, particularly in estimating the fair values of the customer relationships and the trade name intangible assets. The Company used the multi-period excess earnings method to value the customer relationship intangible asset and relief from royalty method to value the trade name intangible asset. The significant assumptions used to estimate the fair value of customer relationships included the forecasted revenue growth, forecasted EBITDA margin and discount rate. The significant assumptions used to estimate the fair value of the trade name included the forecasted revenue growth and royalty rate. All of these significant assumptions are affected by expectations about future market or economic conditions.

*How We Addressed the Matter in Our Audit* We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company's estimation of the fair value of the material acquired intangible assets of Paragon Medical. For example, we tested controls over the valuation of acquired identifiable intangible assets, including controls over management's review of the valuation models and the significant assumptions described above, review of forecasted financial information, as well as verification of underlying data used in the analyses.

To test the estimated fair value of the customer relationship and trade name intangible assets for Paragon Medical, we performed audit procedures that included, among others, assessing the fair value methodologies utilized by management and the significant assumptions discussed above, including the accuracy of the underlying data used in the analyses. For example, when evaluating the significant assumptions, we compared them to current financial and operating plans, market and industry studies, and historical trends. We also performed sensitivity analyses to evaluate the changes in the fair value of the customer relationship and trade name intangible assets that would result from changes in the significant assumptions. We involved our valuation specialists to assist in evaluating the discount rate, royalty rate and valuation methodologies used by the Company.

/s/ ERNST & YOUNG LLP

We have served as the Company's auditor since 1930.

Philadelphia, Pennsylvania

February 20, 2025

**AMETEK, Inc.**  
**Consolidated Statement of Income**  
(In thousands, except per share amounts)

	Year Ended December 31,		
	2024	2023	2022
<b>Net sales</b>	<b>\$ 6,941,180</b>	<b>\$ 6,596,950</b>	<b>\$ 6,150,530</b>
Cost of sales	4,464,713	4,212,485	4,005,261
Selling, general and administrative	696,905	677,006	644,577
Total operating expenses	5,161,618	4,889,491	4,649,838
<b>Operating income</b>	<b>1,779,562</b>	<b>1,707,459</b>	<b>1,500,692</b>
Interest expense	( 112,962 )	( 81,795 )	( 83,186 )
Other (expense) income, net	( 5,061 )	( 19,252 )	11,186
Income before income taxes	1,661,539	1,606,412	1,428,692
Provision for income taxes	285,415	293,224	269,150
<b>Net income</b>	<b>\$ 1,376,124</b>	<b>\$ 1,313,188</b>	<b>\$ 1,159,542</b>
Basic earnings per share	\$ 5.95	\$ 5.70	\$ 5.04
<b>Diluted earnings per share</b>	<b>\$ 5.93</b>	<b>\$ 5.67</b>	<b>\$ 5.01</b>
Weighted average common shares outstanding:			
Basic shares	231,256	230,519	230,208
Diluted shares	232,168	231,509	231,536

See accompanying notes.

**AMETEK, Inc.**  
**Consolidated Statement of Comprehensive Income**  
(In thousands)

	Year Ended December 31,		
	2024	2023	2022
<b>Net income</b>	<b>\$ 1,376,124</b>	<b>\$ 1,313,188</b>	<b>\$ 1,159,542</b>
<b>Other comprehensive income (loss):</b>			
Amounts arising during the period – gains (losses), net of tax (expense) benefit:			
Foreign currency translation:			
Translation adjustments	( 124,959 )	88,613	( 123,756 )
Change in long-term intercompany notes	( 2,748 )	5,420	( 21,419 )
Net investment hedge instruments gain (loss), net of tax of \$( 11,207 ), \$ 8,058 and \$( 17,070 ) in 2024, 2023 and 2022, respectively	34,409	( 24,744 )	52,416
Defined benefit pension plans:			
Net actuarial gain (loss), net of tax of \$( 4,936 ), \$( 3,396 ) and \$ 4,769 in 2024, 2023 and 2022, respectively	15,145	11,869	( 18,238 )
Amortization of net actuarial loss, net of tax of \$( 2,341 ), \$( 2,801 ) and \$( 2,111 ) in 2024, 2023 and 2022, respectively	7,278	8,769	6,420
Amortization of prior service costs, net of tax of \$( 26 ), \$( 25 ) and \$( 25 ) in 2024, 2023 and 2022, respectively	78	76	76
<b>Other comprehensive (loss) income</b>	<b>( 70,797 )</b>	<b>90,003</b>	<b>( 104,501 )</b>
<b>Total comprehensive income</b>	<b>\$ 1,305,327</b>	<b>\$ 1,403,191</b>	<b>\$ 1,055,041</b>

See accompanying notes.



**AMETEK, Inc.**  
**Consolidated Balance Sheet**  
(In thousands, except share amounts)

	December 31,	
	2024	2023
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 373,999	\$ 409,804
Receivables	948,830	1,012,932
Inventories, net	1,021,713	1,132,471
Other current assets	258,490	269,461
Total current assets	2,603,032	2,824,668
Property, plant and equipment, net	818,611	891,293
Right of use assets, net	235,666	229,723
Goodwill	6,555,877	6,447,629
Other intangibles, net	3,915,173	4,165,317
Investments and other assets	502,810	464,903
Total assets	<u>\$ 14,631,169</u>	<u>\$ 15,023,533</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Short-term borrowings and current portion of long-term debt, net	\$ 654,346	\$ 1,417,915
Accounts payable	523,332	516,588
Customer advanced payments	363,555	375,513
Income taxes payable	84,428	69,567
Accrued liabilities and other	472,926	502,990
Total current liabilities	2,098,587	2,882,573
Long-term debt, net	1,425,375	1,895,432
Deferred income taxes	831,030	836,695
Other long-term liabilities	620,873	678,642
Total liabilities	4,975,865	6,293,342
Stockholders' equity:		
Preferred stock, \$ 0.01 par value; authorized 5,000,000 shares; none issued	—	—
Common stock, \$ 0.01 par value; authorized 800,000,000 shares; issued: 2024 – 270,064,222 shares; 2023 – 269,284,250 shares	2,720	2,709
Capital in excess of par value	1,264,670	1,168,694
Retained earnings	11,057,684	9,940,343
Accumulated other comprehensive loss	( 555,739 )	( 484,942 )
Treasury stock: 2024 – 39,364,801 shares; 2023 – 38,354,154 shares	( 2,114,031 )	( 1,896,613 )
Total stockholders' equity	9,655,304	8,730,191
Total liabilities and stockholders' equity	<u>\$ 14,631,169</u>	<u>\$ 15,023,533</u>

See accompanying notes.

**AMETEK, Inc.**  
**Consolidated Statement of Stockholders' Equity**  
(In thousands)

	Year Ended December 31,		
	2024	2023	2022
<b>Capital stock</b>			
Preferred stock, \$ 0.01 par value	\$ —	\$ —	\$ —
Common stock, \$ 0.01 par value			
Balance at the beginning of the year	2,709	2,700	2,689
Shares issued	11	9	11
Balance at the end of the year	2,720	2,709	2,700
<b>Capital in excess of par value</b>			
Balance at the beginning of the year	1,168,694	1,094,236	1,012,526
Issuance of common stock under employee stock plans	48,113	28,259	34,335
Share-based compensation costs	47,863	46,199	47,375
Balance at the end of the year	1,264,670	1,168,694	1,094,236
<b>Retained earnings</b>			
Balance at the beginning of the year	9,940,343	8,857,485	7,900,113
Net income	1,376,124	1,313,188	1,159,542
Cash dividends paid	( 258,782 )	( 230,329 )	( 202,169 )
Other	( 1 )	( 1 )	( 1 )
Balance at the end of the year	11,057,684	9,940,343	8,857,485
<b>Accumulated other comprehensive (loss) income</b>			
Foreign currency translation:			
Balance at the beginning of the year	( 298,835 )	( 368,124 )	( 275,365 )
Translation adjustments	( 124,959 )	88,613	( 123,756 )
Change in long-term intercompany notes	( 2,748 )	5,420	( 21,419 )
Net investment hedge instruments (loss) gain, net of tax of \$( 11,207 ), \$ 8,058 and \$( 17,070 ) in 2024, 2023 and 2022, respectively	34,409	( 24,744 )	52,416
Balance at the end of the year	( 392,133 )	( 298,835 )	( 368,124 )
Defined benefit pension plans:			
Balance at the beginning of the year	( 186,107 )	( 206,821 )	( 195,079 )
Net actuarial gain (loss), net of tax of \$( 4,936 ), \$( 3,396 ) and \$ 4,769 in 2024, 2023 and 2022, respectively	15,145	11,869	( 18,238 )
Amortization of net actuarial loss, net of tax of \$( 2,341 ), \$( 2,801 ) and \$( 2,111 ) in 2024, 2023 and 2022, respectively	7,278	8,769	6,420
Amortization of prior service costs, net of tax of \$( 26 ), \$( 25 ) and \$( 25 ) in 2024, 2023 and 2022, respectively	78	76	76
Balance at the end of the year	( 163,606 )	( 186,107 )	( 206,821 )
Accumulated other comprehensive loss at the end of the year	( 555,739 )	( 484,942 )	( 574,945 )
<b>Treasury stock</b>			
Balance at the beginning of the year	( 1,896,613 )	( 1,902,964 )	( 1,573,000 )
Issuance of common stock under employee stock plans	5,654	14,123	2,857
Purchase of treasury stock	( 223,072 )	( 7,772 )	( 332,821 )
Balance at the end of the year	( 2,114,031 )	( 1,896,613 )	( 1,902,964 )
<b>Total stockholders' equity</b>	<b>\$ 9,655,304</b>	<b>\$ 8,730,191</b>	<b>\$ 7,476,512</b>

See accompanying notes.

**AMETEK, Inc.**  
**Consolidated Statement of Cash Flows**  
(In thousands)

	Year Ended December 31,		
	2024	2023	2022
<b>Cash provided by (used for):</b>			
<b>Operating activities:</b>			
Net income	\$ 1,376,124	\$ 1,313,188	\$ 1,159,542
Adjustments to reconcile net income to total operating activities:			
Depreciation and amortization	382,927	337,636	319,427
Deferred income taxes	(12,943)	(91,903)	(67,818)
Share-based compensation expense	47,863	46,199	47,375
Gain on sale of business/investment	—	—	(3,584)
Gain on sale of facilities	(995)	(120)	(7,054)
Changes in assets and liabilities, net of acquisitions:			
Decrease (increase) in receivables	53,488	8,451	(86,713)
Decrease (increase) in inventories and other current assets	72,997	56,619	(322,467)
(Decrease) increase in payables, accruals and income taxes	(18,480)	10,433	95,481
(Decrease) increase in other long-term liabilities	(41,332)	67,283	47,226
Pension contributions	(8,694)	(8,671)	(8,959)
Other, net	(22,107)	(3,819)	(23,083)
Total operating activities	1,828,848	1,735,296	1,149,373
<b>Investing activities:</b>			
Additions to property, plant and equipment	(127,075)	(136,249)	(139,005)
Purchases of businesses, net of cash acquired	(117,514)	(2,237,910)	(429,714)
Proceeds from sale of business/investment	—	—	3,734
Proceeds from sale of facilities	4,246	880	11,754
Other, net	(4,465)	(3,151)	471
Total investing activities	(244,808)	(2,376,430)	(552,760)
<b>Financing activities:</b>			
Net change in short-term borrowings	(889,737)	892,282	(73,691)
Repayments of long-term borrowings	(300,000)	—	—
Repurchases of common stock	(212,027)	(7,772)	(332,821)
Cash dividends paid	(258,782)	(230,329)	(202,169)
Proceeds from stock option exercises	66,868	50,850	49,937
Other, net	(8,776)	(7,748)	(16,955)
Total financing activities	(1,602,454)	697,283	(575,699)
Effect of exchange rate changes on cash and cash equivalents	(17,391)	8,269	(22,300)
(Decrease) increase in cash and cash equivalents	(35,805)	64,418	(1,386)
<b>Cash and cash equivalents:</b>			
Beginning of year	409,804	345,386	346,772
End of year	\$ 373,999	\$ 409,804	\$ 345,386

See accompanying notes.

**AMETEK, Inc.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**1. Significant Accounting Policies**

*Basis of Consolidation*

The accompanying consolidated financial statements reflect the results of operations, financial position and cash flows of AMETEK, Inc. (the "Company"), and include the accounts of the Company and subsidiaries, after elimination of all intercompany transactions in the consolidation.

*Use of Estimates*

The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates and assumptions.

*Cash Equivalents, Securities and Other Investments*

All highly liquid investments with maturities of three months or less when purchased are considered cash equivalents.

*Accounts Receivable*

The Company maintains allowances for estimated credit losses resulting from the inability of customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses, on all accounts receivable and contract assets, which considers risk of future credit losses based on factors such as historical experience, contract terms, as well as general and market business conditions, country, and political risk. Balances are written off when considered uncollectible. The following table provides a roll forward of the allowance for estimated credit losses:

	2024	2023
	(in thousands)	
Balance at January 1	\$ 13,167	\$ 14,102
Bad debt expense	2,546	3,984
Amounts written off charged against allowance	( 2,506 )	( 4,908 )
Foreign currency translation and other	( 175 )	( 11 )
Balance at December 31	<u>\$ 13,032</u>	<u>\$ 13,167</u>

*Inventories*

The Company predominantly uses the first-in, first-out ("FIFO") method of inventory accounting, which approximates current replacement cost, at December 31, 2024. The last-in, first-out ("LIFO") method of accounting is used to determine cost for 10 % of the Company's inventory at December 31, 2024. For inventories where cost is determined by the LIFO method, the FIFO value would have been \$ 40.8 million and \$ 39.0 million higher than the LIFO value reported in the consolidated balance sheet at December 31, 2024 and 2023, respectively. The Company provides estimated inventory reserves for slow-moving and obsolete inventory based on current assessments about future demand, market conditions, customers who may be experiencing financial difficulties and related management initiatives.

*Business Combinations*

The Company allocates the purchase price of an acquired company, including when applicable, the acquisition date fair value of contingent consideration between tangible and intangible assets acquired and liabilities assumed from the acquired business based on their estimated fair values, with the residual of the purchase price

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

recorded as goodwill. The results of operations of the acquired business are included in the Company's operating results from the date of acquisition.

*Property, Plant and Equipment*

Property, plant and equipment are stated at cost. Expenditures for additions to plant facilities, or that extend their useful lives, are capitalized. The cost of minor tools, jigs and dies, and maintenance and repairs is charged to expense as incurred. Depreciation of plant and equipment is calculated principally on a straight-line basis over the estimated useful lives of the related assets. The range of lives for depreciable assets is generally three to 10 years for machinery and equipment, five to 27 years for leasehold improvements and 25 to 50 years for buildings. Depreciation expense was \$ 135.3 million, \$ 122.5 million and \$ 113.7 million for the years ended December 31, 2024, 2023, and 2022, respectively.

*Goodwill and Other Intangible Assets*

Goodwill and other intangible assets with indefinite lives, primarily trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually.

The Company identifies its reporting units at the component level, which is one level below its operating segments. Generally, goodwill arises from acquisitions of specific operating companies and is assigned to the reporting unit in which the operating company resides. The Company's reporting units are divisions that are one level below its operating segments and for which discrete financial information is prepared and regularly reviewed by segment management.

The Company principally relies on a discounted cash flow analysis to determine the fair value of each reporting unit, which considers cash flows discounted at an appropriate discount rate. The Company believes that market participants would use a discounted cash flow analysis to determine the fair value of its reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization and working capital requirements, which are based on the Company's long-range plan and are considered level 3 inputs. The Company's long-range plan is updated as part of its annual planning process and is reviewed and approved by management. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both equity and debt, including a risk premium.

The impairment test for indefinite-lived intangibles other than goodwill (primarily trademarks and trade names) consists of a comparison of the estimated fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method using level 3 inputs for revenue growth rates and royalty rates. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such trademarks and trade names and not having to pay a royalty for their use.

The Company completed its required annual impairment tests as of October 1, 2024, 2023, and 2022 and determined that the carrying values of the Company's goodwill were not impaired. The Company completed its required annual indefinite-lived intangibles impairment test as of October 1, 2024 and determined that the carrying values of the Company's trademarks and trade names with indefinite lives were not impaired. The Company completed its required annual impairment test in the fourth quarter of 2023 and 2022 and determined that the carrying values of certain of the Company's trademarks and trade names with indefinite lives were impaired and as a result, during the fourth quarter of 2023 and 2022, the Company recorded an immaterial non-cash impairment charge related to certain of the Company's trade names.

Other intangible assets with finite lives are evaluated for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. The carrying value of other intangible assets with finite lives is considered impaired when the total projected undiscounted cash flows from the asset group are less than the carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

the fair value of those assets. Fair value is determined primarily using present value techniques based on projected cash flows from the asset group.

Intangible assets, other than goodwill, with definite lives are amortized over their estimated useful lives. Patents and technology are being amortized over useful lives of nine to 20 years, with a weighted average life of 15 years. Customer relationships are being amortized over a period of ten to 20 years, with a weighted average life of 20 years. On a quarterly basis, the Company evaluates the reasonableness of the estimated useful lives of these intangible assets.

*Financial Instruments and Foreign Currency Translation*

Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Exchange gains and losses from those transactions are included in operating results for the year.

The Company makes infrequent use of derivative financial instruments. Forward contracts are primarily entered into from time to time to hedge debt or foreign currency transactions, thereby minimizing the Company's exposure to foreign currency fluctuation.

In instances where transactions are designated as hedges of an underlying item, the gains and losses on those transactions are included in accumulated other comprehensive income within stockholders' equity to the extent they are effective as hedges. An evaluation of hedge effectiveness is performed by the Company at inception and on an ongoing basis and any changes in the hedge are made as appropriate.

*Leases*

The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. The Company has lease agreements which include lease and non-lease components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized when the obligation is probable.

Operating leases are included in right-of-use ("ROU") assets, accrued liabilities and other, and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term. The Company primarily leases buildings (real estate) and automobiles which are classified as operating leases.

The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company's leases as the reasonably certain threshold is not met.

Lease payments included in the measurement of the lease liability are comprised of fixed and variable payments that depend on an index or rate.

Variable lease payments not dependent on a rate or index associated with the Company's leases are recognized when the events, activities, or circumstances in the lease agreement on which those payments are assessed are probable. Variable lease payments are presented as operating expense in the Company's income statement in the same line item as expense arising from fixed lease payments. Cash used in operations for operating leases is not materially different than total lease costs.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

*Revenue Recognition*

Revenue is derived from sales of products and services. The Company's products and services are marketed and sold worldwide through two operating groups: EIG and EMG. See Note 15 *Descriptive Information about Reportable Segments*.

The majority of the Company's revenues on product sales were recognized at a point in time when the customer obtains control of the product. The transfer in control of the product to the customer was typically evidenced by one or more of the following: the customer having legal title to the product, the Company's present right to payment, the customer's physical possession of the product, the customer accepting the product, or the customer having the benefits of ownership or risk of loss. For a small percentage of sales where title and risk of loss transfers at the point of delivery, the Company recognized revenue upon delivery to the customer, which is the point that control transferred, assuming all other criteria for revenue recognition were met.

The Company determined that revenues from certain of its customer contracts met the criteria of satisfying its performance obligations over time, primarily in the areas of the manufacture of custom-made equipment and for service repairs of customer-owned equipment. Recognizing revenue over time for custom-manufactured equipment is based on the Company's judgment that, in certain contracts, the product does not have an alternative use and the Company has an enforceable right to payment for performance completed to date.

The Company recognizes incremental cost of obtaining contracts as an expense when incurred if the amortization period of the contract cost assets that the Company would have otherwise recognized is one year or less. These costs are included in Selling, general and administrative expenses in the consolidated statement of income.

The determination of the revenue to be recognized in each period for performance obligations satisfied over time is based on the input method. The Company recognizes revenue over time as it performs on these contracts because the transfer of control to the customer occurs over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation. The Company generally uses the total cost-to-cost input method of progress because it best depicts the transfer of control to the customer that occurs as costs are incurred. Under the cost-to-cost method, the extent of progress towards completion is measured based on the proportion of costs incurred to date to the total estimated costs at completion of the performance obligation. On certain contracts, labor hours are used as the measure of progress when it is determined to be a better depiction of the transfer of control to the customer due to the timing and pattern of labor hours incurred.

Performance obligations also include post-delivery service, installation and training. Post-delivery service revenues are recognized over the contract term. Installation and training revenues are recognized over the period the service is provided. Warranty terms in customer contracts can also be considered separate performance obligations if the warranty provides services beyond assurance that a product complies with agreed-upon specification or if a warranty can be purchased separately. The Company does not incur significant obligations for customer returns and refunds.

The Company has certain contracts with variable consideration in the form of volume discounts, rebates and early payment options, which may affect the transaction price used as the basis for revenue recognition.

Payment terms generally begin upon shipment of the product. The Company does have contracts with multiple billing terms that are all due within one year from when the product is delivered. No significant financing component exists. Payment terms are generally 30-60 days from the time of shipment or customer acceptance, but terms can be shorter or longer, not exceeding one year. For customer contracts that have revenue recognized over time, revenue is generally recognized prior to a payment being due from the customer. In such cases, the Company recognizes a contract asset at the time the revenue is recognized. When payment becomes due based on the contract terms, the Company reduces the contract asset and records a receivable. In contracts with billing milestones or in other instances with a long production cycle or concerns about credit, customer advance payments are received. The

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Company may receive a payment in excess of revenue recognized to that date. In these circumstances, a contract liability is recorded. Contract liabilities are derecognized when the performance obligations are satisfied, and revenue is recognized.

*Research and Development*

Research and development costs are included in Cost of sales as incurred and were \$ 236.6 million in 2024, \$ 220.8 million in 2023 and \$ 198.8 million in 2022.

*Shipping and Handling Costs*

Shipping and handling costs are included in Cost of sales and were \$ 87.6 million in 2024, \$ 77.9 million in 2023 and \$ 103.7 million in 2022.

*Share-Based Compensation*

The Company expenses the fair value of share-based awards made under its share-based plans in the consolidated financial statements over their requisite service period of the grants.

*Income Taxes*

The Company conducts a broad range of operations around the world and is therefore subject to complex tax regulations in numerous international taxing jurisdictions, resulting at times in tax audits, disputes and potential litigation, the outcome of which is uncertain. Management must make judgments currently about such uncertainties and determine estimates of the Company's tax assets and liabilities. To the extent the final outcome differs, future adjustments to the Company's tax assets and liabilities may be necessary.

The Company assesses the realizability of its deferred tax assets, taking into consideration the Company's forecast of future taxable income, available net operating loss carryforwards and available tax planning strategies that could be implemented to realize the deferred tax assets. Based on this assessment, management must evaluate the need for, and amount of, valuation allowances against the Company's deferred tax assets.

The Company assesses the uncertainty in its tax positions, by applying a minimum recognition threshold which a tax position is required to meet before a tax benefit is recognized in the financial statements. Once the minimum threshold is met, using a more likely than not standard, a series of probability estimates is made for each item to properly measure and record a tax benefit. The tax benefit recorded is generally equal to the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination. The underlying probabilities are determined based on the best available objective evidence such as recent tax audit outcomes, published guidance, external expert opinion, or by analogy to the outcome of similar issues in the past. There can be no assurance that these estimates will ultimately be realized given continuous changes in tax policy, legislation and audit practice. The Company recognizes interest and penalties accrued related to uncertain tax positions in income tax expense.

*Pensions*

The Company has U.S. and foreign defined benefit and defined contribution pension plans. The key assumptions in determining the Company's pension income or expense are the assumed pension liability discount rate and the expected return on plan assets. All unrecognized prior service costs, remaining transition obligations or assets and actuarial gains and losses have been recognized, net of tax effects, as a charge to accumulated other comprehensive income in stockholders' equity and will be amortized as a component of net periodic pension cost. The Company uses a measurement date of December 31 (its fiscal year end) for its U.S. and foreign defined benefit plans.



AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

### Earnings Per Share

The calculation of basic earnings per share is based on the weighted average number of common shares considered outstanding during the periods. The calculation of diluted earnings per share reflects the effect of all potentially dilutive securities (principally outstanding stock options and restricted stock grants). The number of weighted average shares used in the calculation of basic earnings per share and diluted earnings per share was as follows for the years ended December 31:

	2024	2023	2022
	(In thousands)		
Weighted average shares:			
Basic shares	231,256	230,519	230,208
Equity-based compensation plans	912	990	1,328
Diluted shares	<u>232,168</u>	<u>231,509</u>	<u>231,536</u>

The calculation of diluted earnings per share for 2022 excluded an immaterial number of stock options because the exercise prices of these stock options exceeded the average market price of the Company's common shares, and the effect of their inclusion would have been antidilutive. There were no antidilutive shares in 2024 and 2023.

## 2. Recent Accounting Pronouncements

### Recently Adopted Accounting Pronouncement

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which requires disclosure of significant segment expenses and other segment items on an annual and interim basis under ASC 280. The Company retrospectively adopted ASU 2023-07, effective December 31, 2024, and the adoption resulted in additional disclosures in the Reportable Segments footnote.

### Recent Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires additional disclosures about significant expenses included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Prospective or retrospective application is allowed and early adoption is permitted. The Company has not determined the impact ASU 2024-03 may have on the Company's financial statement disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which improves income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply its guidance prospectively with an option for retrospective application to each period in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company's financial statement disclosures.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

### 3. Revenues

The outstanding contract asset and liability accounts were as follows:

	2024	2023
	(In thousands)	
Contract assets – January 1	\$ 140,826	\$ 119,741
Contract assets – December 31	136,432	140,826
Change in contract assets – (decrease) increase	( 4,394 )	21,085
Contract liabilities – January 1	432,830	398,692
Contract liabilities – December 31	400,689	432,830
Change in contract liabilities – decrease (increase)	32,141	( 34,138 )
Net change	\$ 27,747	\$ ( 13,053 )

The net change in 2024 and 2023 was primarily driven by lower advance payments from customers on long term contracts. For the years ended December 31, 2024 and 2023, the Company recognized revenue of \$ 359 million and \$ 345 million, respectively, that was previously included in the beginning balance of contract liabilities.

Contract assets are reported as a component of Other current assets in the consolidated balance sheet. At December 31, 2024 and 2023, \$ 37.1 million and \$ 57.3 million, respectively, of Customer advanced payments (contract liabilities) were recorded in Other long-term liabilities in the consolidated balance sheet.

The remaining performance obligations exceeding one year as of December 31, 2024 and 2023 were \$ 541.8 million and \$ 607.5 million, respectively. Remaining performance obligations represent the transaction price of firm, non-cancelable orders, with expected delivery dates to customers greater than one year from the balance sheet date, for which the performance obligation is unsatisfied or partially unsatisfied. These performance obligations will be substantially satisfied within two to three years .

#### Geographic Areas

Net sales were attributed to geographic areas based on the location of the customer. Information about the Company's operations in different geographic areas was as follows for the year ended December 31:

	2024		
	EIG	EMG	Total
	(In thousands)		
United States	\$ 2,302,951	\$ 1,346,483	\$ 3,649,434
International <sup>(1)</sup> :			
United Kingdom	106,678	126,846	233,524
European Union countries	549,446	427,239	976,685
Asia	1,213,403	218,770	1,432,173
Other foreign countries	487,437	161,927	649,364
Total international	2,356,964	934,782	3,291,746
Consolidated net sales	\$ 4,659,915	\$ 2,281,265	\$ 6,941,180

(1) Includes U.S. export sales of \$ 1,880.8 million.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

	2023		
	EIG	EMG	Total
	(In thousands)		
United States	\$ 2,377,316	\$ 1,091,468	\$ 3,468,784
International <sup>(1)</sup> :			
United Kingdom	99,718	114,770	214,488
European Union countries	518,758	426,219	944,977
Asia	1,175,703	202,425	1,378,128
Other foreign countries	452,755	137,818	590,573
Total international	2,246,934	881,232	3,128,166
Consolidated net sales	\$ 4,624,250	\$ 1,972,700	\$ 6,596,950

(1) Includes U.S. export sales of \$ 1,732.4 million.

	2022		
	EIG	EMG	Total
	(In thousands)		
United States	\$ 2,171,684	\$ 982,579	\$ 3,154,263
International <sup>(1)</sup> :			
United Kingdom	92,668	117,788	210,456
European Union countries	510,052	420,756	930,808
Asia	1,050,843	266,011	1,316,854
Other foreign countries	404,106	134,043	538,149
Total international	2,057,669	938,598	2,996,267
Consolidated net sales	\$ 4,229,353	\$ 1,921,177	\$ 6,150,530

(1) Includes U.S. export sales of \$ 1,688.7 million

*Major Products and Services*

The Company's major products and services in the reportable segments were as follows for the year ended December 31:

	2024		
	EIG	EMG	Total
	(In thousands)		
Process and analytical instrumentation	\$ 3,232,918	\$ —	\$ 3,232,918
Aerospace and power	1,426,997	624,570	2,051,567
Automation and engineered solutions	—	1,656,695	1,656,695
Consolidated net sales	\$ 4,659,915	\$ 2,281,265	\$ 6,941,180

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

	2023		
	EIG	EMG	Total
	(In thousands)		
Process and analytical instrumentation	\$ 3,267,698	\$ —	\$ 3,267,698
Aerospace and power	1,356,552	588,446	1,944,998
Automation and engineered solutions	—	1,384,254	1,384,254
Consolidated net sales	<u>\$ 4,624,250</u>	<u>\$ 1,972,700</u>	<u>\$ 6,596,950</u>

	2022		
	EIG	EMG	Total
	(In thousands)		
Process and analytical instrumentation	\$ 3,061,263	\$ —	\$ 3,061,263
Aerospace and power	1,168,090	549,735	1,717,825
Automation and engineered solutions	—	1,371,442	1,371,442
Consolidated net sales	<u>\$ 4,229,353</u>	<u>\$ 1,921,177</u>	<u>\$ 6,150,530</u>

*Timing of Revenue Recognition*

The Company's timing of revenue recognition was as follows for the year ended December 31:

	2024		
	EIG	EMG	Total
	(In thousands)		
Products transferred at a point in time	\$ 3,739,209	\$ 2,052,862	\$ 5,792,071
Products and services transferred over time	920,706	228,403	1,149,109
Consolidated net sales	<u>\$ 4,659,915</u>	<u>\$ 2,281,265</u>	<u>\$ 6,941,180</u>

	2023		
	EIG	EMG	Total
	(In thousands)		
Products transferred at a point in time	\$ 3,831,321	\$ 1,772,329	\$ 5,603,650
Products and services transferred over time	792,929	200,371	993,300
Consolidated net sales	<u>\$ 4,624,250</u>	<u>\$ 1,972,700</u>	<u>\$ 6,596,950</u>

	2022		
	EIG	EMG	Total
	(In thousands)		
Products transferred at a point in time	\$ 3,471,118	\$ 1,680,558	\$ 5,151,676
Products and services transferred over time	758,235	240,619	998,854
Consolidated net sales	<u>\$ 4,229,353</u>	<u>\$ 1,921,177</u>	<u>\$ 6,150,530</u>

*Product Warranties*

The Company provides limited warranties in connection with the sale of its products. The warranty periods for products sold vary among the Company's operations, but the majority do not exceed one year. The Company calculates its warranty expense provision based on its historical warranty experience and adjustments are made

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

periodically to reflect actual warranty expenses. Product warranty obligations are reported as a component of Accrued liabilities and other in the consolidated balance sheet.

Changes in the accrued product warranty obligation were as follows:

	2024	2023	2022
	(In thousands)		
Balance at the beginning of the year	\$ 37,087	\$ 26,487	\$ 27,478
Accruals for warranties issued during the year	24,775	23,308	11,414
Settlements made during the year	( 22,953 )	( 14,219 )	( 11,835 )
Warranty accruals related to acquired businesses and other during the year	( 354 )	1,511	( 570 )
Balance at the end of the year	<u>\$ 38,555</u>	<u>\$ 37,087</u>	<u>\$ 26,487</u>

#### 4. Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. The Company utilizes a hierarchy for disclosure of the inputs to the valuations used to measure fair value. The hierarchy prioritizes the inputs into three broad levels as follows:

Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument

Level 3 - unobservable inputs based on the Company's own assumptions used to measure assets and liabilities at fair value

A financial asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

The following tables provide the Company's assets and liabilities that are measured at fair value on a recurring basis at December 31:

	2024			
	Total	Level 1	Level 2	Level 3
	(In thousands)			
Mutual fund investments	\$ 9,124	\$ 9,124	\$ —	\$ —
Foreign currency forward contracts	—	—	—	—

	2023			
	Total	Level 1	Level 2	Level 3
	(In thousands)			
Mutual fund investments	\$ 11,922	\$ 11,922	\$ —	\$ —
Foreign currency forward contracts	2,035	—	2,035	—

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The fair value of mutual fund investments is based on quoted market prices. The mutual fund investments are shown as a component of long-term assets in the consolidated balance sheet. For the years ended December 31, 2024 and 2023, gains and losses on the investments were not material.

#### *Foreign Currency*

At December 31, 2024, the Company had no forward contracts outstanding. At December 31, 2023, the Company had a Euro forward contract for a total notional value of 50.0 million Euros. Foreign currency forward contracts are valued as level 2 assets as they are corroborated by foreign currency exchange rates and shown as a component of other current assets in the consolidated balance sheet. For the year ended December 31, 2024 and 2023, realized gains and losses on foreign currency forward contracts were not significant. The Company does not typically designate its foreign currency forward contracts as accounting hedges.

#### *Financial Instruments*

Cash, cash equivalents and mutual fund investments are recorded at fair value at December 31, 2024 and 2023 in the consolidated balance sheet.

The fair value of short-term borrowings, net approximates the carrying value. The Company's long-term debt, net is all privately held with no public market for this debt, therefore, the fair value of long-term debt, net was computed based on comparable current market data for similar debt instruments and is considered to be a level 3 liability. At December 31, 2024 and 2023, the fair value of long-term debt (including current portion) was \$ 1,778.7 million and \$ 2,087.6 million and the recorded amount of long-term debt (including current portion) was \$ 1,851.9 million and \$ 2,197.5 million, respectively. See Note 10 for long-term debt principal amounts, interest rates and maturities.

### **5. Hedging Activities**

The Company has designated certain foreign-currency-denominated long-term borrowings as hedges of the net investment in certain foreign operations. As of December 31, 2024, and 2023, these net investment hedges included British-pound and Euro-denominated long-term debt. These borrowings were designed to create net investment hedges in each of the designated foreign subsidiaries. The Company designated the British-pound and Euro-denominated loans referred to above as hedging instruments to offset translation gains or losses on the net investment due to changes in the British pound and Euro exchange rates. These net investment hedges are evidenced by management's contemporaneous documentation supporting the hedge designation. Any gain or loss on the hedging instruments (the debt) following hedge designation is reported in accumulated other comprehensive income in the same manner as the translation adjustment on the hedged investment based on changes in the spot rate, which is used to measure hedge effectiveness.

At December 31, 2024 and 2023, the Company had \$ 281.7 million and \$ 286.6 million, respectively, of British-pound denominated loans, and \$ 595.2 million and \$ 580.8 million, respectively, in Euro-denominated loans, which were designated as a hedge against the net investment in Euro and British pound functional currency foreign subsidiaries. As a result of the British-pound and Euro-denominated loans being designated and 100 % effective as net investment hedges, \$ 45.6 million of pre-tax currency remeasurement gains and \$ 32.8 million of pre-tax currency remeasurement losses have been included in the foreign currency translation component of other comprehensive income for the years ended December 31, 2024 and 2023, respectively.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

## 6. Acquisitions

The Company spent \$ 117.5 million in cash, net of cash acquired to acquire Virtek Vision International ("Virtek") in October 2024. Virtek is a leading provider of advanced laser-based projection and inspection systems. Virtek is part of EIG.

The following table represents the allocation of the purchase price for the net assets of Virtek based on the estimated fair values at acquisition (in millions):

Goodwill	\$ 70.7
Other intangible assets	60.0
Deferred income taxes	( 15.9 )
Net working capital and other <sup>(1)</sup>	2.7
Total cash paid	<u>\$ 117.5</u>

(1) Includes \$ 6.6 million in accounts receivable, whose fair value, contractual cash flows and expected cash flows are approximately equal.

The amount allocated to goodwill is reflective of the benefits the Company expects to realize from the acquisitions. Virtek's advanced 3D laser projectors, smart cameras, and quality control inspection systems complement the Company's existing Creaform business capabilities.

At December 31, 2024, the purchase price allocated to other intangible assets of \$ 60.0 million consists of \$ 9.6 million of indefinite-lived intangible trade names, which are not subject to amortization. The remaining \$ 50.4 million of other intangible assets consists of \$ 40.8 million of customer relationships, which are being amortized over a period of 17 years and \$ 9.6 million of purchased technology, which is being amortized over a period of 17 years. Amortization expense for each of the next five years for the acquisitions is expected to be \$ 3.0 million per year.

The Virtek acquisition had an immaterial impact on reported net sales, net income, and diluted earnings per share for the year ended December 31, 2024. Had the acquisition been made at the beginning of 2024 or 2023, unaudited pro forma net sales, net income and diluted earnings per share for the year ended December 31, 2024 and 2023, would not have been materially different than the amounts reported. The Company has not finalized its measurements of certain tangible, intangible assets and liabilities and income taxes for the Virtek acquisition.

The Company finalized its measurements of certain tangible and intangible assets and liabilities for its August 2023 acquisition of United Electronic Industries and its October 2023 acquisition of Amplifier Research Corp, which had no material impact to the consolidated statement of income and balance sheet.

The Company finalized its measurements of certain tangible and intangible assets and liabilities, as well as income tax considerations, for the December 2023 Paragon Medical acquisition. The adjustments include an increase to goodwill of \$ 62.2 million, a decrease to fixed assets of \$ 42.4 million, and a decrease to intangibles of \$ 21.7 million. The final balances for Paragon Medical at December 31, 2024 were \$ 969.2 million of goodwill, \$ 169.0 million of fixed assets, and \$ 852.3 million of intangibles. There was no material impact to the consolidated statement of income.

In 2023, the Company spent \$ 2,237.9 million in cash, net of cash acquired, to acquire Paragon Medical ("Paragon") in December 2023, Amplifier Research Corp. ("Amplifier Research") in October 2023, United Electronic Industries ("UEI") in August 2023, and Bison Gear & Engineering Corp. ("Bison") in March 2023. Paragon is a leading provider of highly engineered medical components and instruments. Amplifier Research is a leading manufacturer of radio frequency and microwave amplifiers and electromagnetic compatibility testing equipment. Bison is a leading manufacturer of highly engineered motion control solutions serving diverse markets and applications. UEI is a leading provider of data acquisition and control solutions for the aerospace, defense,

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

energy and semiconductor industries. UEI and Amplifier Research are part of EIG. Paragon and Bison are part of EMG.

In 2022, the Company spent \$ 429.7 million in cash, net of cash acquired, to acquire Navitar, Inc. ("Navitar") in September 2022 and RTDS Technologies Inc. ("RTDS") in October 2022. Navitar is a market leader in the design, development and manufacturing of customized, fully integrated optical imaging systems, cameras, components and software. RTDS is a leading provider of real-time power simulation systems used by utilities, and research and education institutions in the development and testing of the electric power grid and renewable energy applications. Navitar and RTDS are part of EIG.

*Acquisition subsequent to December 31, 2024*

In January 2025, the Company acquired Kern Microtechnik ("Kern"), a leading manufacturer of high-precision machining and optical inspection solutions supporting a wide range of applications within the medical, semiconductor, research, and space markets. Kern has annual sales of approximately 50 million Euros. Kern will join EIG.

**7. Goodwill and Other Intangible Assets**

The changes in the carrying amounts of goodwill by segment were as follows:

	EIG	EMG	Total
	(In millions)		
Balance at December 31, 2022	\$ 4,236.1	\$ 1,136.5	\$ 5,372.6
Goodwill acquired	79.3	932.4	1,011.7
Purchase price allocation adjustments and other	24.8	—	24.8
Foreign currency translation adjustments	24.8	13.7	38.5
Balance at December 31, 2023	4,365.0	2,082.6	6,447.6
Goodwill acquired	70.7	—	70.7
Purchase price allocation adjustments and other	30.7	61.7	92.4
Foreign currency translation adjustments	( 41.5 )	( 13.3 )	( 54.8 )
Balance at December 31, 2024	<u>\$ 4,424.9</u>	<u>\$ 2,131.0</u>	<u>\$ 6,555.9</u>



AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Other intangible assets were as follows at December 31:

	2024	2023
	(In thousands)	
Definite-lived intangible assets (subject to amortization):		
Patents	\$ 46,043	\$ 47,239
Purchased technology	815,088	914,100
Customer lists	3,823,907	3,743,457
	<u>4,685,038</u>	<u>4,704,796</u>
Accumulated amortization:		
Patents	( 37,977 )	( 38,105 )
Purchased technology	( 378,102 )	( 334,229 )
Customer lists	( 1,377,094 )	( 1,190,906 )
	<u>( 1,793,173 )</u>	<u>( 1,563,240 )</u>
Net intangible assets subject to amortization	<u>2,891,865</u>	<u>3,141,556</u>
Indefinite-lived intangible assets (not subject to amortization):		
Trademarks and trade names	1,023,308	1,023,761
	<u>\$ 3,915,173</u>	<u>\$ 4,165,317</u>

Amortization expense was \$ 247.7 million, \$ 215.1 million, and \$ 205.8 million for the years ended December 31, 2024, 2023 and 2022, respectively. Amortization expense for each of the next five years is expected to approximate \$ 256 million per year, not considering the impact of potential future acquisitions.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

**8. Other Consolidated Balance Sheet Information**

	December 31,	
	2024	2023
	(In thousands)	
<b>INVENTORIES, NET</b>		
Finished goods and parts	\$ 80,491	\$ 136,003
Work in process	171,084	165,914
Raw materials and purchased parts	770,138	830,554
	<u>\$ 1,021,713</u>	<u>\$ 1,132,471</u>
<b>PROPERTY, PLANT AND EQUIPMENT, NET</b>		
Land	\$ 67,640	\$ 67,195
Buildings	449,314	455,015
Machinery and equipment	1,443,288	1,479,702
	<u>1,960,242</u>	<u>2,001,912</u>
Less: Accumulated depreciation	<u>( 1,141,631 )</u>	<u>( 1,110,619 )</u>
	<u>\$ 818,611</u>	<u>\$ 891,293</u>
<b>ACCRUED LIABILITIES AND OTHER</b>		
Employee compensation and benefits	\$ 202,605	\$ 228,389
Product warranty obligation	38,555	37,087
Realignment	55,175	41,540
Short term lease liability	54,736	61,055
Other	121,855	134,919
	<u>\$ 472,926</u>	<u>\$ 502,990</u>

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

## 9. Income Taxes

The components of income before income taxes and the details of the provision for income taxes were as follows for the years ended December 31:

	2024	2023	2022
	(In thousands)		
Income before income taxes:			
Domestic	\$ 991,681	\$ 1,026,113	\$ 893,478
Foreign	669,858	580,299	535,214
Total	<u>\$ 1,661,539</u>	<u>\$ 1,606,412</u>	<u>\$ 1,428,692</u>
Provision for income taxes:			
Current:			
Federal	\$ 120,367	\$ 206,477	\$ 183,619
Foreign	155,055	144,476	119,148
State	22,936	34,173	34,201
Total current	<u>298,358</u>	<u>385,126</u>	<u>336,968</u>
Deferred:			
Federal	( 437 )	( 69,956 )	( 37,810 )
Foreign	( 14,317 )	( 15,113 )	( 20,818 )
State	1,811	( 6,833 )	( 9,190 )
Total deferred	<u>( 12,943 )</u>	<u>( 91,902 )</u>	<u>( 67,818 )</u>
Total provision	<u>\$ 285,415</u>	<u>\$ 293,224</u>	<u>\$ 269,150</u>

Significant components of the deferred tax (asset) liability were as follows at December 31:

	2024	2023
	(In thousands)	
Non-current deferred tax (asset) liability:		
Differences in basis of property and accelerated depreciation <sup>(1)</sup>	\$ 49,513	\$ 63,447
Reserves not currently deductible	( 117,420 )	( 130,761 )
Pensions	89,508	75,834
Differences in basis of intangible assets and accelerated amortization	849,768	880,666
Net operating loss carryforwards	( 116,611 )	( 109,065 )
Share-based compensation	( 14,614 )	( 14,296 )
Foreign Tax Credit Carryforwards	( 2,840 )	( 9,327 )
Unremitted earnings	13,906	15,033
Other	( 19,626 )	( 25,893 )
	<u>731,584</u>	<u>745,638</u>
Less: Valuation allowance	21,305	16,766
	<u>752,889</u>	<u>762,404</u>
Portion included in non-current assets	78,141	74,291
Gross non-current deferred tax liability	<u>\$ 831,030</u>	<u>\$ 836,695</u>

(1) Presented net of deferred tax assets of approximately \$ 48.8 million and \$ 49.6 million at December 31, 2024 and 2023, respectively, resulting from lease obligations.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The Company's effective tax rate reconciles to the U.S. Federal statutory rate as follows for the years ended December 31:

	2024	2023	2022
U.S. Federal statutory rate	21.0 %	21.0 %	21.0 %
State income taxes, net of federal income tax benefit	1.4	1.3	1.6
Foreign operations, net	0.5	0.4	( 1.0 )
U.S. Benefits for Manufacturing, Export and credits	( 3.4 )	( 3.2 )	( 2.9 )
Uncertain Tax Items	( 1.9 )	1.0	1.0
Stock compensation	( 0.5 )	( 0.6 )	( 0.9 )
U.S. Tax / (Benefit) on Foreign Earnings	( 0.3 )	( 2.0 )	( 0.5 )
Other	0.4	0.4	0.5
Consolidated effective tax rate	<u>17.2 %</u>	<u>18.3 %</u>	<u>18.8 %</u>

The Company elected to pay the cash tax cost of the one-time mandatory tax on previously deferred earnings of non-U.S. subsidiaries over an eight-year period. As of December 31, 2024, the Company has a remaining cash tax obligation of \$ 27.4 million, \$ 15.2 million of which is classified as non-current.

The Company has evaluated the impact of the global intangible low-taxed income ("GILTI") section of the Tax Act and has made a tax accounting policy election to record the annual tax cost of GILTI as a current period expense when incurred and, as such, will not be measuring an impact of GILTI in its determination of deferred taxes.

As a result of the one-time mandatory deemed repatriation and the taxable inclusions under the GILTI provisions of the Tax Act, the Company has approximately \$ 1.4 billion in previously taxed income ("PTI") as of December 31, 2024 which can be repatriated without incremental U.S. Federal tax. The Company intends to reinvest its earnings indefinitely in operations outside the United States except to the extent of the PTI. There has been no provision for U.S. deferred income taxes for the undistributed earnings over PTI of approximately \$ 235.8 million and \$ 385.4 million at December 31, 2024 and 2023 respectively because determination of the amount of the unrecognized deferred income tax liability on these undistributed earnings is not practicable.

As of December 31, 2024, and 2023, the Company recorded deferred income taxes totaling \$ 13.9 million and \$ 15.0 million respectively in state income and foreign withholding taxes expected to be incurred when the cash amounts related to the previously taxed income are ultimately repatriated to the U.S.

The Company is acquisitive and at times acquires entities with tax attributes (net operating losses or tax credits) that carry over to post-acquisition tax periods of the Company. At December 31, 2024, the Company had tax effected benefits, net of uncertain tax positions of \$ 116.6 million related to net operating loss carryforwards, which will be available to offset future income taxes payable, subject to certain annual or other limitations based on foreign and U.S. tax laws. This amount includes net operating loss carryforwards of \$ 0.2 million for federal income tax purposes with no valuation allowance for the U.S. consolidated group, \$ 9.0 million for state income tax purposes with a valuation allowance of \$ 3.0 million, and \$ 107.4 million for foreign income tax purposes with a valuation allowance of \$ 5.6 million. The federal and state net operating loss carryforwards, if not used, will expire between 2025 and 2044. The majority of the foreign net operating loss carryforwards can be carried forward indefinitely with the remaining portion set to expire between 2030 and 2044, if not used.

At December 31, 2024, the Company had tax effected benefits of \$ 13.6 million related to tax credit carryforwards, which will be available to offset future income taxes payable, subject to certain annual or other limitations based on foreign and U.S. tax laws. This primarily includes foreign tax credit carryforwards of \$ 2.9 million with no valuation allowance, \$ 9.2 million for state income tax purposes with a valuation allowance of

**AMETEK, Inc.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)**

\$ 8.0 million, and \$ 1.5 million for foreign income tax purposes with a valuation allowance of \$ 0.5 million. These tax credit carryforwards, if not used, will expire between 2025 and 2044.

As of December 31, 2024, the Company has no remaining carryforwards relating to interest expense limitations under IRC Section 163(j). At December 31, 2023, the Company had \$ 13.2 million of IRC Section 163(j) interest expense limitation carryforwards.

The Company maintains a valuation allowance to reduce certain deferred tax assets to amounts that are more likely than not to be realized. This allowance relates to deferred tax assets established for federal, state, and foreign net operating losses, credit carryforwards, and other miscellaneous timing items. In 2024, the Company recorded a net increase of \$ 4.5 million in the valuation allowance.

The increase in the valuation allowance primarily relates to \$ 5.3 million recorded against state tax credits which have been deemed more likely than not to go unused.

At December 31, 2024, the Company had gross unrecognized tax benefits of \$ 201.6 million, of which \$ 158.2 million, if recognized, would impact the effective tax rate. At December 31, 2023, the Company had gross unrecognized tax benefits of \$ 233.5 million, of which \$ 185.2 million, if recognized, would impact the effective tax rate.

At December 31, 2024 and 2023, the Company reported \$ 15.3 million and \$ 18.3 million, respectively, related to interest and penalties as a component of other long term liabilities in the consolidated balance sheet. During 2024, the Company recognized a net benefit of \$ 3.0 million, and in 2023 net expense of \$ 5.9 million, for interest and penalties related to uncertain tax positions in the consolidated statement of income as a component of income tax expense.

Approximately 51% of the Company's overall tax liability is incurred in the United States. The Company files income tax returns in various other state and foreign tax jurisdictions, in some cases for multiple legal entities per jurisdiction. Generally, the Company has open tax years subject to tax audit on average of between three and six years in these jurisdictions. The Company was notified by the Internal Revenue Service ("IRS") that the U.S. consolidated tax group was selected for audit for the 2022 tax year. A preliminary meeting with the IRS and company representatives has been scheduled. The Company has not materially extended any other statutes of limitation for any significant location and has reviewed and accrued for, where necessary, tax liabilities for open periods including state and foreign jurisdictions that remain subject to examination. There have been no penalties asserted or imposed by the IRS related to substantial understatement of income, gross valuation misstatement or failure to disclose a listed or reportable transaction.

During 2024, the Company added \$ 65.5 million of tax, interest and penalties related to identified uncertain tax positions and reversed \$ 100.5 million of tax and interest related to statute expirations and settlement of prior uncertain positions. During 2023, the Company added \$ 75.5 million of tax, interest and penalties related to identified uncertain tax positions and reversed \$ 10.7 million of tax and interest related to statute expirations and settlement of prior uncertain positions.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following is a reconciliation of the liability for uncertain tax positions at December 31:

	2024	2023	2022
	(In millions)		
Balance at the beginning of the year	\$ 233.5	\$ 174.7	\$ 147.0
Additions for tax positions related to the current year	37.2	32.1	29.3
Additions for tax positions of prior years	18.1	34.0	2.1
Reductions for tax positions of prior years	( 22.8 )	( 0.6 )	( 1.0 )
Reductions related to settlements with taxing authorities	( 1.3 )	( 0.1 )	( 0.2 )
Reductions due to statute expirations	( 63.1 )	( 6.6 )	( 2.5 )
Balance at the end of the year	<u>\$ 201.6</u>	<u>\$ 233.5</u>	<u>\$ 174.7</u>

In 2024, the additions above primarily reflect the increase in tax liabilities for uncertain tax positions related to higher transfer pricing risks, and incentives for R&D related activities. The reductions above primarily relate to statute expirations. The net decrease of \$ 31.9 million in uncertain tax positions resulted in a decrease of \$ 25.6 million to income tax expense and the remainder in other balance sheet accounts. At December 31, 2024, tax, interest and penalties of \$ 212.8 million were classified as a non-current liability and \$ 4.2 million was reflected as a reduction against deferred tax assets.

#### 10. Debt

Long-term debt, net consisted of the following at December 31:

	2024	2023
	(In thousands)	
U.S. dollar 3.73 % senior notes due September 2024	\$ —	\$ 300,000
U.S. dollar 3.91 % senior notes due June 2025	50,000	50,000
U.S. dollar 3.96 % senior notes due August 2025	100,000	100,000
U.S. dollar 4.18 % senior notes due December 2025	275,000	275,000
U.S. dollar 3.83 % senior notes due September 2026	100,000	100,000
U.S. dollar 4.32 % senior notes due December 2027	250,000	250,000
U.S. dollar 4.37 % senior notes due December 2028	50,000	50,000
U.S. dollar 3.98 % senior notes due September 2029	100,000	100,000
U.S. dollar 4.45 % senior notes due August 2035	50,000	50,000
British pound 2.59 % senior note due November 2028	187,803	191,076
British pound 2.70 % senior note due November 2031	93,917	95,543
Euro 1.34 % senior notes due October 2026	310,514	331,770
Euro 1.71 % senior notes due December 2027	77,628	82,945
Euro 1.53 % senior notes due October 2028	207,011	221,203
Revolving credit facility borrowings	230,000	1,116,000
Other, principally foreign	1,906	5,534
Less: Debt issuance costs	( 4,058 )	( 5,724 )
Total debt, net	2,079,721	3,313,347
Less: Current portion, net	( 654,346 )	( 1,417,915 )
Total long-term debt, net	<u>\$ 1,425,375</u>	<u>\$ 1,895,432</u>

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Maturities of long-term debt borrowings outstanding at December 31, 2024 were as follows: \$ 410.5 million in 2026; \$ 327.6 million in 2027; \$ 444.8 million in 2028; \$ 100.0 million in 2029; none in 2030; and \$ 142.5 million in 2031 and thereafter.

In the third quarter of 2024, the Company paid in full, at maturity, a \$ 300.0 million in aggregate principal amount of 3.73 % senior notes.

In December 2018, the Company completed a private placement agreement to sell \$ 575 million and 75 million Euros in senior notes to a group of institutional investors (the “2018 Private Placement”) utilizing two funding dates. The first funding occurred in December 2018 for \$ 475 million and 75 million Euros (\$ 77.6 million at December 31, 2024). The second funding was in January 2019 for \$ 100 million. The 2018 Private Placement senior notes carry a weighted average interest rate of 3.93 % and are subject to certain customary covenants, including financial covenants that, among other things, require the Company to maintain certain debt-to-EBITDA (earnings before interest, income taxes, depreciation and amortization) and interest coverage ratios.

In September 2014, the Company issued \$ 300 million in aggregate principal amount of 3.73 % senior notes due September 2024, \$ 100 million in aggregate principal amount of 3.83 % senior notes due September 2026 and \$ 100 million in aggregate principal amount of 3.98 % senior notes due September 2029. In June 2015, the Company issued \$ 50 million in aggregate principal amount of 3.91 % senior notes due June 2025. In August 2015, the Company issued \$ 100 million in aggregate principal amount of 3.96 % senior notes due August 2025 and \$ 50 million in aggregate principal amount of 4.45 % senior notes due August 2035.

In October 2016, the Company issued 300 million Euros (\$ 310.5 million at December 31, 2024) in aggregate principal amount of 1.34 % senior notes due October 2026 and 200 million Euros (\$ 207.0 million at December 31, 2024) in aggregate principal amount of 1.53 % senior notes due October 2028. In November 2016, the Company issued 150 million British pounds (\$ 187.8 million at December 31, 2024) in aggregate principal amount of 2.59 % senior notes due November 2028 and 75 million British pounds (\$ 93.9 million at December 31, 2024) in aggregate principal amount of 2.70 % senior notes due November 2031.

On May 12, 2022, the Company along with certain of its foreign subsidiaries amended its credit agreement dated as of September 22, 2011, as amended and restated as of March 10, 2016 and as further amended and restated as of October 30, 2018 (the “Credit Agreement”). The Credit Agreement amends and restates the Company’s existing revolving credit facility to increase the size from \$ 1.5 billion to \$ 2.3 billion. The Credit Agreement consists of a five-year revolving credit facility with a final maturity date in May 2027. The revolving credit facility total borrowing capacity excludes an accordion feature that permits the Company to request up to an additional \$ 700 million in revolving credit commitments at any time during the life of the Credit Agreement under certain conditions. The credit agreement places certain restrictions on allowable additional indebtedness. At December 31, 2024, the Company had available borrowing capacity of \$ 2,020.3 million under its revolving credit facility, excluding the \$ 700 million accordion feature.

Interest rates on outstanding borrowings under the revolving credit facility are at the applicable benchmark rate plus a negotiated spread or at the U.S. prime rate. At December 31, 2024 and 2023, the Company had \$ 230.0 million and \$ 1,116.0 million of borrowings outstanding under the revolving credit facility, respectively. The weighted average interest rate on the revolving credit facility for the years ended December 31, 2024 and 2023 was 6.31 % and 6.22 %, respectively. The Company had outstanding letters of credit primarily under the revolving credit facility totaling \$ 49.7 million and \$ 54.7 million at December 31, 2024 and 2023, respectively.

The private placements, the senior notes and the revolving credit facility are subject to certain customary covenants, including financial covenants that, among other things, require the Company to maintain certain debt-to-EBITDA and interest coverage ratios. The Company was in compliance with all provisions of the debt arrangements at December 31, 2024.

Foreign subsidiaries of the Company had available credit facilities with local foreign lenders of \$ 75.6 million and \$ 73.8 million at December 31, 2024 and 2023, respectively. At December 31, 2024, foreign subsidiaries had

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

\$ 1.9 million in debt borrowings outstanding, which was reported in short-term borrowings. At December 31, 2023, foreign subsidiaries had \$ 5.5 million of debt borrowings outstanding.

The weighted average interest rate on total debt borrowings outstanding at December 31, 2024 and 2023 was 3.4 % and 4.2 %, respectively.

*Subsequent Event*

On January 6, 2025, the Company established a commercial paper program under which it may issue short-term, unsecured commercial paper notes. Amounts available under the commercial paper program may be borrowed, repaid and re-borrowed, with the aggregate face or principal amount of the notes outstanding under the commercial paper program at any time not to exceed \$ 2.3 billion. The notes will have maturities of up to 364 days from the date of issue. The Company intends the commercial paper program to provide additional financing flexibility for various purposes including acquisitions. The Company expects that outstanding indebtedness of the Company under both the revolving credit facility and the commercial paper program will not exceed \$ 2.3 billion at any time.

**11. Share-Based Compensation**

Under the terms of the Company's stockholder-approved share-based plans, performance restricted stock units ("PRSUs"), incentive and non-qualified stock options and restricted stock have been, and may be, issued to the Company's officers, management-level employees and members of its Board of Directors. Stock options granted generally vest at a rate of one-third on each of the first three anniversaries of the grant date and have a maximum contractual term of ten years. Restricted stock granted to employees generally vests one-third on each of the first three anniversaries of the grant date. Restricted stock granted to non-employee directors generally vests two years after the grant date (cliff vesting) and is subject to accelerated vesting due to certain events, including doubling of the grant price of the Company's common stock as of the close of business during any five consecutive trading days.

*Share Based Compensation Expense*

The Company measures and records compensation expense related to all stock awards by recognizing the grant date fair value of the awards over their requisite service periods in the financial statements. For grants under any of the Company's plans that are subject to graded vesting based on a service condition, the Company recognizes expense on a straight-line basis over the requisite service period for the entire award.

Total share-based compensation expense was as follows for the years ended December 31:

	2024	2023	2022
	(In thousands)		
Stock option expense	\$ 13,892	\$ 14,284	\$ 13,021
Restricted stock expense	20,422	20,792	20,115
PRSU expense	13,549	11,123	14,239
Total pre-tax expense	<u>\$ 47,863</u>	<u>\$ 46,199</u>	<u>\$ 47,375</u>

Pre-tax share-based compensation expense is included in the consolidated statement of income in either Cost of sales or Selling, general and administrative expenses, depending on where the recipient's cash compensation is reported.



AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

*Stock Options*

The fair value of each stock option grant is estimated on the date of grant using a Black-Scholes-Merton option pricing model. The following weighted average assumptions were used in the Black-Scholes-Merton model to estimate the fair values of stock options granted during the years indicated:

	2024	2023	2022
Expected volatility	28.2 %	26.0 %	24.5 %
Expected term (years)	5.0	5.0	5.0
Risk-free interest rate	4.31 %	3.54 %	2.33 %
Expected dividend yield	0.62 %	0.72 %	0.65 %
Black-Scholes-Merton fair value per stock option granted	\$ 56.42	\$ 38.11	\$ 32.54

Expected volatility is based on the historical volatility of the Company's stock over the stock options' expected term. The Company used historical exercise data to estimate the stock options' expected term, which represents the period of time that the stock options granted are expected to be outstanding. Management anticipates that the future stock option holding periods will be similar to the historical stock option holding periods. The risk-free interest rate for periods within the expected term of the stock option is based on the U.S. Treasury yield curve at the time of grant. The expected dividend yield is calculated by dividing the Company's annual dividend, based on the most recent quarterly dividend rate, by the Company's closing common stock price on the grant date. Compensation expense recognized for all share-based awards is net of estimated forfeitures. The Company's estimated forfeiture rates are based on its historical experience.

The following is a summary of the Company's stock option activity and related information for the year ended December 31, 2024:

	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value
	(In thousands)		(Years)	(In millions)
Outstanding at the beginning of the year	2,741	\$ 101.20		
Granted	231	181.93		
Exercised	( 779 )	85.77		
Forfeited	( 53 )	150.00		
Outstanding at the end of the year	2,140	\$ 114.33	6.5	\$ 141.4
Exercisable at the end of the year	1,514	\$ 98.55	5.7	\$ 123.7

The aggregate intrinsic value of stock options exercised during 2024, 2023 and 2022 was \$ 73.5 million, \$ 54.9 million and \$ 50.3 million, respectively. The total fair value of stock options vested during 2024, 2023 and 2022 was \$ 14.9 million, \$ 12.8 million and \$ 11.4 million, respectively.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following is a summary of the Company's non-vested stock option activity and related information for the year ended December 31, 2024:

	Shares	Weighted Average Grant Date Fair Value
	(In thousands)	
Non-vested stock options outstanding at the beginning of the year	910	\$ 34.98
Granted	231	56.42
Vested	( 462 )	32.26
Forfeited	( 53 )	44.68
Non-vested stock options outstanding at the end of the year	626	\$ 44.32

As of December 31, 2024, there was approximately \$ 16 million of expected future pre-tax compensation expense related to the 0.6 million non-vested stock options outstanding, which is expected to be recognized over a weighted average period of less than two years .

*Restricted Stock*

The fair value of restricted shares under the Company's restricted stock arrangement is determined by the product of the number of shares granted and the Company's closing common stock price on the grant date. Upon the grant of restricted stock, the fair value of the restricted shares (unearned compensation) at the grant date is charged as a reduction of capital in excess of par value in the Company's consolidated balance sheet and is amortized to expense on a straight-line basis over the vesting period, which is the same as the calculated derived service period as determined on the grant date.

The following is a summary of the Company's non-vested restricted stock activity and related information for the year ended December 31, 2024:

	Shares	Weighted Average Grant Date Fair Value
	(In thousands)	
Non-vested restricted stock outstanding at the beginning of the year	296	\$ 135.39
Granted	149	181.74
Vested	( 141 )	132.82
Forfeited	( 27 )	155.27
Non-vested restricted stock outstanding at the end of the year	277	\$ 159.71

The total fair value of restricted stock vested during 2024, 2023 and 2022 was \$ 20.0 million, \$ 20.5 million and \$ 17.7 million, respectively. The weighted average fair value of restricted stock granted per share during 2024 and 2023 was \$ 181.74 and \$ 139.08 , respectively. As of December 31, 2024, there was approximately \$ 27 million of expected future pre-tax compensation expense related to the 0.3 million non-vested restricted shares outstanding, which is expected to be recognized over a weighted average period of less than two years .

*Performance Restricted Stock Units*

The PRSUs vest over a period up to three years from the grant date based on continuous service, with the number of shares earned ( 0 % to 200 % of the target award) depending upon the extent to which the Company achieves certain financial and market performance targets measured over the period from January 1 of the year of grant through December 31 of the third year. Half of the PRSUs are valued in a manner similar to restricted stock as the financial targets are based on the Company's operating results. The grant date fair value of these PRSUs are

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

recognized as compensation expense over the vesting period based on the number of awards expected to vest at each reporting date. The other half of the PRSUs were valued using a Monte Carlo model as the performance target is related to the Company's total shareholder return compared to a group of peer companies, which represents a market condition. The Company recognizes the grant date fair value of these awards as compensation expense ratably over the vesting period.

The following is a summary of the Company's non-vested performance restricted stock activity and related information for the year ended December 31, 2024:

	Shares	Weighted Average Grant Date Fair Value
	(In thousands)	
Non-vested performance restricted stock outstanding at the beginning of the year	239	\$ 131.90
Granted	77	167.79
Performance assumption change <sup>1</sup>	24	121.91
Vested	( 99 )	121.91
Forfeited	( 6 )	155.83
Non-vested performance restricted stock outstanding at the end of the year	<u>235</u>	<u>\$ 150.92</u>

<sup>1</sup> Reflects the number of PRSUs above target levels based on performance metrics.

As of December 31, 2024, there was approximately \$ 5 million of expected future pre-tax compensation expense related to the 0.2 million non-vested performance restricted shares outstanding, which is expected to be recognized over a weighted average period of less than one year .

The Company issues previously unissued shares when stock units are exercised, and shares are issued from treasury stock upon the award of restricted stock.

## 12. Retirement Plans and Other Postretirement Benefits

### *Retirement and Pension Plans*

The Company sponsors several retirement and pension plans covering eligible salaried and hourly employees. The plans generally provide benefits based on participants' years of service and/or compensation. The following is a brief description of the Company's retirement and pension plans.

The Company maintains contributory and non-contributory defined benefit pension plans. Benefits for eligible salaried and hourly employees under all defined benefit plans are funded through trusts established in conjunction with the plans. The Company's funding policy with respect to its defined benefit plans is to contribute amounts that provide for benefits based on actuarial calculations and the applicable requirements of U.S. federal and local foreign laws. The Company estimates that it will make both required and discretionary cash contributions of approximately \$ 7 million to \$ 10 million to its worldwide defined benefit pension plans in 2025.

The Company uses a measurement date of December 31 (its fiscal year end) for its U.S. and foreign defined benefit pension plans.

The Company sponsors a 401(k) retirement and savings plan for eligible U.S. employees. Participants in the retirement and savings plan may contribute a specified portion of their compensation on a pre-tax basis, Roth basis, or after-tax basis, which varies by location. The Company matches employee contributions ranging from 33 % to 100 %, up to a maximum percentage ranging from 1 % to 8 % of eligible compensation or up to a maximum of \$ 1,200 per participant in some locations.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The Company's retirement and savings plan has a defined contribution retirement feature principally to cover U.S. salaried employees joining the Company after December 31, 1996. Under the retirement feature, the Company makes contributions for eligible employees based on a pre-established percentage of the covered employee's salary subject to pre-established vesting. Employees of certain of the Company's foreign operations participate in various local defined contribution plans.

The Company has non-qualified unfunded retirement plans for certain Directors and retired employees. It also provides supplemental retirement benefits, through contractual arrangements and/or a Supplemental Executive Retirement Plan ("SERP") covering certain current and former executives of the Company. These supplemental benefits are designed to compensate the executive for retirement benefits that would have been provided under the Company's primary retirement plan, except for statutory limitations on compensation that must be taken into account under those plans. The plan permits deferred amounts to be deemed invested in either, or a combination of, an interest-bearing account, phantom mutual fund or collective investment trust accounts or the equivalent of a fund which invests in shares of the Company's common stock on behalf of the employee. The amount owed to participants is an unfunded and unsecured general obligation which is payable out of either the general assets of the Company or a grant of shares of the Company's common stock upon retirement or termination. The Company is providing for these obligations by charges to earnings over the applicable periods.

The following tables set forth the changes in net projected benefit obligation and the fair value of plan assets for the funded and unfunded defined benefit plans for the years ended December 31:

U.S. Defined Benefit Pension Plans:

	2024	2023
	(In thousands)	
Change in projected benefit obligation:		
Net projected benefit obligation at the beginning of the year	\$ 366,248	\$ 383,143
Service cost	1,177	1,205
Interest cost	18,998	20,840
Actuarial (gains) losses	( 10,115 )	10,229
Gross benefits paid	( 30,000 )	( 49,169 )
Net projected benefit obligation at the end of the year	<u>\$ 346,308</u>	<u>\$ 366,248</u>
Change in plan assets:		
Fair value of plan assets at the beginning of the year	\$ 599,886	\$ 569,049
Actual return on plan assets	46,900	79,366
Employer contributions	650	640
Gross benefits paid	( 30,000 )	( 49,169 )
Fair value of plan assets at the end of the year	<u>\$ 617,436</u>	<u>\$ 599,886</u>

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Foreign Defined Benefit Pension Plans:

	2024	2023
	(In thousands)	
Change in projected benefit obligation:		
Net projected benefit obligation at the beginning of the year	\$ 215,482	\$ 198,744
Service cost	1,623	1,615
Interest cost	9,087	9,369
Foreign currency translation adjustments	( 5,162 )	10,312
Actuarial (gains) losses	( 18,872 )	7,575
Expenses paid from assets	( 579 )	( 552 )
Gross benefits paid	( 10,776 )	( 11,581 )
Net projected benefit obligation at the end of the year	<u>\$ 190,803</u>	<u>\$ 215,482</u>
Change in plan assets:		
Fair value of plan assets at the beginning of the year	\$ 174,443	\$ 159,592
Actual return on plan assets	( 2,327 )	10,132
Employer contributions	8,044	8,031
Foreign currency translation adjustments	( 3,038 )	8,821
Expenses paid from assets	( 579 )	( 552 )
Gross benefits paid	( 10,776 )	( 11,581 )
Fair value of plan assets at the end of the year	<u>\$ 165,767</u>	<u>\$ 174,443</u>

The projected benefit obligation assumptions impacting net actuarial losses (gains) primarily consist of changes in discount and mortality rates.

The accumulated benefit obligation consisted of the following at December 31:

U.S. Defined Benefit Pension Plans:

	2024	2023
	(In thousands)	
Funded plans	\$ 339,029	\$ 357,498
Unfunded plans	2,214	2,558
Total	<u>\$ 341,243</u>	<u>\$ 360,056</u>

Foreign Defined Benefit Pension Plans:

	2024	2023
	(In thousands)	
Funded plans	\$ 155,368	\$ 178,854
Unfunded plans	35,246	36,360
Total	<u>\$ 190,614</u>	<u>\$ 215,214</u>

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Weighted average assumptions used to determine benefit obligations at December 31:

	2024	2023
U.S. Defined Benefit Pension Plans:		
Discount rate	5.74 %	5.38 %
Rate of compensation increase (where applicable)	3.75 %	3.75 %
Foreign Defined Benefit Pension Plans:		
Discount rate	5.20 %	4.36 %
Rate of compensation increase (where applicable)	3.00 %	3.00 %

The following is a summary of the fair value of plan assets for U.S. plans at December 31:

Asset Class	2024				2023		
	Total	Level 1	Level 2	Level 3	Total	Level 1	Level 2
(In thousands)							
Corporate debt instruments	\$ 2,595	\$ —	\$ 2,595	\$ —	\$ 5,295	\$ —	\$ 5,295
Corporate debt instruments – Preferred	18,027	—	18,027	—	16,004	—	16,004
Corporate stocks – Common	56,258	56,258	—	—	43,287	43,287	—
Municipal bonds	1,456	—	1,456	—	1,253	—	1,253
Hedge Funds	31,900	—	—	31,900	—	—	—
Registered investment companies	145,380	145,380	—	—	169,794	169,794	—
U.S. Government securities	1,141	—	1,141	—	1,262	—	1,262
Total investments	256,757	201,638	23,219	31,900	236,895	213,081	23,814
Investments measured at net asset value	360,679	—	—	—	362,991	—	—
Total investments	\$ 617,436	\$ 201,638	\$ 23,219	\$ 31,900	\$ 599,886	\$ 213,081	\$ 23,814

U.S. equity securities and global equity securities categorized as level 1 are traded on national and international exchanges and are valued at their closing prices on the last trading day of the year. Some U.S. equity securities and global equity securities are public investment vehicles valued using the Net Asset Value ("NAV") provided by the fund manager. The NAV is the total value of the fund divided by the number of shares outstanding.

Fixed income securities categorized as level 2 are valued by the trustee using pricing models that use verifiable observable market data, bids provided by brokers or dealers or quoted prices of securities with similar characteristics. Hedge funds are considered level 3 investments as their values are determined by the sponsor using unobservable market data.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following is a summary of the changes in the fair value of the U.S. plans' level 3 investments (fair value determined using significant unobservable inputs):

	Hedge Funds
	(In thousands)
Balance, December 31, 2023	\$ —
Actual return on assets:	
Unrealized losses relating to instruments still held at the end of the year	—
Realized gains (losses) relating to assets sold during the year	—
Purchases, sales, issuances and settlements, net	31,900
Balance, December 31, 2024	\$ 31,900

The expected long-term rate of return on these plan assets was 7.46 % in 2024 and 7.59 % in 2023. Equity securities included 200,057 shares of AMETEK, Inc. common stock with a market value of \$ 36.1 million ( 5.8 % of total plan investment assets) at December 31, 2024 and 232,710 shares of AMETEK, Inc. common stock with a market value of \$ 38.4 million ( 6.4 % of total plan investment assets) at December 31, 2023.

The objectives of the Company's U.S. defined benefit plans' investment strategy are to maximize the plans' funded status and minimize Company contributions and plan expense. Because the goal is to optimize returns over the long term, an investment policy that favors equity holdings has been established. Since there may be periods of time where both equity and mutual fund markets provide poor returns, an allocation to alternative assets may be made to improve the overall portfolio's diversification and return potential. The Company periodically reviews its asset allocation, taking into consideration plan liabilities, plan benefit payment streams and the investment strategy of the pension plans. The actual asset allocation is monitored frequently relative to the established targets and ranges and is re-balanced when necessary. The target allocations for the U.S. defined benefits plans are approximately 51 % equity securities, 29 % fixed income securities and 20 % other securities and/or cash.

The equity portfolio is diversified by market capitalization and style. The equity portfolio also includes international components.

The objective of the mutual fund portion of the pension assets is to provide interest rate sensitivity for a portion of the assets and to provide diversification. The mutual fund portfolio is diversified within certain quality and maturity guidelines to minimize the adverse effects of interest rate fluctuations.

Certain investments are prohibited and include venture capital, private placements, unregistered or restricted stock, margin trading, commodities, short selling and rights and warrants. Foreign currency futures, options and forward contracts may be used to manage foreign currency exposure.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following is a summary of the fair value of plan assets for foreign defined benefit pension plans at December 31:

Asset Class	2024		2023	
	Total	Level 3	Total	Level 3
(In thousands)				
Life insurance	\$ 10,766	\$ 10,766	\$ 12,619	\$ 12,619
Total investments	10,766	10,766	12,619	12,619
Investments measured at net asset value	155,001	—	161,824	—
Total investments	\$ 165,767	\$ 10,766	\$ 174,443	\$ 12,619

Life insurance assets are considered level 3 investments as their values are determined by the sponsor using unobservable market data.

Life insurance assets categorized as level 3 are valued based on unobservable inputs and cannot be corroborated using verifiable observable market data. Investments in level 3 funds are redeemable, however, cash reimbursement may be delayed, or a portion held back until asset finalization.

The following is a summary of the changes in the fair value of the foreign plans' level 3 investments (fair value determined using significant unobservable inputs):

	Life Insurance
	(In thousands)
Balance, December 31, 2022	\$ 13,043
Actual return on assets:	
Unrealized losses relating to instruments still held at the end of the year	\$ ( 424 )
Realized gains (losses) relating to assets sold during the year	\$ —
Purchases, sales, issuances and settlements, net	\$ —
Balance, December 31, 2023	\$ 12,619
Actual return on assets:	
Unrealized losses relating to instruments still held at the end of the year	\$ ( 1,853 )
Realized gains (losses) relating to assets sold during the year	\$ —
Purchases, sales, issuances and settlements, net	\$ —
Balance, December 31, 2024	\$ 10,766

The objective of the Company's foreign defined benefit plans' investment strategy is to maximize the long-term rate of return on plan investments, subject to a reasonable level of risk. Liability studies are also performed on a regular basis to provide guidance in setting investment goals with an objective to balance risks against the current and future needs of the plans. The trustees consider the risk associated with the different asset classes, relative to the plans' liabilities and how this can be affected by diversification, and the relative returns available on equities, mutual fund investments, real estate and cash. Also, the likely volatility of those returns and the cash flow requirements of the plans are considered. It is expected that equities will outperform mutual fund investments over the long term. However, the trustees recognize the fact that mutual fund investments may better match the liabilities for pensioners. Because of the relatively young active employee group covered by the plans and the immature nature of the plans, the trustees have chosen to adopt an asset allocation strategy more heavily weighted toward equity investments. This asset allocation strategy will be reviewed, from time to time, in view of changes in market conditions and in the plans' liability profile. The target allocations for the foreign defined benefit plans are approximately 23 % equity securities, 70 % fixed income securities and 7 % other securities, insurance or cash.



AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The assumption for the expected return on plan assets was developed based on a review of historical investment returns for the investment categories for the defined benefit pension assets. This review also considered current capital market conditions and projected future investment returns. The estimates of future capital market returns by asset class are lower than the actual long-term historical returns. Therefore, the assumed rate of return for U.S. plans is 7.13 % and 5.78 % for foreign plans in 2025.

The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with a projected benefit obligation in excess of plan assets and pension plans with an accumulated benefit obligation in excess of plan assets were as follows at December 31:

U.S. Defined Benefit Pension Plans:

	Projected Benefit Obligation Exceeds Fair Value of Assets		Accumulated Benefit Obligation Exceeds Fair Value of Assets	
	2024	2023	2024	2023
(In thousands)				
Benefit obligation	\$ 2,214	\$ 2,558	\$ 2,214	\$ 2,558
Fair value of plan assets	—	—	—	—

Foreign Defined Benefit Pension Plans:

	Projected Benefit Obligation Exceeds Fair Value of Assets		Accumulated Benefit Obligation Exceeds Fair Value of Assets	
	2024	2023	2024	2023
(In thousands)				
Benefit obligation	\$ 35,435	\$ 132,796	\$ 35,246	\$ 132,527
Fair value of plan assets	2,316	88,028	2,316	88,028

The following table provides the amounts recognized in the consolidated balance sheet at December 31:

	2024	2023
(In thousands)		
Funded status asset (liability):		
Fair value of plan assets	\$ 783,203	\$ 774,329
Projected benefit obligation	( 537,111 )	( 581,730 )
Funded status at the end of the year	\$ 246,092	\$ 192,599
Amounts recognized in the consolidated balance sheet consisted of:		
Non-current asset for pension benefits (other assets)	\$ 281,425	\$ 239,925
Current liabilities for pension benefits	( 2,294 )	( 2,816 )
Non-current liability for pension benefits	( 33,039 )	( 44,510 )
Net amount recognized at the end of the year	\$ 246,092	\$ 192,599

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following table provides the amounts recognized in accumulated other comprehensive income, net of taxes, at December 31:

<u>Net amounts recognized:</u>	2024	2023
	(In thousands)	
Net actuarial loss	\$ 162,086	\$ 184,489
Prior service costs	1,519	1,616
Transition asset	1	2
Total recognized	<u>\$ 163,606</u>	<u>\$ 186,107</u>

The following table provides the components of net periodic pension benefit expense (income) for the years ended December 31:

	2024	2023	2022
	(In thousands)		
Defined benefit plans:			
Service cost	\$ 2,800	\$ 2,820	\$ 4,919
Interest cost	28,085	30,209	20,124
Expected return on plan assets	( 54,672 )	( 52,289 )	( 60,104 )
Settlement	—	—	( 58 )
Amortization of:			
Net actuarial loss	9,619	11,569	8,531
Prior service costs	103	101	100
Transition asset	1	1	1
Total net periodic benefit income	<u>( 14,064 )</u>	<u>( 7,589 )</u>	<u>( 26,487 )</u>
Other plans:			
Defined contribution plans	44,898	43,044	39,326
Foreign plans and other	8,575	9,015	8,373
Total other plans	<u>53,473</u>	<u>52,059</u>	<u>47,699</u>
Total net pension expense	<u>\$ 39,409</u>	<u>\$ 44,470</u>	<u>\$ 21,212</u>

The total net periodic benefit expense (income) is included in Cost of sales, General and administrative expense and Other income and expense in the consolidated statement of income. Unrecognized gains and losses are amortized into future net periodic pension cost using the 10% corridor method over the expected remaining life of the employee group.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following weighted average assumptions were used to determine the above net periodic pension benefit income for the years ended December 31:

	2024	2023	2022
<b>U.S. Defined Benefit Pension Plans:</b>			
Discount rate	5.38 %	5.65 %	3.02 %
Expected return on plan assets	7.46 %	7.59 %	6.75 %
Rate of compensation increase (where applicable)	3.75 %	3.75 %	3.75 %
<b>Foreign Defined Benefit Pension Plans:</b>			
Discount rate	4.36 %	4.73 %	1.78 %
Expected return on plan assets	6.49 %	6.41 %	5.85 %
Rate of compensation increase (where applicable)	3.00 %	2.50 %	2.50 %

*Estimated Future Benefit Payments*

The estimated future benefit payments for U.S. and foreign plans are as follows: 2025 – \$ 42.9 million; 2026 – \$ 43.2 million; 2027 – \$ 43.0 million; 2028 – \$ 43.2 million; 2029 – \$ 42.8 million; 2030 to 2034 - \$ 208.1 million. Future benefit payments primarily represent amounts to be paid from pension trust assets. Amounts included that are to be paid from the Company's assets are not significant in any individual year.

*Postretirement Plans and Post-employment Benefits*

The Company provides limited postretirement benefits other than pensions for certain retirees and a small number of former employees. Benefits under these arrangements are not funded and are not significant.

The Company also provides limited post-employment benefits for certain former or inactive employees after employment but before retirement. Those benefits are not significant in amount.

The Company has a deferred compensation plan, which allows employees whose compensation exceeds the statutory IRS limit for retirement benefits to defer a portion of earned bonus compensation. The plan permits deferred amounts to be deemed invested in either, or a combination of, an interest-bearing account, phantom mutual fund accounts or the equivalent of a fund which invests in shares of the Company's common stock on behalf of the employee. The amount owed to participants is an unfunded and unsecured general obligation which is payable out of either the general assets of the Company or a grant of shares of the Company's common stock. The amount deferred under the plan, including income earned, was \$ 44.5 million and \$ 35.9 million at December 31, 2024 and 2023, respectively. Administrative expense for the deferred compensation plan is borne by the Company and is not significant.

### 13. Contingencies

*Indemnifications*

In conjunction with certain acquisition and divestiture transactions, the Company may agree to make payments to compensate or indemnify other parties for possible future unfavorable financial consequences resulting from specified events (e.g., breaches of contract obligations or retention of previously existing environmental, tax or employee liabilities) whose terms range in duration and often are not explicitly defined. Where appropriate, the obligation for such indemnifications is recorded as a liability. Because the amount of these types of indemnifications generally is not specifically stated, the overall maximum amount of the obligation under such indemnifications cannot be reasonably estimated. Further, the Company indemnifies its directors and officers for claims against them in connection with their positions with the Company. Historically, any such costs incurred to settle claims related to these indemnifications have been minimal for the Company. The Company believes that future payments, if any, under all existing indemnification agreements would not have a material impact on its consolidated results of operations, financial position or cash flows.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

#### *Asbestos Litigation*

The Company (including its subsidiaries) has been named as a defendant in a number of asbestos-related lawsuits. Certain of these lawsuits relate to a business which was acquired by the Company and do not involve products which were manufactured or sold by the Company. In connection with these lawsuits, the seller of such business has agreed to indemnify the Company against these claims (the "Indemnified Claims"). The Indemnified Claims have been tendered to, and are being defended by, such seller. The seller has met its obligations, in all respects, and the Company does not have any reason to believe such party would fail to fulfill its obligations in the future. To date, no judgments have been rendered against the Company as a result of any asbestos-related lawsuit. The Company believes that it has good and valid defenses to each of these claims and intends to defend them vigorously.

#### *Environmental Matters*

Certain historic processes in the manufacture of products have resulted in environmentally hazardous waste by-products as defined by federal and state laws and regulations. At December 31, 2024, the Company is named a Potentially Responsible Party ("PRP") at 13 non-AMETEK-owned former waste disposal or treatment sites (the "non-owned" sites). The Company is identified as a "de minimis" party in a majority of these sites based on the low volume of waste attributed to the Company relative to the amounts attributed to other named PRPs. The Company is participating in the investigation and/or related required remediation as part of a PRP Group and reserves have been established sufficient to satisfy the Company's expected obligations. The Company historically has resolved these issues within established reserve levels and reasonably expects this result will continue. In addition to these non-owned sites, the Company has an ongoing practice of providing reserves for probable remediation activities at certain of its current or previously owned manufacturing locations (the "owned" sites). For claims and proceedings against the Company with respect to other environmental matters, reserves are established once the Company has determined that a loss is probable and estimable. This estimate is refined as the Company moves through the various stages of investigation, risk assessment, feasibility study and corrective action processes. In certain instances, the Company has developed a range of estimates for such costs and has recorded a liability based on the best estimate. It is reasonably possible that the actual cost of remediation of the individual sites could vary from the current estimates and the amounts accrued in the consolidated financial statements; however, the amounts of such variances are not expected to result in a material change to the consolidated financial statements. In estimating the Company's liability for remediation, the Company also considers the likely proportionate share of the anticipated remediation expense and the ability of the other PRPs to fulfill their obligations.

Total environmental reserves at December 31, 2024 and 2023 were \$ 29.8 million and \$ 37.1 million, respectively, for both non-owned and owned sites. In 2024, the Company recorded \$ 9.7 million in reserves. Additionally, in 2024 the Company spent \$ 17.0 million on environmental matters. The total environmental expense is included in Other income and expense in the consolidated statement of income.

The Company has agreements with other former owners of certain of its acquired businesses, as well as new owners of previously owned businesses. Under certain of the agreements, the former or new owners retained, or assumed and agreed to indemnify the Company against, certain environmental and other liabilities under certain circumstances. The Company and some of these other parties also carry insurance coverage for some environmental matters.

The Company believes it has established reserves for the environmental matters described above, which are sufficient to perform all known responsibilities under existing claims and consent orders. In the opinion of management, based on presently available information and the Company's historical experience related to such matters, an adequate provision for probable costs has been made and the ultimate cost resulting from these actions is not expected to materially affect the consolidated results of operations, financial position or cash flows of the Company.

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

#### 14. Leases and Other Commitments

##### Leases

The Company has commitments under operating leases for certain facilities, vehicles and equipment used in its operations. Cash used in operations for operating leases was not materially different from operating lease expense for the years ended December 31, 2024 and 2023. Our leases have initial lease terms ranging from 1 month to 15 years.

The components of lease expense were as follows:

	2024	2023	2022
	(In thousands)		
Operating lease cost	\$ 76,315	\$ 63,049	\$ 59,296
Variable lease cost	11,730	11,384	11,096
Total lease cost	<u>\$ 88,045</u>	<u>\$ 74,433</u>	<u>\$ 70,392</u>

Supplemental balance sheet information related to leases was as follows:

	December 31,	
	2024	2023
	(In thousands)	
Right of use assets, net	\$ 235,666	\$ 229,723
Lease liabilities included in Accrued liabilities and other	54,736	61,055
Lease liabilities included in Other long-term liabilities	190,017	182,436
Total lease liabilities	<u>\$ 244,753</u>	<u>\$ 243,491</u>

Supplemental cash flow information and other information related to leases was as follows for the year ended December 31:

	2024	2023
	(In thousands)	
Right-of-use assets obtained in exchange for new operating liabilities	\$ 44,079	\$ 95,052
Weighted-average remaining lease terms – operating leases (years)	6.49	6.66
Weighted-average discount rate – operating leases	4.74 %	4.48 %

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Maturities of lease liabilities as of December 31, 2024 were as follows:

Lease Liability Maturity Analysis	Operating Leases	
	(In thousands)	
2025	\$	61,789
2026		52,241
2027		39,654
2028		29,419
2029		23,576
Thereafter		71,426
Total lease payments		278,105
Less: imputed interest		33,352
	\$	244,753

The Company does not have any significant leases that have not yet commenced.

#### Other Commitments

As of December 31, 2024, and 2023, the Company had \$ 761.9 million and \$ 790.0 million, respectively, in purchase obligations outstanding, which primarily consisted of contractual commitments to purchase certain inventories at fixed prices.

The Company does not provide significant guarantees on a routine basis. The Company primarily issues guarantees, stand-by letters of credit and surety bonds in the ordinary course of its business to provide financial or performance assurance to third parties on behalf of its consolidated subsidiaries to support or enhance the subsidiary's stand-alone creditworthiness. The amounts subject to certain of these agreements vary depending on the covered contracts outstanding at any particular point in time. At December 31, 2024, the maximum amount of future payment obligations relative to these various guarantees was \$ 261.2 million and the outstanding liability under certain of those guarantees was \$ 173.1 million .

## 15. Reportable Segments and Geographic Areas Information

#### Descriptive Information about Reportable Segments

The Company has two reportable segments, EIG and EMG. The Company's operating segments are determined based on information utilized by the Chief Executive Officer, its chief operating decision maker ("CODM"). Certain of the Company's operating segments have been aggregated for segment reporting purposes primarily on the basis of product type, production processes, distribution methods and similarity of economic characteristics.

EIG manufactures advanced instruments for the process, power and industrial, and aerospace markets. It provides process and analytical instruments for the oil and gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage industries. EIG also provides instruments to the laboratory equipment, ultra-precision manufacturing, medical, and test and measurement markets. It makes power quality monitoring and metering devices, uninterruptible power supplies, programmable power equipment, electromagnetic compatibility test equipment and gas turbines sensors. EIG also provides dashboard instruments for heavy trucks and other vehicles, as well as instrumentation and controls for the food and beverage industries. It supplies the aerospace and defense industry with aircraft and engine sensors, embedded computing systems, monitoring systems, power supplies, fuel and fluid measurement systems, and data acquisition systems.

EMG designs and manufactures highly engineered medical components and devices, automation solutions, thermal management systems, specialty metals and electrical interconnects. EMG products include single-use and consumable surgical instruments, implantable components, and drug delivery systems used across a wide range of medical applications. It also manufactures highly engineered electrical connectors and electronic packaging used to

AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

protect sensitive electronic devices. EMG makes precision motion control products for data storage, medical devices, business equipment, automation and other applications. It supplies high-purity powdered metals, strip and foil, specialty clad metals and metal matrix composites. EMG also manufactures motors used in commercial appliances, food and beverage machines, hydraulic pumps and industrial blowers. It produces motor-blower systems and heat exchangers used in thermal management and other applications on a variety of military and commercial aircraft and military ground vehicles. EMG also operates a global network of aviation maintenance, repair and overhaul facilities.

*Measurement of Segment Results*

The CODM reviews segment operating income statements in order to assess performance and allocate resources to each segment. Sales and operating income are key metrics monitored by the CODM when determining each segment's financial condition and operating performance. In addition, the CODM receives depreciation, amortization, research, development, and engineering costs, capital spending, and assets of each segment on a quarterly basis to monitor cash flow and asset needs of each segment.

Segment operating income represents net sales less all direct costs and expenses (including certain administrative and other expenses) applicable to each segment but does not include interest expense. Net sales by segment are reported after elimination of intra- and inter-segment sales and profits, which are insignificant in amount. Reported segment assets include allocations directly related to the segment's operations. Corporate assets consist primarily of investments, pensions, insurance deposits and deferred taxes.

*Reportable Segment Financial Information (in thousands):*

	EMG	EIG	Corporate	Total Consolidated
<b>2024</b>				
Net Sales	\$ 2,281,265	\$ 4,659,915	\$ —	\$ 6,941,180
Cost of sales <sup>(1)</sup>	1,736,694	2,728,019	—	4,464,713
Selling expense	88,070	503,487	—	591,557
Segment Operating Income	456,501	1,428,409	—	1,884,910
Corporate G&A	—	—	105,348	105,348
Operating Income	456,501	1,428,409	( 105,348 )	1,779,562
Interest expense	—	—	( 112,962 )	( 112,962 )
Other (expense) income, net	—	—	( 5,061 )	( 5,061 )
Income before Income Taxes	\$ 456,501	\$ 1,428,409	\$ ( 223,371 )	\$ 1,661,539
Depreciation	\$ 58,049	\$ 71,351	\$ 5,866	\$ 135,266
Amortization	74,452	173,209	—	247,661
Total depreciation and amortization	\$ 132,501	\$ 244,560	\$ 5,866	\$ 382,927
Research, Development & Engineering costs <sup>(2)</sup>	\$ 72,434	\$ 299,441	\$ —	\$ 371,875
Assets	\$ 4,758,856	\$ 9,302,031	\$ 570,282	\$ 14,631,169
Capital Expenditures <sup>(3)</sup>	\$ 41,022	\$ 58,859	\$ 28,277	\$ 128,158

(1) Includes \$ 29.2 million in EMG in for Paragon integration costs.

(2) Included in cost of sales.

(3) Includes \$ 1.1 million in EIG from acquired businesses.

**AMETEK, Inc.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)**

	EMG	EIG	Corporate	Total Consolidated
<b>2023</b>				
Net Sales	\$ 1,972,700	\$ 4,624,250	\$ —	\$ 6,596,950
Cost of sales	1,393,086	2,819,399	—	4,212,485
Selling expense	83,045	493,889	—	576,934
Segment Operating Income	496,569	1,310,962	—	1,807,531
Corporate G&A	—	—	100,072	100,072
Operating Income	496,569	1,310,962	( 100,072 )	1,707,459
Interest expense	—	—	( 81,795 )	( 81,795 )
Other (expense) income, net	—	—	( 19,252 )	( 19,252 )
Income before Income Taxes	\$ 496,569	\$ 1,310,962	\$ ( 201,119 )	\$ 1,606,412
Depreciation	\$ 40,443	\$ 77,344	\$ 4,715	\$ 122,502
Amortization	43,471	171,663	—	215,134
Total depreciation and amortization	\$ 83,914	\$ 249,007	\$ 4,715	\$ 337,636
Research, Development & Engineering costs <sup>(1)</sup>	\$ 68,960	\$ 282,701	\$ —	\$ 351,661
Assets	\$ 4,957,944	\$ 9,559,282	\$ 506,307	\$ 15,023,533
Capital Expenditures <sup>(2)</sup>	\$ 272,060	\$ 86,616	\$ 12,385	\$ 371,061

(1) Included in cost of sales.

(2) Includes \$ 223.7 million in EMG, and \$ 11.1 million in EIG from acquired businesses.

	EMG	EIG	Corporate	Total Consolidated
<b>2022</b>				
Net Sales	\$ 1,921,177	\$ 4,229,353	\$ —	\$ 6,150,530
Cost of sales <sup>(1)</sup>	1,337,108	2,668,153	—	4,005,261
Selling expense	80,476	471,471	—	551,947
Segment Operating Income	503,593	1,089,729	—	1,593,322
Corporate G&A	—	—	92,630	92,630
Operating Income	503,593	1,089,729	( 92,630 )	1,500,692
Interest expense	—	—	( 83,186 )	( 83,186 )
Other income (expense), net	—	—	11,186	11,186
Income before Income Taxes	\$ 503,593	\$ 1,089,729	\$ ( 164,630 )	\$ 1,428,692
Depreciation	\$ 37,474	\$ 73,093	\$ 3,095	\$ 113,662
Amortization	40,422	165,343	—	205,765
Total depreciation and amortization	\$ 77,896	\$ 238,436	\$ 3,095	\$ 319,427
Research, Development & Engineering costs <sup>(2)</sup>	\$ 63,892	\$ 258,178	\$ —	\$ 322,070
Assets	\$ 2,617,685	\$ 9,430,797	\$ 382,638	\$ 12,431,120
Capital Expenditures <sup>(3)</sup>	\$ 38,186	\$ 93,505	\$ 19,757	\$ 151,448

(1) Includes \$ 7.1 million in EMG from a gain on the sale of a facility.

(2) Included in cost of sales.

(3) Includes \$ 12.3 million in EIG and \$ 0.1 million in Corporate from acquired businesses.



AMETEK, Inc.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

### Geographic Areas

Information about the Company's operations in different geographic areas for the years ended December 31, 2024 and 2023 is shown below.

	2024	2023
	(In thousands)	
Long-lived assets from continuing operations (excluding intangible assets):		
United States	\$ 590,386	\$ 646,381
International <sup>(1)</sup> :		
United Kingdom	68,239	73,328
European Union countries	84,707	95,781
Asia	12,416	13,351
Other foreign countries	62,863	62,452
Total international	228,225	244,912
Total consolidated	<u>\$ 818,611</u>	<u>\$ 891,293</u>

(1) Represents long-lived assets of foreign-based operations only.

### 16. Additional Consolidated Income Statement and Cash Flow Information

Included in other income (expense), net are interest and other investment income of \$ 6.8 million, \$ 12.0 million and \$ 1.0 million for 2024, 2023 and 2022, respectively. Income taxes paid in 2024, 2023 and 2022 were \$ 302.2 million, \$ 336.2 million and \$ 299.3 million, respectively. Cash paid for interest was \$ 113.9 million, \$ 66.3 million and \$ 80.2 million in 2024, 2023 and 2022, respectively.

### 17. Stockholders' Equity

In 2023, the Company repurchased approximately 0.1 million shares of its common stock for \$ 7.8 million in cash under its share repurchase authorization. On May 5, 2022, the Company's Board of Directors approved a \$ 1 billion authorization of its common stock, which replaced the previous \$ 500 million authorization announced in February 2019. In 2024, the Company repurchased approximately 1.3 million shares of its common stock for \$ 223.1 million in cash under its share repurchase authorization. At December 31, 2024, \$ 593.1 million was available under the Company's Board of Directors authorization for future share repurchases.

Effective February 9, 2024, the Company's Board of Directors approved a 12 % increase in the quarterly cash dividend on the Company's common stock to \$ 0.28 per common share from \$ 0.25 per common share.

At December 31, 2024, the Company held 39.4 million shares in its treasury at a cost of \$ 2,114.0 million, compared with 38.4 million shares at a cost of \$ 1,896.6 million at December 31, 2023. The number of shares outstanding at December 31, 2024 was 230.7 million shares, compared with 230.9 million shares at December 31, 2023.

### Subsequent Events

Effective February 7, 2025, the Company's Board of Directors approved an 11 % increase in the quarterly cash dividend on its common stock to \$ 0.31 per share from \$ 0.28 per share.

Effective February 7, 2025, the Company's Board of Directors approved a \$ 1.25 billion share repurchase authorization. This new authorization replaces the previous \$ 1 billion share repurchase authorization approved in May 2022.

**Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure**

None.

**Item 9A. Controls and Procedures**

*Disclosure Controls and Procedures*

The Company maintains a system of disclosure controls and procedures that is designed to provide reasonable assurance that information, which is required to be disclosed, is accumulated and communicated to management in a timely manner. Under the supervision and with the participation of our management, including the Company's principal executive officer and principal financial officer, we have evaluated the effectiveness of our system of disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of December 31, 2024. Based on that evaluation, the Company's principal executive officer and principal financial officer concluded that the Company's disclosure controls and procedures are effective at the reasonable assurance level.

Such evaluation did not identify any change in the Company's internal control over financial reporting during the quarter ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

*Internal Control over Financial Reporting*

Management's report on the Company's internal controls over financial reporting is included in Part II, Item 8 of this Annual Report on Form 10-K. The report of the independent registered public accounting firm with respect to the effectiveness of internal control over financial reporting is included in Part II, Item 8 of this Annual Report on Form 10-K.

**Item 9B. Other Information**

*Insider Trading Arrangements and Policies*

During the quarter ended December 31, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

**Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections**

None.

### PART III

#### Item 10. Directors, Executive Officers and Corporate Governance

a) Directors of the Registrant.

Information with respect to Directors of the Company is set forth under the heading "Election of Directors" in the Company's Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

b) Executive Officers of the Registrant.

Information with respect to executive officers of the Company is set forth under the heading "Executive Officers" in the Company's Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

c) Identification of the Audit Committee.

Information concerning the audit committee of the Company is set forth under the heading "Committees of the Board" in the Company's Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

d) Audit Committee Financial Experts.

Information concerning the audit committee financial experts of the Company is set forth under the heading "Committees of the Board" in the Company's Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

e) Corporate Governance/Nominating Committee.

Information concerning any material changes to the way in which security holders may recommend nominees to the Company's Board of Directors is set forth under the heading "Information about the 2026 Annual Meeting" in the Company's Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

f) Code of Ethics for Chief Executive Officer and Senior Financial Officers.

The Company has adopted a Code of Ethics for the principal executive officer, principal financial officer and principal accounting officer, which may be found on the Company's website at [www.ametek.com](http://www.ametek.com). Any amendments to the Code of Ethics or any grant of a waiver from the provisions of the Code of Ethics requiring disclosure under applicable U.S. Securities and Exchange Commission rules will be disclosed on the Company's website.

#### Item 11. Executive Compensation

Information regarding executive compensation, including the "Compensation Discussion and Analysis," the "Compensation Committee Report," "Compensation Tables" and "Potential Payments Upon Termination or Change of Control" is set forth under the heading "Executive Compensation" in the Company's Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

**Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**

Information regarding security ownership of certain beneficial owners and management appearing under “Stock Ownership of Executive Officers and Directors” and “Beneficial Ownership of Principal Stockholders” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders is incorporated herein by reference.

**Item 13. Certain Relationships and Related Transactions, and Director Independence**

Information appearing under “Certain Relationships and Related Transactions” and “Independence” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders is incorporated herein by reference.

**Item 14. Principal Accountant Fees and Services**

Information appearing under “Ratification of Appointment of Independent Registered Public Accounting Firm” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders is incorporated herein by reference.

**PART IV**

**Item 15. Exhibits and Financial Statement Schedules**

(a)(1) Financial Statements:

Financial statements are shown in the Index to Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.

(a)(2) Financial Statement Schedules:

Financial statement schedules have been omitted because either they are not applicable or the required information is included in the financial statements or the notes thereto.

(a)(3) Exhibits:

<u>Exhibit Number</u>	<u>Description</u>	<u>Incorporated Herein by Reference to</u>
3.1*	<a href="#">Conformed Copy of Amended and Restated Certificate of Incorporation of AMETEK, Inc. as amended to and including May 9, 2019.</a>	
3.2	<a href="#">By-Laws of AMETEK, Inc. as amended to and including November 9, 2018.</a>	Exhibit 3.2 to Form 10-Q dated March 31, 2020, SEC File No. 1-12981.
4.1*	<a href="#">Description of the Registrant's Securities</a>	
4.3†	<a href="#">AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan, dated as of May 3, 2011 (the "2011 Plan").</a>	Exhibit 4 to Form S-8 dated May 6, 2011, SEC File No. 1-12981.
4.4†	<a href="#">Amendment No. 1 to the 2011 Plan.</a>	Exhibit 4.5 to 2012 Form 10-K, SEC File No. 1-12981.
4.5†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan</a>	Exhibit 4.3 to Form S-8 dated May 8, 2020, No. 1-12981
10.1†	<a href="#">AMETEK, Inc. Retirement Plan for Directors, amended and restated effective January 1, 2005.</a>	Exhibit 10.4 to Form 10-Q dated September 30, 2007, SEC File No. 1-12981.
10.2†	<a href="#">AMETEK, Inc. Director's Deferred Compensation Plan, amended and restated as of October 1, 2018.</a>	Exhibit 10.1 to Form 10-Q dated September 30, 2018, SEC File No. 1-12981.
10.3†	<a href="#">AMETEK, Inc. Deferred Compensation Plan, amended and restated as of June 15, 2018.</a>	Exhibit 10.1 to Form 10-Q dated June 30, 2018, SEC File No. 1-12981.
10.5†	<a href="#">AMETEK, Inc. 2004 Executive Death Benefit Plan, amended and restated effective January 1, 2017.</a>	Exhibit 10.5 to 2016 Form 10-K, SEC File No. 1-12981.
10.6†	<a href="#">AMETEK, Inc. Directors' Death Benefit Plan, effective January 1, 2005.</a>	Exhibit 10.3 to Form 10-Q dated September 30, 2007, SEC File No. 1-12981.

[Table of Contents](#)

<b>Exhibit Number</b>	<b>Description</b>	<b>Incorporated Herein by Reference to</b>
10.7†	<a href="#">Form of Executive Change of Control Separation Agreement between AMETEK, Inc. and a named executive.</a>	Exhibit 10.7 to Form 10-Q dated September 30, 2007, SEC File No. 1-12981.
10.8	<a href="#">Amended and Restated Termination and Change of Control Agreement between AMETEK, Inc. and a named executive, dated February 19, 2024.</a>	Exhibit 10.8 to Form 10-K dated December 31, 2023, SEC File No. 1-12981.
10.9†	<a href="#">AMETEK, Inc. Retirement and Savings Plan, amended and restated as of September 4, 2018.</a>	Exhibit 10.2 to Form 10-Q dated September 30, 2018, SEC File No. 1-12981.
10.10†	<a href="#">AMETEK, Inc. Supplemental Executive Retirement Plan, amended and restated as of October 1, 2018.</a>	Exhibit 10.3 to Form 10-Q dated September 30, 2018, SEC File No. 1-12981.
10.11†	<a href="#">Form of Performance Restricted Stock Unit Agreement for Chief Executive Officer.</a>	Exhibit 10.1 to Form 10-Q dated March 31, 2018, SEC File No. 1-12981.
10.12†	<a href="#">Form of Performance Restricted Stock Unit Agreement.</a>	Exhibit 10.2 to Form 10-Q dated March 31, 2018, SEC File No. 1-12981.
10.13†	<a href="#">AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan, Form of Restricted Stock Agreement for non-employee Directors.</a>	Exhibit 10.1 to Form 8-K dated May 8, 2018, SEC File No. 1-12981.
10.14†	<a href="#">AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan, Form of Restricted Stock Agreement for Chief Executive Officer.</a>	Exhibit 10.2 to Form 8-K dated May 8, 2018, SEC File No. 1-12981.
10.15†	<a href="#">AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan, Form of Restricted Stock Agreement for Employees.</a>	Exhibit 10.3 to Form 8-K dated May 8, 2018, SEC File No. 1-12981.
10.16†	<a href="#">AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan, Form of Global Non-Qualified Stock Option Agreement for Employees.</a>	Exhibit 10.4 to Form 8-K dated May 8, 2018, SEC File No. 1-12981.
10.24	<a href="#">AMETEK, Inc. Note Purchase Agreement, as of September 30, 2014.</a>	Exhibit 10.1 to Form 8-K dated October 2, 2014, SEC File No. 1-12981.
10.25	<a href="#">Amendment No. 1 to Note Purchase Agreement, as of September 30, 2014.</a>	Exhibit 10.1 to Form 10-Q dated September 30, 2016, SEC File No. 1-12981.
10.26	<a href="#">AMETEK, Inc. Note Purchase Agreement, as of October 31, 2016.</a>	Exhibit 10.1 to Form 8-K dated November 2, 2016, SEC File No. 1-12981.
10.27	<a href="#">AMETEK, Inc. 2018 Note Purchase Agreement, dated as of December 13, 2018.</a>	Exhibit 10.1 to Form 8-K dated December 13, 2018, SEC File No. 1-12981.
10.28†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Performance Restricted Stock Unit Award for Chief Executive Officer</a>	Exhibit 10.1 to Form 10-Q dated March 31, 2021, SEC File No. 1-12981.
10.29†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Performance Restricted Stock Unit Award</a>	Exhibit 10.2 to Form 10-Q dated March 31, 2021, SEC File No. 1-12981.

## [Table of Contents](#)

<b>Exhibit Number</b>	<b>Description</b>	<b>Incorporated Herein by Reference to</b>
10.30†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Restricted Stock Award for Chief Executive Officer</a>	Exhibit 10.3 to Form 10-Q dated March 31, 2021, SEC File No. 1-12981.
10.31†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Restricted Stock Award for Non-Employee Directors</a>	Exhibit 10.4 to Form 10-Q dated March 31, 2021, SEC File No. 1-12981.
10.32†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Restricted Stock Award</a>	Exhibit 10.5 to Form 10-Q dated March 31, 2021, SEC File No. 1-12981.
10.33†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Global Non-Qualified Stock Option Award for Chief Executive Officer</a>	Exhibit 10.6 to Form 10-Q dated March 31, 2021, SEC File No. 1-12981.
10.34†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Global Non-Qualified Stock Option Award</a>	Exhibit 10.7 to Form 10-Q dated March 31, 2021, SEC File No. 1-12981.
10.35†	<a href="#">Amendment No. 1 to AMETEK Inc. 2020 Omnibus Incentive Compensation Plan</a>	Exhibit 10.35 to Form 10-K dated December 31, 2022, SEC File No. 1-12981.
10.36†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan, Form of Restricted Stock Unit Award for Non-U.S. Recipients</a>	Exhibit 10.36 to Form 10-K dated December 31, 2023, SEC File No. 1-12981.
10.37†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan and 2020 France Option Sub-Plan Form of France Non-Qualified Stock Option Award</a>	Exhibit 10.37 to Form 10-K dated December 31, 2023, SEC File No. 1-12981.
10.38†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Global Non-Qualified Stock Option Award - 2024 version</a>	Exhibit 10.38 to Form 10-K dated December 31, 2023, SEC File No. 1-12981.
10.39†	<a href="#">AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Global Non-Qualified Stock Option Award for Chief Executive Officer - 2024 version</a>	Exhibit 10.39 to Form 10-K dated December 31, 2023, SEC File No. 1-12981.
10.40	<a href="#">Amended and Restated Credit Agreement, dated May 12, 2022, by and among AMETEK, Inc., the Foreign Subsidiary Borrowers thereto, with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent, and Bank of America, N.A., PNC Bank, National Association, Truist Bank and Wells Fargo Bank, National Association, as Co-Syndication Agents.</a>	Exhibit 10.1 to Form 8-K dated May 12, 2022, SEC File No. 1-12981.
10.41	<a href="#">Amended and Restated Credit Agreement, dated June 17, 2024, by and among AMETEK, Inc., the Foreign Subsidiary Borrowers thereto, with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent, and Bank of America, N.A., PNC Bank, National Association, Truist Bank and Wells Fargo Bank, National Association, as Co-Syndication Agents.</a>	Exhibit 10.2 to Form 10-Q dated June 30, 2024, SEC File No. 1-12981.

[Table of Contents](#)

<b>Exhibit Number</b>	<b>Description</b>	<b>Incorporated Herein by Reference to</b>
19.1*	<a href="#">Insider Trading and Information Policy</a>	
21*	<a href="#">Subsidiaries of the Registrant.</a>	
23*	<a href="#">Consent of Independent Registered Public Accounting Firm.</a>	
97.1	<a href="#">Executive Compensation Recoupment Policy in Restatement Situations</a>	Exhibit 97.1 to Form 10-K dated December 31, 2023, SEC File No. 1-12981.
31.1*	<a href="#">Certification of Chief Executive Officer, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>	
31.2*	<a href="#">Certification of Chief Financial Officer, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>	
32.1*	<a href="#">Certification of Chief Executive Officer, Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>	
32.2*	<a href="#">Certification of Chief Financial Officer, Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>	
101.INS*	XBRL Instance Document.	
101.SCH*	XBRL Taxonomy Extension Schema Document.	
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.	
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.	
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.	
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.	
104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibit 101).	

† Management contract or compensatory plan required to be filed pursuant to Item 601 of Regulation S-K.

\* Filed electronically herewith.

**Item 16. Form 10-K Summary**

None.



**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMETEK, Inc.

By: /s/ DAVID A. ZAPICO

David A. Zapico

Chief Executive Officer

Date : February 20, 2025

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ DAVID A. ZAPICO</u> David A. Zapico	Chairman of the Board of Directors and Chief Executive Officer (Principal Executive Officer)	February 20, 2025
<u>/s/ DALIP M. PURI</u> Dalip M. Puri	Executive Vice President – Chief Financial Officer (Principal Financial Officer)	February 20, 2025
<u>/s/ THOMAS M. MONTGOMERY</u> Thomas M. Montgomery	Senior Vice President – Comptroller (Principal Accounting Officer)	February 20, 2025
<u>/s/ THOMAS A. AMATO</u> Thomas A. Amato	Director	February 20, 2025
<u>/s/ TOD E. CARPENTER</u> Tod E. Carpenter	Director	February 20, 2025
<u>/s/ ANTHONY J. CONTI</u> Anthony J. Conti	Director	February 20, 2025
<u>/s/ STEVEN W. KOHLHAGEN</u> Steven W. Kohlhagen	Director	February 20, 2025
<u>/s/ GRETCHEN W. MCCLAIN</u> Gretchen W. McClain	Director	February 20, 2025
<u>/s/ KARLEEN M. OBERTON</u> Karleen M. Oberton	Director	February 20, 2025
<u>/s/ DEAN SEAVERS</u> Dean Seavers	Director	February 20, 2025
<u>/s/ SUZANNE L. STEFANY</u> Suzanne L. Stefany	Director	February 20, 2025

**CONFORMED COPY OF AMENDED AND RESTATED**

**CERTIFICATE OF INCORPORATION OF**

**AMETEK, INC.**

**AS AMENDED TO DATE**

[Conformed copy giving effect to all amendments since the date of the filing of the Amended and Restated Certificate of Incorporation on April 24, 2007.]

FIRST. The name of the corporation is AMETEK, INC. (the "Company").

SECOND. The address of the Company's registered office in the State of Delaware is 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, Delaware 19808. The name of the Company's registered agent at such address is Corporation Service Company.

THIRD. The purpose of the Company is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware ("DGCL").

FOURTH. Section 1. Authorized Capital Stock. The Company is authorized to issue two classes of capital stock, designated Common Stock and Preferred Stock. The total number of shares of capital stock that the Company is authorized to issue is 805,000,000 shares, consisting of 800,000,000 shares of Common Stock, par value \$0.01 per share, and 5,000,000 shares of Preferred Stock, par value \$0.01 per share.

Section 2. Preferred Stock. The Preferred Stock may be issued in one or more series. The Board of Directors of the Company (the "Board") is hereby authorized to issue the shares of Preferred Stock in such series and to fix from time to time before issuance the number of shares to be included in any such series and the designation, relative powers, preferences, rights, qualifications, limitations and restrictions of all shares of such series. The authority of the Board with respect to each such series will include, without limiting the generality of the foregoing, the determination of any or all of the following:

- (a) the number of shares of any series and the designation to distinguish the shares of such series from the shares of all other series;
  - (b) the voting powers, if any, and whether such voting powers are full or limited in such series;
  - (c) the redemption provisions, if any, applicable to such series, including the redemption price or prices to be paid;
-

(d) whether dividends, if any, will be cumulative or noncumulative, the dividend rate of such series, and the dates and preferences of dividends on such series;

(e) the rights of such series upon the voluntary or involuntary dissolution of, or upon any distribution of the assets of, the Company;

(f) the provisions, if any, pursuant to which the shares of such series are convertible into, or exchangeable for, shares of any other class or classes or of any other series of the same or any other class or classes of stock, or any other security, of the Company or any other corporation or other entity, and the price or prices or the rates of exchange applicable thereto;

(g) the right, if any, to subscribe for or to purchase any securities of the Company or any other corporation or other entity;

(h) the provisions, if any, of a sinking fund applicable to such series; and

(i) any other relative, participating, optional, or other special powers, preferences, rights, qualifications, limitations, or restrictions thereof;

all as may be determined from time to time by the Board and stated in the resolution or resolutions providing for the issuance of such Preferred Stock (collectively, a "Preferred Stock Designation").

Section 3. Common Stock. Except as may otherwise be provided in a Preferred Stock Designation, the holders of Common Stock will be entitled to one vote on each matter submitted to a vote at a meeting of stockholders for each share of Common Stock held of record by such holder as of the record date for such meeting.

FIFTH. The Board may make, amend, and repeal the By-Laws of the Company. Any By- Law made by the Board under the powers conferred hereby may be amended or repealed by the Board or by the stockholders in the manner provided in the By-Laws of the Company.

Notwithstanding the foregoing and anything contained in this Amended and Restated Certificate of Incorporation to the contrary, By-Laws 3, 8, 10, 11, 12, 13 and 39 may not be amended or repealed by the stockholders, and no provision inconsistent therewith may be adopted by the stockholders, without the affirmative vote of the holders of at least 80% of the Voting Stock, voting together as a single class. The Company may in its By-Laws confer powers upon the Board in addition to the foregoing and in addition to the powers and authorities expressly conferred upon the Board by applicable law. For the purposes of this Amended and Restated Certificate of Incorporation, "Voting Stock" means stock of the Company of any class or series entitled to vote generally in the election of Directors. Notwithstanding anything contained in this Amended and Restated Certificate of Incorporation to the contrary, the affirmative vote of the holders of at least 80% of the Voting Stock, voting together as a single class, is required to amend or repeal, or to adopt any provisions inconsistent with, this Article Fifth.

SIXTH. Subject to the rights of the holders of any series of Preferred Stock:

(a) any action required or permitted to be taken by the stockholders of the Company must be effected at a duly called annual or special meeting of stockholders of the Company and may not be effected by any consent in writing of such stockholders; and

(b) special meetings of stockholders of the Company may be called only by (i) the Chairman of the Board (the "Chairman"), (ii) the Corporate Secretary of the Company (the "Secretary") within 10 calendar days after receipt of the written request of a majority of the total number of Directors which the Company would have if there were no vacancies (the "Whole Board"), or (iii) the Secretary upon the written request made in accordance with and subject to the By-Laws of holders of record, who hold a "net long position" (as defined in the By-Laws), of not less than fifty percent (50%) of the then outstanding shares of the Voting Stock of the Company.

At any annual meeting or special meeting of stockholders of the Company, only such business will be conducted or considered as has been brought before such meeting in the manner provided in the By-Laws of the Company. Notwithstanding anything contained in this Amended and Restated Certificate of Incorporation to the contrary, the affirmative vote of at least 80% of the Voting Stock, voting together as a single class, will be required to amend or repeal, or adopt any provision inconsistent with, this Article Sixth.

SEVENTH. Section 1. Number, Election, and Terms of Directors

Subject to the rights, if any, of the holders of any series of Preferred Stock to elect additional Directors under circumstances specified in a Preferred Stock Designation, the number of the Directors of the Company will not be less than three nor more than 12 and will be fixed from time to time in the manner described in the By-Laws of the Company. The Directors, other than those who may be elected by the holders of any series of Preferred Stock, will be classified with respect to the time for which they severally hold office into three classes, as nearly equal in number as possible, designated Class I, Class II, and Class III. The Directors elected to Class I will hold office for a term expiring at the annual meeting of stockholders to be held in 2019; the Directors elected to Class II will hold office for a term expiring at the annual meeting of stockholders to be held in 2020; and the Directors elected to Class III will hold office for a term expiring at the annual meeting of stockholders to be held in 2021, with the members of each class to hold office until their successors are elected and qualified. At each succeeding annual meeting of the Company, the successors of the class of Directors whose terms expire at that meeting will be elected to hold office for a term expiring at the annual meeting of stockholders held in the third year following the year of their election. Election of Directors of the Company need not be by written ballot unless requested by the Chairman or by the holders of a majority of the Voting Stock present in person or represented by proxy at a meeting of the stockholders at which Directors are to be elected.

Directors shall be elected at a duly called meeting of the stockholders at which a quorum is present. In any uncontested election of Directors, a nominee shall be elected as a Director at such a meeting if the votes of shares of capital stock of the Company present in person or represented by proxy at the meeting and entitled to vote in the election of Directors cast "for" such nominee's election exceed the votes of shares of capital stock of the Company present in

person or represented by proxy at the meeting and entitled to vote in the election of Directors cast

“against” such nominee’s election (with “abstentions” and “broker non-votes” not counted as votes cast either “for” or “against” that nominee’s election). In a contested election, Directors shall be elected by plurality vote of all votes cast at such a meeting. An election is considered contested if the Board determines that (a) there are more nominees for election than positions on the Board to be filled or (b) one or more nominees for election to the Board was nominated other than by or at the direction of the Board.

If, in any uncontested election, an incumbent Director is duly nominated for re-election but is not elected, then such incumbent Director shall promptly tender his or her resignation to the Board for consideration. The Board shall make a decision on whether to accept or reject such Director’s resignation, or whether to take other appropriate action, and will publicly disclose its decision. The Board may delegate to the Corporate Governance/Nominating Committee (or to such other committee as the Board may duly designate from time to time) responsibility for making a recommendation to the Board regarding such matters. An incumbent Director required to tender his or her resignation pursuant to this Section 1 of Article Seventh will not participate in any decision of the Board regarding such resignation, or in any recommendation of any committee relating thereto, or in any deliberations of the Board or any such committee relating thereto.

If a Director tenders his or her resignation in the circumstances contemplated by the immediately preceding paragraph and such resignation is accepted by the Board, or if a nominee for Director is not elected and the nominee is not an incumbent Director, then the Board may fill the resulting vacancy pursuant to the terms of this Amended and Restated Certificate of Incorporation and of the By-Laws of the Company relating to the filling of Board vacancies generally, or may decrease the size of the Board pursuant to the terms of this Amended and Restated Certificate of Incorporation. If a Director tenders his or her resignation in the circumstances contemplated by the immediately preceding paragraph and such resignation is not accepted by the Board, then such Director shall continue to serve until such Director’s successor has been duly elected and qualified or until his or her earlier death, resignation or removal as provided in this Amended and Restated Certificate of Incorporation and in the By-Laws of the Company.

This Section 1 of Article Seventh shall be subject, in all respects, to the rights, if any, of the holders of Preferred Stock, in each case as specified in more detail in the applicable Preferred Stock Designation.

Section 2. Nomination of Director Candidates. Advance notice of stockholder nominations for the election of Directors must be given in the manner provided in the By-Laws of the Company.

Section 3. Newly Created Directorships and Vacancies. Subject to the rights, if any, of the holders of any series of Preferred Stock to elect additional Directors under circumstances specified in a Preferred Stock Designation, newly created directorships resulting from any increase in the number of Directors and any vacancies in the Board resulting from death, resignation, disqualification, removal, or other cause will be filled solely by the affirmative vote of a majority of the remaining Directors then in office, even though less than a quorum of the

Board, or by a sole remaining Director. Any Director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the class of Directors in which the new directorship was created or the vacancy occurred and until such Director's successor has

been elected and qualified. No decrease in the number of Directors constituting the Board may shorten the term of any incumbent Director.

Section 4. Removal. Subject to the rights, if any, of the holders of any series of Preferred Stock to elect additional Directors under circumstances specified in a Preferred Stock Designation, any Director may be removed from office by the stockholders only for cause and only in the manner provided in this Section 4. At any annual meeting or special meeting of the stockholders, the notice of which states that the removal of a Director or Directors is among the purposes of the meeting, the affirmative vote of the holders of at least a majority of the Voting Stock, voting together as a single class, may remove such Director or Directors for cause. Except as may be provided by applicable law, cause for removal will be deemed to exist only if the Director whose removal is proposed has been adjudged by a court of competent jurisdiction to be liable to the Company or its stockholders for misconduct as a result of (a) a breach of such Director's duty of loyalty to the Company, (b) any act or omission by such Director not in good faith or which involves a knowing violation of law, or (c) any transaction from which such Director derived an improper personal benefit, and such adjudication is no longer subject to direct appeal.

Section 5. Amendment, Repeal, Etc. Notwithstanding anything contained in this Amended and Restated Certificate of Incorporation to the contrary, the affirmative vote of at least 80% of the Voting Stock, voting together as a single class, is required to amend or repeal, or adopt any provision inconsistent with, this Article Seventh.

EIGHTH. To the fullest extent permitted by the Delaware General Corporation Law, a director of the Company shall not be liable to the Company or its stockholders for monetary damages for any breach of a fiduciary duty as a director. If the Delaware General Corporation Law is hereafter amended to authorize the further elimination or limitation of the liability of a director, then the liability of a director of the Company shall be eliminated or limited to the fullest extent permitted by the Delaware Corporation law, as so amended. Any repeal or modification of the foregoing provisions of this Article EIGHTH by the stockholders of the Company shall not adversely affect any right or protection of a director of the Company existing at the time of such repeal or modification.

NINTH. Each person who is or was or had agreed to become a Director or officer of the Company, and each such person who is or was serving or who had agreed to serve at the request of the Board or an officer of the Company as an employee or agent of the Company or as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other entity, whether for profit or not for profit (including the heirs, executors, administrators, or estate of such person), will be indemnified by the Company to the fullest extent permitted by the Delaware General Corporation Law as the same may be amended or supplemented. The right of indemnification provided in this Article Ninth (a) will not be exclusive of any other rights to which any person seeking indemnification may otherwise be entitled, including without limitation pursuant to any contract approved by a majority of the Whole Board (whether or not the Directors approving such contract are or are to be parties to such contract or similar contracts), and (b) will be applicable to matters otherwise within its scope whether or not such

matters arose or arise before or after the adoption of this Article Ninth. Without limiting the generality or the effect of the foregoing, the Company may adopt By-Laws, or enter into one or

more agreements with any person, which provide for indemnification greater or different than that provided in this Article Ninth or the Delaware General Corporation Law. Notwithstanding anything contained in this Amended and Restated Certificate of Incorporation to the contrary, the amendment or repeal of, or adoption of any provision inconsistent with, this Article Ninth will require the affirmative vote of the holders of at least 80% of the Voting Stock, voting together as a single class. Any amendment or repeal of, or adoption of any provision inconsistent with, this Article Tenth will not adversely affect any right or protection existing hereunder prior to such amendment, repeal, or adoption.

TENTH. Whenever a compromise or arrangement is proposed between the Company and its creditors or any class of them and/or between the Company and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of the Company or any creditor or stockholder thereof or on the application of any receiver or receivers appointed for the Company under the provisions of Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for the Company under the provisions of Section 279 of Title 8 of the Delaware Code, order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders, of the Company, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders, of the Company, as the case may be, agree to any compromise or arrangement and to any reorganization of the Company as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of the Company, as the case may be, and also on the Company.

IN WITNESS WHEREOF, the undersigned has executed and acknowledged this Conformed Copy of the Certificate of Incorporation of AMETEK, Inc. this 9<sup>th</sup> day of May, 2019.

	Inc.	AMETEK,
		/s/
By:	ROBERT S. FEIT	Robert S.
Name:	Feit	Senior
Title:	Vice President, General Counsel and Corporate Secretary	

**DESCRIPTION OF THE REGISTRANT'S SECURITIES  
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES  
EXCHANGE ACT OF 1934**

AMETEK, Inc. ("we," "our," or the "Company") has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.

**DESCRIPTION OF COMMON STOCK**

The general terms and provisions of our common stock are summarized below. This summary does not purport to be complete and is subject to, and is qualified in its entirety by express reference to, the provisions of our Amended and Restated Certificate of Incorporation (as amended to date, our "Charter") and By-laws (as amended to date, our "By-laws"), each of which is filed, or incorporated by reference, as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part. We encourage you to read our Charter and By-laws and the applicable provisions of the General Corporation Law of the State of Delaware (the "DGCL") for additional information.

**Authorized Shares**

Under our Charter, we have the authority to issue 800,000,000 shares of common stock, with a par value of \$0.01 per share.

**Voting Rights**

Holders of our common stock are entitled to one vote per share on all matters voted on by our stockholders.

**Dividend Rights**

The holders of our common stock are entitled to receive dividends when, as, and if declared by our board of directors out of legally available funds, subject to the rights of any then outstanding preferred stock.

**Liquidation Rights**

Upon a liquidation or dissolution of the Company, whether voluntary or involuntary, all shares of our common stock are entitled to share equally and ratably in the assets available for distribution to holders of common stock after payment of all of our prior obligations, subject to the rights of any then outstanding preferred stock.

**Other Matters**

The holders of our common stock have no preemptive, conversion or exchange rights. There are no redemption or sinking fund provisions applicable to our common stock.

---



## Certain Anti-Takeover Effects

Certain provisions of the DGCL and our Charter and By-laws contain provisions that could have certain anti-takeover effects and may delay, deter or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, as discussed below:

*Authorized but Unissued Shares.* Subject to the requirements of the New York Stock Exchange and other applicable law, our authorized but unissued shares of common stock may be available for future issuance without stockholder approval. We may use these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans.

*Undesignated Preferred Stock.* Our Charter provides that our board of directors may issue up to 5,000,000 shares of preferred stock and fix the designations, relative powers, preferences, rights, qualifications, limitations and restrictions related to that preferred stock.

*Advance Notice Requirements.* Our By-laws establish an advance notice procedure for stockholders seeking to nominate candidates for election to the board of directors or for proposing matters which can be acted upon at stockholders' meetings.

*Special Meetings of Stockholders.* Our Charter and By-laws vest the power to call special meetings of our stockholders in the chairman of our board of directors, our board of directors and stockholders of record, who hold a "net long position" (as defined in our By-laws), of not less than 50% of our then outstanding voting stock (subject to the procedures and other requirements set forth in our By-laws).

*No Action by Written Consent.* Our Charter provides that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of the stockholders and may not be effected by any consent in writing of such stockholders.

*Classified Board of Directors.* Our board of directors is divided into three classes with staggered terms of three years each, so that the term of one class expires at each annual meeting of the stockholders.

*Proxy Access.* Our By-laws contain provisions which provide that a stockholder, or group of up to 20 stockholders, that has owned continuously for at least three years capital stock of the Company representing an aggregate of at least 3% of the Company's voting stock, may nominate and include in the Company's proxy materials a specified number of director nominees, provided that the stockholder(s) and nominee(s) satisfy the requirements in our By-laws. The maximum number of stockholder nominees is the greater of (x) two or (y) a number that does not exceed 20% of the total number of our directors in office as of the last day on which notice of a nomination may be delivered or, if such amount is not a whole number, the closest whole number below 20%.

*No Cumulative Voting.* Our Charter and By-laws do not provide for cumulative voting on the election of directors.

*Delaware Business Combination Statute.* As a Delaware corporation, we are subject to Section 203 of the DGCL. In general, Section 203 of the DGCL provides that we may not engage in certain

---

“business combinations” with any “interested stockholder” for a three-year period following the time that such stockholder becomes an interested stockholder unless:

- prior to such time, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
- upon consummation of the transaction which resulted in the stockholder becoming an “interested stockholder,” the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced (excluding certain shares); or
- on or subsequent to such time, the business combination is approved by our board of directors and authorized at a meeting of stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.

Generally, a “business combination” includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an “interested stockholder” is a person who, together with that person’s affiliates and associates, owns, or within the previous three years owned, 15% or more of our voting stock.

#### **Exclusive Forum for Adjudication of Disputes**

Our By-laws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if such court lacks jurisdiction, another state court located within the State of Delaware, or if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (a) any derivative action or other proceeding brought on behalf of the Company, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or to the Company’s stockholders, creditors or other constituents, (c) any action asserting a claim against the Company or any director or officer of the Company arising pursuant to any provision of the DGCL or our Charter or By-Laws, or (d) any action asserting a claim against the Company or any director or officer of the Company governed by the internal affairs doctrine. Our By-laws provide that any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company shall be deemed to have notice of and consented to the exclusive forum provision.

#### **Listing**

Our common stock is traded on the New York Stock Exchange under the trading symbol “AME.”



## POLICIES AND PROCEDURES MANUAL

<b>Instruction Number:</b> PP#100.00.03	<b>Date Issued:</b> 11/9/18
<b>Subject:</b> Insider Trading and Information Policy	
<b>Effective Date:</b> 4/26/10 Last Revised: 11/2/23	<b>Number of pages:</b> 9

### 1.0 PURPOSE AND SCOPE:

- 1.1 AMETEK, Inc. (the "Company") prohibits the disclosure or misuse of confidential information obtained by employees in connection with their employment. In addition, the law requires that trades in Company securities by members of its Board of Directors (which, for purposes of this policy, includes Directors Emeritus), officers and employees who possess material non-public information be prohibited until the information has been publicly disclosed and adequately disseminated. To help its directors, officers and employees comply with insider trading laws and to prevent even the appearance of improper trading, the Company has adopted this Insider Trading and Information Policy. *It is important that you review this policy carefully.*
- 1.2 This policy applies to all transactions in Company securities, including transactions in common stock, options, preferred stock, restricted stock, restricted stock units, and any other type of securities that Company may issue. This policy applies to such securities regardless of the type of account they are held in (i.e., a brokerage, 401(k) account or other retirement account).
- 1.3 This policy applies to the following individuals (collectively, "Covered Persons"):
  - all directors (including directors emeritus),
  - all officers and employees of Company, and
  - a spouse, partner and minor children, no matter where they live, of a person listed above and anyone else living in a household of a person listed above.

This policy also applies to any entity over which a Covered Person has significant influence as it relates to security trading decisions of that entity, such as a corporation, partnership, trust and estate.

---

Sections 5 – 7 of this policy shall apply only to directors (including directors emeritus), officers and employees of the Company.

## 2.0 POLICY:

### **Specific Guidance**

- 2.1 Insider Trading: You may not buy, sell or otherwise trade in securities of the Company while you possess material, non-public information about the Company. You must maintain the confidentiality of information belonging to or relating to the Company and learned through your employment with the Company.
- 2.2 Tipping: Providing material nonpublic information to another person who may trade or advise others to trade on the basis of that information is known as “tipping” and is illegal. Therefore, no officer, director or employee may “tip” or provide material nonpublic information concerning the Company to any person who is not a director, officer or employee of the Company, unless required as part of that person’s duties for the Company and authorized by the Chief Financial Officer and General Counsel.
- 2.3 Trading in Securities of Other Companies: No officer, director or employee may, while in possession of material, non-public information about any other public company gained in the course of employment with the Company: (a) trade in the securities of the other public company, (b) “tip” or disclosure such material non-public information concerning that company to anyone, or (c) give trading advice of any kind to anyone concerning the other public company.

### **Specific Definitions**

#### 2.4 What is Material Information?

In general, information about Company should be considered “Material Information” if:

- a reasonable investor would consider the information significant when making the decision to invest or to sell, or
- the information would be significant as part of the total mix of information available to an investor, for purposes of making a decision.

In simple terms, if it is likely to affect the price of the Company’s stock, it should be considered material. There is no bright line test for determining materiality. It is very important to remember that whether information is

---

material will be viewed by enforcement authorities with the benefit of hindsight, including a change in stock price.

The following illustrates examples of information that ordinarily should be considered material:

- 2.4.1 Financial results, especially earnings, earnings estimates or operating results;
  - 2.4.2 Internal financial projections that vary from publicly stated financial projections;
  - 2.4.3 Gain or loss of major contract, order, customer, supplier, or finance source;
  - 2.4.4 An important new product or service;
  - 2.4.5 Significant operating or financial changes, such as cash-flow reductions, major write-offs or the shutdown or curtailment of any important facility of a company;
  - 2.4.6 Mergers and acquisitions ("M&A") activity, including joint ventures or other investments, or the termination thereof;
  - 2.4.7 The initiation or resolution of significant litigation or a significant litigation development;
  - 2.4.8 Significant changes in the Company's management;
  - 2.4.9 A change in the Company's independent registered public accounting firm;
  - 2.4.10 A change or proposed change in the Company's dividend amount or policy;
  - 2.4.11 A significant government investigation;
  - 2.4.12 Significant raw material shortages;
  - 2.4.13 A significant cybersecurity incident or investigation;
  - 2.4.14 The possibility of a public or private offering of debt or securities, a stock split, or a repurchase of securities by the Company; or
-

2.4.15 Any other event that would be expected to affect the value in the market of Company securities.

## 2.5 When is Information Considered Public?

If you are aware of material, non-public information, you may trade only when you are certain that official announcements of the material information have been sufficiently publicized so that the public has had the opportunity to evaluate the information. As a normal rule, information is considered non-public until at least one full business day after the information is released by the Company to investors through a widely circulated news wire service (such as Dow Jones, Bloomberg, PR Newswire, etc.). For example, if an announcement is made on Monday afternoon during the trading day, trading should not occur until Wednesday morning. If you have questions concerning the nature of any information you possess, please contact the Corporate Secretary for guidance before trading in any Company securities.

## 3.0 SPECIAL RESTRICTIONS FOR SECTION 16 INSIDERS

3.1 General: Section 16 Insiders are subject to additional restrictions on their purchases and sales of Company securities. "Section 16 Insider" means:

- each member of the Board of Directors of the Company, any Directors Emeritus if designated by the Board as a Section 16 Insider; and
- Company officers designated by the Board as "Section 16 officers" of the Company.

The additional restrictions, which include the blackout periods and pre-clearance of securities transactions, also apply to:

- a spouse, partner and minor children, no matter where they live, of a Section 16 Insider and anyone else living in a Section 16 Insider's household; and
- any entity over which a Section 16 Insider has significant influence as it relates to security trading decisions of that entity, such as a corporation, partnership, trust and estate.

3.2 Blackout Periods: All transactions in Company securities by Section 16 Insiders are prohibited during a quarterly or other Blackout Period, as described below. Prohibited transactions include open market purchases or sales of Company securities, the "cashless" exercise of securities options and any changes to investments in Company securities held under the Company's 401(k) Plan or other Company retirement plan that has any Company securities as an investment option.

---

Exceptions to trading prohibition during Blackout Periods

- The exercise and holding of Company securities under a stock option grant or similar award where the underlying shares are to be held following the exercise. The disposition of any Company securities after they are acquired by such exercise is subject to the prohibition on trading during Blackout Periods.
- The surrender to the Company of shares to pay the option exercise price, tax withholding obligations, or other associated costs, in connection with vesting of restricted stock, exercise of stock options or similar equity awards.

Quarterly Blackout Periods:

The Company's announcement of its quarterly financial results almost always has the potential to have a material effect on the market for Company securities. Therefore, to avoid even the appearance that a Section 16 Insider is trading while in possession of material, non-public information, Blackout Periods will be in effect commencing at the close of business on the last business day of a fiscal quarter and ending after the first full trading day following the issuance of the earnings press release. For example, if an earnings press release is issued before the opening of trading on a Wednesday, the Blackout Period will be in effect until the opening of trading on the Thursday that is one full business day later. If the earnings press release is issued during the trading day or following the trading day on a Thursday, the Blackout Period will be in effect until the opening of trading on the Monday that is one full business day later.

Other Blackout Periods:

Other special situation Blackout Periods may be placed into effect as needed (for example, in connection with a material M&A transaction).

Moreover, any person who possesses material, non-public, information concerning the Company must not engage in transactions in Company securities until at least one full trading day has elapsed following public disclosure of the information.

---

- 3.3 Preclearance of Transactions in Company Securities The Company requires Section 16 Insiders to pre-clear proposed trades at least one business day in advance with the Corporate Secretary or his or her designee. The Section 16 Insider is not permitted to seek pre-clearance if he or she is aware of material non-public information about the Company.
- 3.4 Derivative Transactions: Section 16 Insiders may not engage in derivative transactions in Company securities, such as “put” and “call” options (e.g., to sell or buy securities with a certain time period and at a specified price). In addition, Section 16 Insiders may not engage in short sales of Company securities, defined as sales of securities that are not then owned.
- 3.5 Prohibition on Hedging: Section 16 Insiders are not permitted to purchase financial instruments (i.e., prepaid variable forward contracts, collars, equity swaps and exchange funds) that are designed to hedge or offset any decrease in the market value of Company securities.
- 3.6 Prohibition on Pledging Company Securities: Section 16 Insiders may not pledge Company securities. This prohibition relates to any type of pledge arrangement, including margin accounts covering Company securities.
- 3.7 Recovery of Short-Swing Profits: Any profit realized by a Section 16 Insider on a “short swing” transaction (i.e., purchase and sale, or sale and purchase within a period of less than six months) is recoverable by the Company. This applies to trades involving securities considered by the SEC to be beneficially owned by a Section 16 Insider which include securities held in the name of the Insider, a spouse or minor child, or by a relative living in the same household. **Any Section 16 Insider should advise his or her broker of that status prior to initiating any trade.**
- 3.8 Reporting Requirements: Section 16 is enforced through the reporting provisions of Section 16(a), which requires Section 16 Insiders to report their transactions in Company securities to the SEC and stock exchanges. Timely filing of Section 16(a) reports is crucial. The Company must identify in the proxy statement those persons who failed to file reports or who filed delinquent reports in the previous year. Section 16 Insiders may also be subject to substantial monetary penalties for missing Section 16(a) deadlines. Required Section 16(a) reports are:
- Form 3 - Filed within 10 days of the time an individual becomes a Section 16 Insider.
  - Form 4 - Filed within 2 business days after the day most transactions are executed, including (a) option grants and exercises; (b) purchases or sales of stock, regardless of whether
-



the transactions occur in the open market, as a result of a fund switch in a Company retirement plan, or between you and the Company; (c) surrender of shares to pay tax liability or the exercise price of an option or (d) gifts of securities (which may include certain transfers without consideration in connection with formation of trust and estate planning matters).

- Form 5 - Filed within 45 days of the fiscal year end for certain transactions exempt from Section 16(b) liability. Forms 5 are mainly used to report small acquisitions from a source other than the Company.

The preparation and filing of Forms 3, 4 and 5 are the sole responsibility of the Section 16 Insider. However, as a practical matter, the Corporate Secretary will assist you by preparing the Forms for your review and signature.

In addition to the obligation for the Section 16 insider to file these reports, the Company is required to make certain quarterly and annual disclosures regarding transactions in Company securities by Section 16 insiders.

**Given these disclosure requirements, Section 16 insiders are required to report to the Corporate Secretary of the Company, as promptly as practicable but in any event within 24 hours after it is completed, all transactions in Company securities, as well as the information requested by the Corporate Secretary to facilitate these disclosure requirements.**

#### 4.0 POTENTIAL PENALTIES AND DISCIPLINARY ACTION:

- 4.1 Penalties Applicable to Insider Traders: The government can seek civil penalties against a person who trades while in possession of material, non-public information of up to three times the profit gained or loss avoided. If tipping is involved, both the tippee who traded and the tipper are subject to this penalty. A court may also impose fines of up to \$5 million, and prison terms of up to 20 years. In addition, individuals may be prohibited from serving as directors of the Company or any other public company. The law also gives private persons the right to sue people who trade on the basis of material, non-public information.
  - 4.2 Liability of Controlling Persons: The SEC also may impose liability on the Company and any other "controlling person" of an insider trading violator for up to the greater of \$1,000,000 or three times the amount of profit gained or loss avoided as a result of the insider trading violation.
-

- 4.3 Company Discipline: Violation of this policy or federal or state insider trading or tipping laws may, in the case of a director, subject the director to removal proceedings in accordance with the Company's Amended and Restated Certificate of Incorporation and, in the case of any officer or employee, subject the officer or employee to disciplinary action by the Company up to and including termination for cause.

- 5.0 CONFIDENTIALITY: You must maintain the confidentiality of information belonging to or relating to the Company or relating to others and obtained through a relationship with the Company. Adhering to this principle is a condition of continued employment.

Some practical steps to be taken to preserve confidentiality include:

- 5.1 Don't discuss material information in public places where you can be overheard, such as elevators, hallways, restaurants, airplanes or taxicabs.
- 5.2 Don't read confidential documents in public places or discard them where they can be retrieved by others. Don't leave confidential documents in unattended conference rooms. Don't leave confidential papers lying where visitors can see them.
- 5.3 Be aware that voices carry and that conversations conducted on speaker telephones in offices and on cell phones may be overheard easily.
- 5.4 Be aware that conversations about where the Company's personnel are traveling or the presence of certain visitors in the office may reveal confidential information.
- 5.5 Under no circumstances are you to provide confidential Company documents or information, including documents relating to customers, competitors or suppliers of the Company to third parties, without the express consent of the Chief Financial Officer or the General Counsel.

6.0 RESPONSIBILITY:

- 6.1 Company General Managers are responsible for communicating Company policy to all personnel. Exhibit A (attached) should be posted on bulletin boards throughout the Company.
  - 6.2 Company General Managers, Division Controllers, Business Unit Managers and Business Unit Controllers are responsible for conducting a survey of key personnel, at least annually, using the questionnaire issued annually under policy PP #100.20.02, Conflict of Interest and Business Conduct (see Exhibit #1 thereto).
-

6.3 The Business Unit Controllers are responsible for conducting annual surveys, using the same questionnaire referred to in paragraph 6.2, of all other officers and appropriate key personnel.

- 7.0 RESPONDING TO INQUIRIES FROM THE PRESS AND OTHERS: If someone outside the Company, such as the news media or a securities analyst or investor, asks you questions, either directly or through another person, do not attempt to answer them. You should obtain the name of the person making the inquiry and immediately notify the Vice President of Investor Relations at the Corporate Office, who will handle the matter.
-

PP #100.00.03 Exhibit A

**NOTICE TO ALL AMETEK EMPLOYEES****TRADING SECURITIES USING NON-PUBLIC  
INFORMATION IS ILLEGAL**

Federal and state securities laws, as well as AMETEK policy, prohibit AMETEK personnel from buying, selling and otherwise trading a company's securities based on non-public information which is obtained through special knowledge of such company's affairs. This is known as "insider trading." A conviction of "insider trading" carries serious civil and criminal penalties, including:

- Up to a \$5 million fine per violation (no matter how small the profit)
- Jail sentences for up to 20 years
- Fines up to three times the profit made or loss avoided by the violator
- Liable for up to three times the profit made or loss avoided by those to whom you give information

If you are aware of material information relating to AMETEK, its suppliers or its customers, or information relating to companies with which AMETEK is negotiating or competing, you may not buy, sell or otherwise trade securities of AMETEK or these companies or disclose this information to or "tip" any other person outside AMETEK until the information has been disclosed and absorbed by the public. These restrictions also apply to your family members and others in your household.

You should consider material information to be any information that is likely to affect the price of AMETEK's stock. You could be aware of material information if, for example, you learn of recent AMETEK financial results or financial projections, or those of a major customer, especially earnings information, or you learn of possible significant acquisitions or joint ventures, other purchases and sales of or investments in other companies. The same is true if you know that AMETEK or one of its customers has just obtained or lost a major contract or account, or has made a significant product development.

**Information is non-public**, unless it has been adequately disclosed to investors through a widely circulated news wire service, such as Dow Jones, Bloomberg, PR Newswire, etc. The fact that many co-workers and others know the same material information does not mean the information is public. As a normal rule, any person who possesses material, non-public information must not engage in transactions in AMETEK securities until at least one full trading day has elapsed following public disclosure of the information.

If you have a question as to whether certain information is material or if it has been adequately disclosed to the public, you should contact your General Manager or the Corporate Secretary. In the meantime, you may not trade in the relevant securities or disclose the information to people outside AMETEK until you have received a response that you are permitted to do so.

A more complete statement of AMETEK's policy on these matters can be obtained from SharePoint, or you may ask your General Manager or the Corporate Secretary for a complete statement.

**SUBSIDIARIES OF AMETEK, INC.**  
**AS OF DECEMBER 31, 2024**

**Exhibit 21**

<b>Company</b>	<b>State or other jurisdiction of incorporation or organization</b>	<b>Percentage of voting securities owned by its immediate parent*</b>
1295720 B.C. Ltd.	Canada	100%
4DSP, LLC	Nevada	100%
Abaco Systems Holding Corp.	Delaware	100%
Abaco Systems Limited	United Kingdom	100%
Abaco Systems Private Limited	India	100%
Abaco Systems Technology Corp.	New York	100%
Abaco Systems, Inc.	Delaware	100%
Abaco UK Holdco Limited	United Kingdom	100%
Advanced Measurement Technology, Inc.	Delaware	100%
AEM Limited	United Kingdom	100%
AIP/MPM Holdings, Inc.	Delaware	100%
Airtechnology Pension Trustees Limited	United Kingdom	100%
Akron Standard Bestry (Guangzhou) Measurement Equipment Co., Ltd.	China	50%
Alphasense Limited	United Kingdom	100%
Amekai (BVI) Ltd.	British Virgin Islands	50%
Amekai Meter (Xiamen) Co., Ltd.	China	100%
Amekai Singapore Private Ltd.	Singapore	50%
Amekai Taiwan Co., Ltd.	Taiwan	50%
AMETEK (Barbados) SRL	Barbados	100%
AMETEK (Bermuda), Ltd.	Bermuda	100%
AMETEK (GB) Limited	United Kingdom	100%
AMETEK (Thailand) Co., Ltd.	Thailand	99.999%
AMETEK Advanced Industries, Inc.	Delaware	100%
AMETEK Aegis, Inc.	Delaware	100%
AMETEK Aerospace & Defense Group UK Ltd.	United Kingdom	100%
AMETEK Aerospace & Power Holdings, Inc.	Delaware	100%
AMETEK Aircraft Parts & Accessories, Inc.	Delaware	100%
AMETEK Airtechnology Group Limited	United Kingdom	100%
AMETEK Ameron, LLC	Delaware	100%
AMETEK Arizona Instrument LLC	Arizona	100%
AMETEK B.V.	The Netherlands	100%
AMETEK Bison Gear & Engineering, Inc.	Illinois	100%
AMETEK Canada 3 ULC	Canada	100%
AMETEK Canada Limited Partnership	Canada	99.98%
AMETEK Co., Ltd.	Japan	100%
AMETEK Commercial Enterprise Shanghai	China	100%
AMETEK Creaform ULC	Canada	99.90%
AMETEK CTS Europe GmbH	Germany	100%
AMETEK CTS GmbH	Switzerland	100%

## SUBSIDIARIES OF AMETEK, INC.

AS OF DECEMBER 31, 2024

Company	State or other jurisdiction of incorporation or organization	Percentage of voting securities owned by its immediate parent*
AMETEK Customer Service S. de R. L. de C.v.	Mexico	100%
AMETEK d.o.o. Subotica	Serbia	100%
AMETEK Denmark A/S	Denmark	100%
AMETEK do Brasil Ltda.	Brazil	99%
AMETEK Edinburgh Holdings LP	Scotland	99%
AMETEK Elektromotory, s.r.o	Czech Republic	99.97%
AMETEK EMG Holdings, Inc.	Delaware	100%
AMETEK Engineered Materials Sdn. Bhd.	Malaysia	100%
AMETEK Europe, L.L.C.	Berwyn, PA	100%
AMETEK European Holdings GmbH	Germany	100%
AMETEK European Holdings Limited	United Kingdom	100%
AMETEK Finland Oy	Finland	100%
AMETEK Germany GmbH	Germany	100%
AMETEK Global Limited	United Kingdom	100%
AMETEK Global Tubes, LLC	Delaware	59.50%
AMETEK GmbH	Germany	31.99%
AMETEK Grundbesitz GmbH	Germany	100%
AMETEK Haydon Kerk, Inc.	Delaware	100%
AMETEK Holdings de Mexico, S. de R.L.	Mexico	50%
AMETEK Holdings SARL	France	74%
AMETEK Hong Kong Private Limited	Hong Kong	100%
AMETEK HSA, Inc.	Delaware	100%
AMETEK Industrial Technology (Shanghai) Co., Ltd.	China	100%
AMETEK Instrumentos, S.L.	Spain	100%
AMETEK Instruments Group UK Limited	United Kingdom	100%
AMETEK Instruments India Private Limited	India	100%
AMETEK International Limited	United Kingdom	100%
AMETEK Korea Co., Ltd.	Korea	100%
AMETEK Lamb Motores de Mexico, S. de R.L. de C.V.	Mexico	99.99%
AMETEK Land, Inc.	Delaware	100%
AMETEK Latin America Holding Company S.à r.l.	Luxembourg	100%
AMETEK Magnetrol USA, LLC	Delaware	100%
AMETEK Material Analysis Holdings GmbH	Germany	100%
AMETEK Mexico Holding Company, LLC	Delaware	100%
AMETEK Middle East FZE	United Arab Emirates	100%
AMETEK Motors Asia Pte. Ltd.	Singapore	100%
AMETEK MRO Florida, Inc.	Delaware	100%
AMETEK Nordic AB	Sweden	100%
AMETEK PIP Holdings, Inc.	Delaware	100%
AMETEK Precitech, Inc.	Delaware	100%
AMETEK Programmable Power, Inc.	Delaware	100%
AMETEK S.A.S.	France	76.7%
AMETEK S.r.l.	Italy	14.0%
AMETEK SCP (Barrow) Limited	United Kingdom	100%
AMETEK SCP, Inc.	Rhode Island	100%
AMETEK Singapore Private Ltd.	Singapore	100%
AMETEK Solution ULC	Canada	100%

## SUBSIDIARIES OF AMETEK, INC.

AS OF DECEMBER 31, 2024

Company	State or other jurisdiction of incorporation or organization	Percentage of voting securities owned by its immediate parent*
AMETEK Taiwan Co. Ltd.	Taiwan	50.5%
AMETEK Technical & Industrial Products, Inc.	Minnesota	51.9%
AMETEK Thermal Systems, Inc.	Delaware	100%
AMETEK TP, Inc.	Pennsylvania	100%
AMETEK UK Finance Limited	United Kingdom	100%
AMETEK Vietnam Company Limited	Vietnam	100%
Amplifier Reasearch Corp.	Pennsylvania	100%
Amptek, Inc.	Delaware	100%
Antavia SAS	France	100%
AR Modular RF Corp.	Washington	100%
ASP Navigate Acquisition Corp.	Delaware	100%
ASP Navigate Holdings, Inc.	Delaware	100%
ASP Navigate Intermediate Holdings, Inc.	Delaware	100%
Atlas Material Holdings Corporation	Delaware	100%
Atlas Material Testing Technology (India) Private Limited	India	100%
Atlas Material Testing Technology BV	The Netherlands	100%
Atlas Material Testing Technology GmbH	Germany	100%
Atlas Material Testing Technology L.L.C.	Delaware	100%
Atlas Netherlands AcquisitionCo Coöperatief U.A.	The Netherlands	99.99%
Avicenna Technology, Inc.	Minnesota	100%
Boston Endo-Surgical Technologies LLC	Delaware	100%
CAMECA Instruments, Inc.	New York	100%
CAMECA SAS	France	96.15%
Chandler Instruments Company L.L.C.	Texas	100%
Coining, Inc.	Delaware	100%
Controls Southeast, Inc.	North Carolina	100%
Crank Software ULC	Canada	100%
Creaform Software Inc.	Canada	100%
Creaform Inc.	Canada	100%
Creaform U.S.A. Inc.	Delaware	100%
Crystal Engineering Corporation	California	100%
Direl GmbH	Germany	100%
Direl Holding GmbH	Germany	100%
Drake Air, Inc.	Oklahoma	100%
Dunkermotoren GmbH	Germany	100%
Dunkermotoren Taicang Co., Ltd.	China	100%
Dunkermotoren USA Inc.	Delaware	100%
Economy Spring, LLC	Delaware	100%
EGS Automation GmbH	Germany	100%
EMA Corp.	Delaware	98.43%
EMA Finance 1 LLC	Delaware	100%
EMA Finance 2 LLC	Delaware	100%
EMA Finance 3, LLC	Delaware	100%
EMA Germany GmbH	Germany	100%

## SUBSIDIARIES OF AMETEK, INC.

AS OF DECEMBER 31, 2024

Company	State or other jurisdiction of incorporation or organization	Percentage of voting securities owned by its immediate parent*
EMA MX, LLC	Delaware	100%
Fine Tubes Limited	United Kingdom	100%
FMH Aerospace Corp.	California	100%
Forza Silicon Corporation	California	100%
Frameffair Limited	United Kingdom	100%
Gatan, Inc.	Pennsylvania	100%
Glasseal Products, Inc.	New Jersey	100%
Grabner Instruments Messtechnik Gesellschaft m.b.H.	Austria	100%
Hamilton Precision Metals, Inc.	Delaware	100%
Haydon Kerk Motion Solutions, Inc.	Massachusetts	100%
Haydon Linear Motors (Changzhou) Co., Ltd.	China	100%
HCC Industries, Inc.	Delaware	100%
HDR Power Systems, LLC	Delaware	100%
Hermetic Seal Corporation	Delaware	100%
innoRIID GmbH	Germany	100%
IntelliPower, Inc.	California	100%
La Vezzi Precision, Inc.	Illinois	100%
Lacey Manufacturing Company LLC	Delaware	100%
Land Instruments International Ltd.	United Kingdom	100%
Life Sciences Design & Development, LLC	Delaware	100%
Life Sciences Vandalia, LLC	Ohio	100%
Magnetrol International N.V.	Belgium	100%
Marox Corporation	Massachusetts	100%
MCG Acquisition Corporation	Minnesota	100%
Med-Aide Design Group, LLC	Pennsylvania	100%
MI Technologies, LLC	Delaware	100%
Micro-Poise Industrial Equipment (Beijing) Ltd.	China	100%
Micro-Poise Measurement Systems, LLC	Delaware	100%
Milmega Limited	United Kingdom	100%
MLV 68 Sp. Z.o.o.	Polland	100%
MOCON Europe A/S	Denmark	100%
MOCON, Inc.	Minnesota	100%
Modern Field Holdings, Inc.	British Virgin Islands	7.6%
Motec GmbH	Germany	100%
Motec USA LLC	Delaware	100%
Muirhead Aerospace Limited	United Kingdom	100%
MW Life Sciences, Inc.	Delaware	100%
MW Madsen Holdings, LLC	Delaware	100%
Navitar, Inc.	New York	100%
Nearfield Systems, LLC	California	100%
NewAge Testing Instruments, Inc.	Pennsylvania	100%



## SUBSIDIARIES OF AMETEK, INC.

AS OF DECEMBER 31, 2024

Company	State or other jurisdiction of incorporation or organization	Percentage of voting securities owned by its immediate parent*
NSI-MI Technologies Inc.	Delaware	100%
Nu Instruments Limited	United Kingdom	100%
OBCORP LLC	Missouri	100%
Pacific Design Technologies, Inc.	California	100%
Paragon Acquisition Corp.	Indiana	100%
Paragon Medical Europe S.a.r.l.	Switzerland	100%
Paragon Medical International, Inc.	Indiana	100%
Paragon Medical, Device (Changzhou) Co. Ltd.	China	100%
Paragon Medical, Inc.	Indiana	100%
Paragon Siechnice Sp. Z.o.o.	Poland	100%
Patriot Sensors & Controls Corporation	Delaware	100%
Petrolab, L.L.C.	Delaware	100%
Pixelink, Inc.	Canada	100%
Platinum Surgical Instruments, Inc.	Wisconsin	100%
PMG Acquisition Corporation	Delaware	100%
PMG Intermediate Holding Corporation	Delaware	100%
Powervar Deutschland GmbH	Germany	100%
Powervar Mexico S.A. de C.V.	Mexico	99.998%
Powervar, Inc.	Illinois	100%
Precision Engineered Products Holdings Inc.	Delaware	100%
Precision Engineered Products, LLC	Delaware	100%
Rauland-Borg Corporation	Illinois	100%
Rauland-Borg Corporation of Florida	Delaware	100%
Reichert, Inc.	Delaware	100%
Responder Systems Corporation	California	100%
RETE Holding GmbH	Germany	100%
Rotron Incorporated	New York	100%
RTDS Technologies Inc.	Canada	100%
Sealtron, Inc.	Delaware	100%
Seiko EG&G Co. Ltd.	Japan	49%
Six Brookside Drive Corporation	Connecticut	100%
SkyBitz Petroleum Logistics LLC	South Carolina	100%
SkyBitz Tank Monitoring Corporation	Illinois	100%
SkyBitz, Inc.	Delaware	100%
Solartron Metrology Limited	United Kingdom	100%
Solidstate Controls Mexico, S.A. de C.V.	Mexico	99.998%
Solidstate Controls, Inc. de Argentina S.R.L.	Argentina	90%
Solidstate Controls, LLC	Delaware	100%
Sound Com Corporation	Ohio	100%
Southern Aero Partners, Inc.	Oklahoma	100%
Special Optics, Inc.	New Jersey	100%
SPECTRO Analytical Instruments (Pty) Ltd	South Africa	100%
SPECTRO Analytical Instruments GmbH	Germany	100%
SPECTRO Analytical Instruments, Inc.	Delaware	100%
Spectro Scientific, Inc.	Massachusetts	100%
Spectro, Inc.	Massachusetts	100%

**SUBSIDIARIES OF AMETEK, INC.**  
**AS OF DECEMBER 31, 2024**

<b>Company</b>	<b>State or other jurisdiction of incorporation or organization</b>	<b>Percentage of voting securities owned by its immediate parent*</b>
Sunpower, Inc.	Ohio	100%
Superior Tube Company, Inc.	Pennsylvania	100%
Taylor Hobson Inc.	Delaware	100%
Taylor Hobson Limited	United Kingdom	100%
Taylor Hobson Trustees Limited	United Kingdom	100%
Technical Manufacturing Corporation	Delaware	100%
Technical Services for Electronics, Inc.	Minnesota	100%
Telular Corporation	Delaware	100%
Trigon International LLC	Delaware	100%
Tritex Corporation	Delaware	100%
Tubes Holdco Limited	United Kingdom	100%
Universal Analyzers Inc.	Nevada	100%
Virtek Vision Deutschland GmbH	Germany	100%
Virtek Vision International Inc.	Canada	100%
Virtek Vision UK Limited	United Kingdom	100%
Virtek Vision USA Inc.	Delaware	100%
Vision Research Europe B.V.	The Netherlands	100%
Vision Research S.R.L.	Romania	100%
Vision Research, Inc.	Delaware	100%
VTI Instruments Private Limited	India	99.999%
VTI Integrated Systems Private Limited	India	99.89%
Zemetrics, Inc.	Delaware	100%
Zygo Corporation	Delaware	100%
Zygo Germany GmbH	Germany	41.36%
Zygo Pte Ltd.	Singapore	100%
Zygo Richmond Corporation	Delaware	100%
ZygoLamda Metrology Instrument (Shanghai) Co., Ltd.	China	100%

(\*) Exclusive of directors' qualifying shares and shares held by nominees as required by the laws of the jurisdiction of incorporation.

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the following Registration Statements:

- (1) Registration Statement (Form S-8 No. 333-173988) pertaining to the AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan,
- (2) Registration Statement (Form S-8 No. 333-87491) pertaining to the AMETEK Retirement and Savings Plan,
- (3) Registration Statement (Form S-8 No. 333-91507) pertaining to the AMETEK, Inc. Deferred Compensation Plan,
- (4) Registration Statement (Form S-8 No. 333-176068) pertaining to the Hamilton Precision Metals 401(k) Employee Savings Plan and Solidstate Controls, Inc. Hourly Employees' (CWA) Retirement Plan,
- (5) Registration Statement (Form S-8 No. 333-214847) pertaining to the Superior Tube Company, Inc. Union 401(k) Plan,
- (6) Registration Statement (Form S-3 No. 333-75892) of AMETEK, Inc. and,
- (7) Registration Statement (Form S-8 No. 333-238099) pertaining to the AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan.

of our reports dated February 20, 2025, with respect to the consolidated financial statements of AMETEK, Inc. and the effectiveness of internal control over financial reporting of AMETEK, Inc., included in this Annual Report (Form 10-K) of AMETEK, Inc. for the year ended December 31, 2024.

/s/ ERNST & YOUNG LLP

Philadelphia, Pennsylvania  
February 20, 2025

# CERTIFICATIONS

I, David A. Zapico, certify that:

1. I have reviewed this Annual Report on Form 10-K of AMETEK, Inc.(the "registrant");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 20, 2025

/s/ DAVID A. ZAPICO

David A. Zapico

Chairman of the Board and Chief Executive Officer

# CERTIFICATIONS

I, Dalip M. Puri, certify that:

1. I have reviewed this Annual Report on Form 10-K of AMETEK, Inc.(the "registrant");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 20, 2025

/s/ DALIP M. PURI

Dalip M. Puri

Executive Vice President – Chief Financial Officer

**AMETEK, Inc.**

**Certification Pursuant to  
18 U.S.C. Section 1350,  
as Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Annual Report of AMETEK, Inc. (the "Company") on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, David A. Zapico, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (a) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (b) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ DAVID A. ZAPICO

---

David A. Zapico

Chairman of the Board and Chief Executive Officer

Date: February 20, 2025

A signed original of this written statement required by Section 906 has been provided to AMETEK, Inc. and will be retained by AMETEK, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

**AMETEK, Inc.**

**Certification Pursuant to  
18 U.S.C. Section 1350,  
as Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Annual Report of AMETEK, Inc. (the "Company") on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Dalip M. Puri, Executive Vice President – Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (a) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (b) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ DALIP M. PURI

---

Dalip M. Puri

Executive Vice President – Chief Financial Officer

Date: February 20, 2025

A signed original of this written statement required by Section 906 has been provided to AMETEK, Inc. and will be retained by AMETEK, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.